Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,50.0,59,DB00386,Alseroxylon
,31838561,Objective response rates,Objective response rates were 50.0% (95% CI 37.4-62.6%) for Oral-VRL and 53.7% (95% CI 41.1-66.0%) for IV-VRL.,"Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31838561/),%,53.7,60,DB00386,Alseroxylon
,8892677,trough,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],461,275,DB00386,Alseroxylon
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],1134,276,DB00386,Alseroxylon
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],821,277,DB00386,Alseroxylon
,8892677,peak blood levels,"The median trough and peak blood levels of SDZ PSC 833 ranged from 461/1134 ng/ml at 5 mg/kg/day to 821/2663 ng/ml at 15 mg/kg, respectively.","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [ml],2663,278,DB00386,Alseroxylon
,8892677,plasma AUC 0-->96 h,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[ng] / [h·ml],77,279,DB00386,Alseroxylon
,8892677,clearance,"With addition of SDZ PSC 833 (5 mg/kg) the mean plasma AUC 0-->96 h of doxorubicin as compared with control patients treated with VAD increased from 779 to 1510 ng/ml/h (P=0.0071), while the doxorubicin clearance was reduced from 47.6 to 27.8 l/h/m2 (P=0.0002).","Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8892677/),[l] / [h·m2],47.6,280,DB00386,Alseroxylon
,16840188,overall response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,85,284,DB00386,Alseroxylon
,16840188,complete response rate,"Best response included five CR, six PR, one SD and one PD with an overall response rate of 85% and complete response rate of 38%.","Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840188/),%,38,285,DB00386,Alseroxylon
,580048,cumulative urinary excretion,"Three-day cumulative urinary excretion was 22% by i.v. route and 13% by oral route in dogs, being 29% in human subjects after oral administration.",Absorption and excretion of 3H-raubasine in human subjects and dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,22,557,DB00386,Alseroxylon
,580048,cumulative urinary excretion,"Three-day cumulative urinary excretion was 22% by i.v. route and 13% by oral route in dogs, being 29% in human subjects after oral administration.",Absorption and excretion of 3H-raubasine in human subjects and dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,13,558,DB00386,Alseroxylon
,580048,cumulative urinary excretion,"Three-day cumulative urinary excretion was 22% by i.v. route and 13% by oral route in dogs, being 29% in human subjects after oral administration.",Absorption and excretion of 3H-raubasine in human subjects and dogs. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,29,559,DB00386,Alseroxylon
,580048,cumulative faecal excretion,Three-day cumulative faecal excretion in dogs was 51% by i.v. route and 57% by oral route whilst it was 24% in humans.,Absorption and excretion of 3H-raubasine in human subjects and dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,51,560,DB00386,Alseroxylon
,580048,cumulative faecal excretion,Three-day cumulative faecal excretion in dogs was 51% by i.v. route and 57% by oral route whilst it was 24% in humans.,Absorption and excretion of 3H-raubasine in human subjects and dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,57,561,DB00386,Alseroxylon
,580048,cumulative faecal excretion,Three-day cumulative faecal excretion in dogs was 51% by i.v. route and 57% by oral route whilst it was 24% in humans.,Absorption and excretion of 3H-raubasine in human subjects and dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,24,562,DB00386,Alseroxylon
,580048,intestinal absorption,"From a comparison between the urinary excretion values observed after i.v. and oral administration, a RAU intestinal absorption of 59% may be obtained.",Absorption and excretion of 3H-raubasine in human subjects and dogs. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580048/),%,59,563,DB00386,Alseroxylon
,26763764,elimination half-life,"Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours.","Switching Opioid-Dependent Patients From Methadone to Morphine: Safety, Tolerability, and Methadone Pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26763764/),h,59,2269,DB00386,Alseroxylon
,28302582,circulation time,"CPD100 elimination from the circulation after injection in mouse was characterized by a very short circulation time (~0.44h), lower area under the curve (AUC) (33μgh/mL) and high clearance (916mL/h/kg) and lower volume of distribution (17.4mL/kg).",Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),h,0.44,3814,DB00386,Alseroxylon
,28302582,area under the curve (AUC),"CPD100 elimination from the circulation after injection in mouse was characterized by a very short circulation time (~0.44h), lower area under the curve (AUC) (33μgh/mL) and high clearance (916mL/h/kg) and lower volume of distribution (17.4mL/kg).",Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),[μgh] / [ml],33,3815,DB00386,Alseroxylon
,28302582,clearance,"CPD100 elimination from the circulation after injection in mouse was characterized by a very short circulation time (~0.44h), lower area under the curve (AUC) (33μgh/mL) and high clearance (916mL/h/kg) and lower volume of distribution (17.4mL/kg).",Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),[ml] / [h·kg],916,3816,DB00386,Alseroxylon
,28302582,volume of distribution,"CPD100 elimination from the circulation after injection in mouse was characterized by a very short circulation time (~0.44h), lower area under the curve (AUC) (33μgh/mL) and high clearance (916mL/h/kg) and lower volume of distribution (17.4mL/kg).",Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),[ml] / [kg],17.4,3817,DB00386,Alseroxylon
,28302582,circulation time,Total drug elimination from the circulation after the administration of liposomal formulation was characterized by prolonged circulation time (5.5h) along with increase in the AUC (56μgh/mL) for CPD100 Li and (9.5h) with AUC (170μgh/mL) for CPD100PEGLi.,Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),h,5.5,3818,DB00386,Alseroxylon
,28302582,AUC,Total drug elimination from the circulation after the administration of liposomal formulation was characterized by prolonged circulation time (5.5h) along with increase in the AUC (56μgh/mL) for CPD100 Li and (9.5h) with AUC (170μgh/mL) for CPD100PEGLi.,Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),[μgh] / [ml],56,3819,DB00386,Alseroxylon
,28302582,AUC,Total drug elimination from the circulation after the administration of liposomal formulation was characterized by prolonged circulation time (5.5h) along with increase in the AUC (56μgh/mL) for CPD100 Li and (9.5h) with AUC (170μgh/mL) for CPD100PEGLi.,Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),h,9.5,3820,DB00386,Alseroxylon
,28302582,AUC,Total drug elimination from the circulation after the administration of liposomal formulation was characterized by prolonged circulation time (5.5h) along with increase in the AUC (56μgh/mL) for CPD100 Li and (9.5h) with AUC (170μgh/mL) for CPD100PEGLi.,Characterization of pegylated and non-pegylated liposomal formulation for the delivery of hypoxia activated vinblastine-N-oxide for the treatment of solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28302582/),[μgh] / [ml],170,3821,DB00386,Alseroxylon
,24530388,relative bioavailability,The relative bioavailability of VP-β-CD-TA COE-loaded NLC was 592% compared with VP suspension and 92% higher than VP-NLC.,"A novel oral delivery system consisting in ""drug-in cyclodextrin-in nanostructured lipid carriers"" for poorly water-soluble drug: vinpocetine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24530388/),%,592,5302,DB00386,Alseroxylon
,24530388,relative bioavailability,The relative bioavailability of VP-β-CD-TA COE-loaded NLC was 592% compared with VP suspension and 92% higher than VP-NLC.,"A novel oral delivery system consisting in ""drug-in cyclodextrin-in nanostructured lipid carriers"" for poorly water-soluble drug: vinpocetine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24530388/),%,92,5303,DB00386,Alseroxylon
,6500775,absorption rate constants,Differences in absorption rate constants in aged and young volunteers (0.53 h-1 and 0.73 h-1 respectively) are analysed.,Pharmacokinetic study of vincamine teprosilate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500775/),1/[h],0.53,5342,DB00386,Alseroxylon
,6500775,absorption rate constants,Differences in absorption rate constants in aged and young volunteers (0.53 h-1 and 0.73 h-1 respectively) are analysed.,Pharmacokinetic study of vincamine teprosilate. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500775/),1/[h],0.73,5343,DB00386,Alseroxylon
,6500775,bioavailability,Vincamine teprosilate bioavailability after oral administration was found to be 20 +/- 5%.,Pharmacokinetic study of vincamine teprosilate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500775/),%,20,5344,DB00386,Alseroxylon
,27557783,PFS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,4,6132,DB00386,Alseroxylon
,27557783,PFS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,17,6133,DB00386,Alseroxylon
,27557783,OS,"Median PFS and OS were 4 months (95 % CI, 2.8-6.9) and 17.5 months (95 % CI, 10.8-24.5), respectively.","Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,17,6134,DB00386,Alseroxylon
,27557783,Cmax,The mean plasma VNR Cmax ranged from 1 to 2.7 ng/ml (Tmax 1.1 h) and no evidence of drug accumulation was found.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),[ng] / [ml],1 to 2.7,6135,DB00386,Alseroxylon
,27557783,Tmax,The mean plasma VNR Cmax ranged from 1 to 2.7 ng/ml (Tmax 1.1 h) and no evidence of drug accumulation was found.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),h,1.1,6136,DB00386,Alseroxylon
,27557783,PFS,Increased PFS (11.3 vs. 2.8 months; P = 0.0298) was observed in patients with sB7-H3 levels <30.25 ng/mL.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,11.3,6137,DB00386,Alseroxylon
,27557783,PFS,Increased PFS (11.3 vs. 2.8 months; P = 0.0298) was observed in patients with sB7-H3 levels <30.25 ng/mL.,"Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557783/),month,2.8,6138,DB00386,Alseroxylon
,15606445,C(max),"For L-arginine, mean C(max) +/- SEM (range) was 42 +/- 2.2 (28-63) microg ml(-1) and t(max) (range) was 0.88 (0.50-1.5) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[μg] / [ml],42,6659,DB00386,Alseroxylon
,15606445,t(max),"For L-arginine, mean C(max) +/- SEM (range) was 42 +/- 2.2 (28-63) microg ml(-1) and t(max) (range) was 0.88 (0.50-1.5) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,0.88,6660,DB00386,Alseroxylon
,15606445,C(max),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[ng] / [ml],42,6661,DB00386,Alseroxylon
,15606445,t(max),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,0.57,6662,DB00386,Alseroxylon
,15606445,"AUC(0,8 h)","For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),[h·ng] / [ml],65,6663,DB00386,Alseroxylon
,15606445,t(1/2),"For yohimbine, mean C(max) was 42 +/- 11 (2.8-128) ng ml(-1); t(max) was 0.57 (0.25-1.0) h; mean AUC(0,8 h) was 65 +/- 24 (5.4-332), ng ml(-1) h and t(1/2) was 1.0 +/- 0.34 (0.40-6.0) h.","An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15606445/),h,1.0,6664,DB00386,Alseroxylon
,19708032,MTD,"The MTD of VSLI was 2.25 mg/m(2) based on dose-limiting toxicities of grade 3 motor neuropathy, grade 4 seizure, and grade 4 hepatotoxicity in 1 patient each at the 2.4 mg/m(2) dose level.",Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708032/),[mg] / [m(2],2.25,6901,DB00386,Alseroxylon
,19708032,CR rate,A complete response (CR) was achieved in 7 of 36 patients (19%) based on an intent-to-treat analysis; the CR rate was 29% for the 14 patients who underwent therapy as their first salvage attempt.,Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19708032/),,29,6902,DB00386,Alseroxylon
,26578094,flow rate,"The analytes were separated on a Purospher® STAR RP18 UHPLC column (2 µm, 2.1 × 100 mm) by gradient elution using a mobile phase composed of methanol and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.","Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26578094/),[ml] / [min],0.3,9419,DB00386,Alseroxylon
,26578094,m/z,"Brucine, strychnine, brucine N-oxide and IS were detected in positive ion multiple reaction monitoring mode by means of an electrospray ionization interface (m/z 395.2 → 324.1, m/z 335.2 → 184.1, m/z 411.2 → 394.2, m/z 243.1 → 226.1).","Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26578094/),,411.2,9420,DB00386,Alseroxylon
,26578094,m/z,"Brucine, strychnine, brucine N-oxide and IS were detected in positive ion multiple reaction monitoring mode by means of an electrospray ionization interface (m/z 395.2 → 324.1, m/z 335.2 → 184.1, m/z 411.2 → 394.2, m/z 243.1 → 226.1).","Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26578094/),,394.2,9421,DB00386,Alseroxylon
,26578094,m/z,"Brucine, strychnine, brucine N-oxide and IS were detected in positive ion multiple reaction monitoring mode by means of an electrospray ionization interface (m/z 395.2 → 324.1, m/z 335.2 → 184.1, m/z 411.2 → 394.2, m/z 243.1 → 226.1).","Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26578094/),,243.1,9422,DB00386,Alseroxylon
,26578094,m/z,"Brucine, strychnine, brucine N-oxide and IS were detected in positive ion multiple reaction monitoring mode by means of an electrospray ionization interface (m/z 395.2 → 324.1, m/z 335.2 → 184.1, m/z 411.2 → 394.2, m/z 243.1 → 226.1).","Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26578094/),,226.1,9423,DB00386,Alseroxylon
,3802707,serum clearance,"The bolus vinblastine serum clearance was 552 +/- 182 ml/min/m2, with a terminal half-life of 29.2 +/- 11.2 hours.",Interpatient and intrapatient variability in vinblastine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802707/),[ml] / [m2·min],552,9827,DB00386,Alseroxylon
,3802707,terminal half-life,"The bolus vinblastine serum clearance was 552 +/- 182 ml/min/m2, with a terminal half-life of 29.2 +/- 11.2 hours.",Interpatient and intrapatient variability in vinblastine pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802707/),h,29.2,9828,DB00386,Alseroxylon
,3802707,infusion clearance,"After steady state was achieved (2 weeks), the infusion clearance was 646 +/- 221 ml/min/m2.",Interpatient and intrapatient variability in vinblastine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802707/),[ml] / [m2·min],646,9829,DB00386,Alseroxylon
,3802707,clearance,The infusion clearance decreased over the duration of the infusion (726 vs. 489 ml/min/m2; P = 0.001;months 1 vs. 4).,Interpatient and intrapatient variability in vinblastine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802707/),[ml] / [m2·min],726,9830,DB00386,Alseroxylon
,3802707,clearance,The infusion clearance decreased over the duration of the infusion (726 vs. 489 ml/min/m2; P = 0.001;months 1 vs. 4).,Interpatient and intrapatient variability in vinblastine pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802707/),[ml] / [m2·min],489,9831,DB00386,Alseroxylon
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],155.9,10708,DB00386,Alseroxylon
,20920295,AUC₀₋₇,"Mean AUC₀₋₇ (days) was 155.9 versus 152.4 mg*h/mL for Prolastin-C and Prolastin, respectively.",Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920295/),[h·mg] / [ml],152.4,10709,DB00386,Alseroxylon
,28551311,half-life (T1/2),"After a single intravenous administration of 10mg/kg mitragynine, mitragynine showed a two-compartmental drug elimination pattern with half-life (T1/2) of approximately 13h.",Evaluation of pharmacokinetics and blood-brain barrier permeability of mitragynine using in vivo microdialysis technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28551311/),h,13,11215,DB00386,Alseroxylon
,12389069,absolute bioavailability,"The mean absolute bioavailability was 36%, with moderate interindividual (CV=20%) and intraindividual (CV=19%) variability.",A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389069/),%,36,12703,DB00386,Alseroxylon
,12389069,bioavailability (F,By means of the simultaneous analysis of oral and intravenous data the bioavailability (F=36%) and its associated variability were estimated.,A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12389069/),%,36,12704,DB00386,Alseroxylon
,1116154,t1/2,"Clearance of radioactivity from the blood was biphasic, with t1/2 values for a first rapid phase of 4.25 and 4.78 min, and for a slower phase of 185 and 195 min.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),min,4.25,13766,DB00386,Alseroxylon
,1116154,t1/2,"Clearance of radioactivity from the blood was biphasic, with t1/2 values for a first rapid phase of 4.25 and 4.78 min, and for a slower phase of 185 and 195 min.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),min,4.78,13767,DB00386,Alseroxylon
,1116154,t1/2,"Clearance of radioactivity from the blood was biphasic, with t1/2 values for a first rapid phase of 4.25 and 4.78 min, and for a slower phase of 185 and 195 min.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),min,185,13768,DB00386,Alseroxylon
,1116154,t1/2,"Clearance of radioactivity from the blood was biphasic, with t1/2 values for a first rapid phase of 4.25 and 4.78 min, and for a slower phase of 185 and 195 min.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),min,195,13769,DB00386,Alseroxylon
,1116154,volume of the central compartment,"The volume of the central compartment was calculated as 29.7 and 39.4 liters, while the total fictive volume of distribution was 86.4 and 111.4 liters.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),l,29.7,13770,DB00386,Alseroxylon
,1116154,volume of the central compartment,"The volume of the central compartment was calculated as 29.7 and 39.4 liters, while the total fictive volume of distribution was 86.4 and 111.4 liters.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),l,39.4,13771,DB00386,Alseroxylon
,1116154,total fictive volume of distribution,"The volume of the central compartment was calculated as 29.7 and 39.4 liters, while the total fictive volume of distribution was 86.4 and 111.4 liters.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),l,86.4,13772,DB00386,Alseroxylon
,1116154,total fictive volume of distribution,"The volume of the central compartment was calculated as 29.7 and 39.4 liters, while the total fictive volume of distribution was 86.4 and 111.4 liters.",The pharmacokinetics of 4-acetyl tritium vinblastine in two patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1116154/),l,111.4,13773,DB00386,Alseroxylon
,21658147,clearance,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[min·ml] / [m(2],482,15054,DB00386,Alseroxylon
,21658147,area under the curve,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[mcg] / [h·l],49.7,15055,DB00386,Alseroxylon
,21658147,Cmax,"The median clearance, area under the curve and Cmax of vincristine was 482 mL/min/m(2) (range 132-698), 49.7 mcg/L.h (16.5-143.1) and 3.5 mcg/L (1.0-31.2), respectively.","Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21658147/),[mcg] / [l],3.5,15056,DB00386,Alseroxylon
,3609075,clearance,"In 8 patients with normal function of the liver and the kidneys, the median clearance of N-PAB was 6.86 ml/min/kg and the median volume of distribution was 1.56 l/kg.",Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],6.86,16372,DB00386,Alseroxylon
,3609075,volume of distribution,"In 8 patients with normal function of the liver and the kidneys, the median clearance of N-PAB was 6.86 ml/min/kg and the median volume of distribution was 1.56 l/kg.",Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[l] / [kg],1.56,16373,DB00386,Alseroxylon
,3609075,clearance,Two patients had a clearly diminished clearance of 1.58 ml/min/kg without obvious impairment of liver or renal function.,Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],1.58,16374,DB00386,Alseroxylon
,3609075,clearance,One patient with chronic glomerulonephritis (plasma creatinine 3.4 mg/dl) had a N-PAB clearance of 2.79 ml/min/kg.,Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3609075/),[ml] / [kg·min],2.79,16375,DB00386,Alseroxylon
,1835590,maximum tolerated dose,Myelosuppression was the dose-limiting toxicity and the maximum tolerated dose was 45 mg/m2.,"Phase I study of vintriptol, a tryptophan ester of vinblastine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835590/),[mg] / [m2],45,16566,DB00386,Alseroxylon
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],22.9,16945,DB00386,Alseroxylon
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h·m2],48.0,16946,DB00386,Alseroxylon
,8549031,clearance rate,A lower vinorelbine clearance rate was observed in the five patients with more than 75% LVRT (22.9 L/hr/m2) compared with the 10 patients with no liver metastases (48.0 L/hr/m2) and the 12 patients with 25% to 75% LVRT (45.3 L/hr/m2).,Pharmacokinetics of vinorelbine in patients with liver metastases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549031/),[l] / [h],45,16947,DB00386,Alseroxylon
,455583,Serum half-lives,"Serum half-lives were 2 min, 50 min, and 24 h for the fast, middle, and slow phases, respectively.",Clinical pharmacokinetics of vindesine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455583/),min,2,17341,DB00386,Alseroxylon
,455583,Serum half-lives,"Serum half-lives were 2 min, 50 min, and 24 h for the fast, middle, and slow phases, respectively.",Clinical pharmacokinetics of vindesine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455583/),min,50,17342,DB00386,Alseroxylon
,455583,Serum half-lives,"Serum half-lives were 2 min, 50 min, and 24 h for the fast, middle, and slow phases, respectively.",Clinical pharmacokinetics of vindesine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455583/),h,24,17343,DB00386,Alseroxylon
,19589735,quantification limit,The quantification limit was 0.2 ng/mL within a linear range of 0.2-1000 ng/mL.,Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[ng] / [ml],0.2,19041,DB00386,Alseroxylon
,19589735,maximum plasma concentration,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[ng] / [ml],424,19042,DB00386,Alseroxylon
,19589735,time to reach maximum plasma concentration,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),h,1.26,19043,DB00386,Alseroxylon
,19589735,elimination half-life,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),h,3.85,19044,DB00386,Alseroxylon
,19589735,apparent total clearance,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[l] / [h·kg],6.35,19045,DB00386,Alseroxylon
,19589735,apparent volume of distribution,"The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration: 424 ng/mL; time to reach maximum plasma concentration: 1.26 h; elimination half-life: 3.85 h, apparent total clearance: 6.35 L/h/kg, and apparent volume of distribution: 37.90 L/kg.",Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19589735/),[l] / [kg],37.90,19046,DB00386,Alseroxylon
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],16.3,19185,DB00386,Alseroxylon
,17579865,peak plasma level,Mean peak plasma level after intravenous etoposide was significantly higher compared to oral administration (16.3+/-3.7 vs. 12.0+/-4.2 microg/ml; P=0.015).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[μg] / [ml],12.0,19186,DB00386,Alseroxylon
,17579865,bioavailability,The mean bioavailability of oral etoposide was 58+/-15% with an interpatient variability of 26%.,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,58,19187,DB00386,Alseroxylon
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],74.0,19188,DB00386,Alseroxylon
,17579865,AUC,Mean AUC after a 100 mg/m2 intravenous and a 200 mg/m2 oral dose of etoposide were 74.0+/-18.3 and 84.9+/-29.6 microg h/ml (P=0.481).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[h·μg] / [ml],84.9,19189,DB00386,Alseroxylon
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,39.4,19190,DB00386,Alseroxylon
,17579865,excretion,Urinary etoposide excretion as percentage of administered dose was 39.4+/-10.6% after intravenous infusion versus 35.4+/-9.4% after oral intake (P=0.422).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),%,35.4,19191,DB00386,Alseroxylon
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],18.5,19192,DB00386,Alseroxylon
,17579865,Renal clearance,Renal clearance was also very similar with intravenous and oral route (18.5+/-7.4 vs. 16.7+/-6.6 ml/min; P=0.546).,Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17579865/),[ml] / [min],16.7,19193,DB00386,Alseroxylon
,10850396,elimination half-life,The Rituximab elimination half-life of approximately 20 days accounts for the demonstrated accumulation of MAb in serum samples.,Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850396/),d,20,19743,DB00386,Alseroxylon
,11852999,absolute gran,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),1/[(mm)^3],200,22892,DB00386,Alseroxylon
,11852999,time to this nadir,"The median absolute granulocyte count nadir for all courses was 200 mm(-3) (range, 0.1-7700 mm(-3)), and the median time to this nadir was 9 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,9,22893,DB00386,Alseroxylon
,11852999,platelet nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),k,163,22894,DB00386,Alseroxylon
,11852999,time to this nadir,"The median platelet nadir was 163 (range, 27-401 k), and the median time to this nadir was 8 days (range, 7-30).",Phase I study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11852999/),d,8,22895,DB00386,Alseroxylon
,7700168,volume of distribution at steady-state,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),[l] / [(m)^2],360,23189,DB00386,Alseroxylon
,7700168,total body clearance,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),[ml] / [(m)^2·min],431,23190,DB00386,Alseroxylon
,7700168,elimination half-life,"Estimated pharmacokinetic parameters were highly variable; mean (S.D.) volume of distribution at steady-state was 360 (176) L.m-2; total body clearance was 431 (238) ml.min-1.m-2, and elimination half-life was 823 (390) min.",Vincristine disposition in children with acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7700168/),min,823,23191,DB00386,Alseroxylon
,1564097,detection limit,The method had good accuracy and precision and the detection limit (0.3 ng/ml with a signal-to-noise ratio of 3:1) allowed the assessment of vincamine concentrations in plasma in pharmacokinetic studies on healthy human volunteers.,Determination of vincamine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564097/),[ng] / [ml],0.3,23196,DB00386,Alseroxylon
,1564097,signal-to-noise ratio,The method had good accuracy and precision and the detection limit (0.3 ng/ml with a signal-to-noise ratio of 3:1) allowed the assessment of vincamine concentrations in plasma in pharmacokinetic studies on healthy human volunteers.,Determination of vincamine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564097/),,3:1,23197,DB00386,Alseroxylon
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,75,24119,DB00386,Alseroxylon
,11103239,index,"However, the dialysis index was about 75 and 85% in the 3rd and 4th cycles, respectively.","[Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11103239/),,85,24120,DB00386,Alseroxylon
,16988826,AUC dose,"Plasma and urine concentrations of LC and ALC from 11 patients on carboplatin therapy (1 h intravenous infusion; AUC dose 4.8 +/- 1.1 mg/ml min) in combination with docetaxel, paclitaxel or vinorelbine, were determined by high-performance liquid chromatography with fluorimetric detection.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[mg] / [min·ml],4.8,24369,DB00386,Alseroxylon
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],47.8,24370,DB00386,Alseroxylon
,16988826,plasma concentrations,"Before carboplatin therapy, the mean +/- SD plasma concentrations of LC and ALC were 47.8 +/- 10.9 and 7.04 +/- 1.04 nmoles/ml, respectively, and remained constant throughout the entire study period.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[nmoles] / [ml],7.04,24371,DB00386,Alseroxylon
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],115,24372,DB00386,Alseroxylon
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],480,24373,DB00386,Alseroxylon
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],41,24374,DB00386,Alseroxylon
,16988826,urinary excretion,"In contrast, urinary excretion of LC and ALC, increased significantly during the chemotherapy from 115 +/- 105 to 480 +/- 348 micromoles/day (P < 0.01) and from 41 +/- 41 to 89 +/- 52 micromoles/day (P < 0.05) for LC and ALC, respectively, subsequently reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[μmoles] / [d],89,24375,DB00386,Alseroxylon
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],1.67,24376,DB00386,Alseroxylon
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],9.05,24377,DB00386,Alseroxylon
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],4.02,24378,DB00386,Alseroxylon
,16988826,renal clearance,"Similarly, the renal clearance of LC and ALC increased substantially during chemotherapy from 1.67 +/- 1.43 to 9.05 +/- 9.52 ml/min (P < 0.05) and from 4.02 +/- 4.51 to 7.97 +/- 5.05 ml/min (P = not significant) for LC and ALC, respectively, reverting to normal 6 days after the end of chemotherapy.",Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16988826/),[ml] / [min],7.97,24379,DB00386,Alseroxylon
,2225313,initial,"Following a single i.v. dose, decay of total tritium in plasma was tetraphasic, with a rapid initial t1/2 alpha of 0.044 +/- 0.013 h, followed by a t1/2 beta of 0.54 +/- 0.22 h and a t1/2 gamma of 9.48 +/- 4.89 h; the terminal t1/2 gamma was 219 +/- 57 h.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),h,0.044,24471,DB00386,Alseroxylon
,2225313,t1/2 alpha,"Following a single i.v. dose, decay of total tritium in plasma was tetraphasic, with a rapid initial t1/2 alpha of 0.044 +/- 0.013 h, followed by a t1/2 beta of 0.54 +/- 0.22 h and a t1/2 gamma of 9.48 +/- 4.89 h; the terminal t1/2 gamma was 219 +/- 57 h.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),h,0.044,24472,DB00386,Alseroxylon
,2225313,t1/2 beta,"Following a single i.v. dose, decay of total tritium in plasma was tetraphasic, with a rapid initial t1/2 alpha of 0.044 +/- 0.013 h, followed by a t1/2 beta of 0.54 +/- 0.22 h and a t1/2 gamma of 9.48 +/- 4.89 h; the terminal t1/2 gamma was 219 +/- 57 h.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),h,0.54,24473,DB00386,Alseroxylon
,2225313,t1/2 gamma,"Following a single i.v. dose, decay of total tritium in plasma was tetraphasic, with a rapid initial t1/2 alpha of 0.044 +/- 0.013 h, followed by a t1/2 beta of 0.54 +/- 0.22 h and a t1/2 gamma of 9.48 +/- 4.89 h; the terminal t1/2 gamma was 219 +/- 57 h.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),h,9.48,24474,DB00386,Alseroxylon
,2225313,terminal t1/2 gamma,"Following a single i.v. dose, decay of total tritium in plasma was tetraphasic, with a rapid initial t1/2 alpha of 0.044 +/- 0.013 h, followed by a t1/2 beta of 0.54 +/- 0.22 h and a t1/2 gamma of 9.48 +/- 4.89 h; the terminal t1/2 gamma was 219 +/- 57 h.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),h,219,24475,DB00386,Alseroxylon
,2225313,plasma clearance,"The mean plasma clearance of total tritium was 0.054 +/- 0.044 l.kg/h, and the mean volume of distribution was 14.3 +/- 5.4 l/kg; mean urinary excretion was 13.6% +/- 4.3% of the delivered radioactivity.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),[kg·l] / [h],0.054,24476,DB00386,Alseroxylon
,2225313,volume of distribution,"The mean plasma clearance of total tritium was 0.054 +/- 0.044 l.kg/h, and the mean volume of distribution was 14.3 +/- 5.4 l/kg; mean urinary excretion was 13.6% +/- 4.3% of the delivered radioactivity.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),[l] / [kg],14.3,24477,DB00386,Alseroxylon
,2225313,urinary excretion,"The mean plasma clearance of total tritium was 0.054 +/- 0.044 l.kg/h, and the mean volume of distribution was 14.3 +/- 5.4 l/kg; mean urinary excretion was 13.6% +/- 4.3% of the delivered radioactivity.",Clinical pharmacokinetics of intravenously injected tritiated vinzolidine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225313/),%,13.6,24478,DB00386,Alseroxylon
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.01,25530,DB00386,Alseroxylon
,17051369,plasma AUC ratios,"The mean plasma concentration profile of vinorelbine administered with aprepitant was identical to that following vinorelbine administered alone, with geometric mean vinorelbine plasma AUC ratios of treatment B day 1/treatment A day 1 and of treatment B day 8/treatment A day of 1.01 (0.93, 1.10) and 1.00 (0.92, 1.08), respectively.",Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17051369/),,1.00,25531,DB00386,Alseroxylon
,21586299,plasma half-life,"Preventive lacosamide treatment (30 mg/kg subcutaneously b.i.d. for 17 days) was well tolerated, and pharmacokinetic analysis revealed a peak plasma concentration 2 h post-injection with a plasma half-life of approximately 3 h.",Lacosamide has protective disease modifying properties in experimental vincristine neuropathy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586299/),h,3,26736,DB00386,Alseroxylon
,14634791,CL,"Typical population estimates of CL and central distribution volume (V(1)) were 74.2 l/h and 7.8 l, respectively.",Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14634791/),[l] / [h],74.2,27046,DB00386,Alseroxylon
,14634791,central distribution volume (V(1)),"Typical population estimates of CL and central distribution volume (V(1)) were 74.2 l/h and 7.8 l, respectively.",Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14634791/),l,7.8,27047,DB00386,Alseroxylon
,8400355,Cmax,"In the dog, NVB pharmacokinetic parameters, Cmax, tmax, AUC, t1/2 and Cl, were 49.0-1021.0 ng/ml, 1.14-3.69 h, 370.0-11754.5 ng/ml h, 19.3-64.3 h and 0.46-1.47 l/h/kg, respectively.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[ng] / [ml],49.0-1021.0,27280,DB00386,Alseroxylon
,8400355,Cmax,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[mg] / [ml],877.6,27281,DB00386,Alseroxylon
,8400355,tmax,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),h,1.14,27282,DB00386,Alseroxylon
,8400355,AUC,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[ng] / [h·ml],7004.8,27283,DB00386,Alseroxylon
,8400355,t1/2,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),h,18.2,27284,DB00386,Alseroxylon
,8400355,Cl,"Pharmacokinetic parameters estimated from monkey data were essentially the same as those of the dog (Cmax, 877.6 mg/ml; tmax, 1.14 h; AUC, 7004.8 ng/ml h; t1/2, 18.2 h) except for Cl (10.40 l/h/kg), which was about 10-fold that of the dog.",Pharmacokinetics of navelbine after oral administration in the dog and the monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400355/),[l] / [h·kg],10.40,27285,DB00386,Alseroxylon
,3664483,plasma clearance,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),[l] / [h·kg],0.27 to 1.49,27883,DB00386,Alseroxylon
,3664483,distribution volume,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),[l] / [kg],8.2 to 48.2,27884,DB00386,Alseroxylon
,3664483,terminal half-life,"The pharmacokinetics of navelbine were characterized by a high plasma clearance (0.27 to 1.49 liter.h-1.kg-1), a large distribution volume (8.2 to 48.2 liter.kg-1), and a long terminal half-life (22.1 to 67.8 h).",Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3664483/),h,22.1 to 67.8,27885,DB00386,Alseroxylon
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],274.2,28183,DB00386,Alseroxylon
,12894568,peak concentrations,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [ml],458,28184,DB00386,Alseroxylon
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[min·ng] / [ml],"8,344",28185,DB00386,Alseroxylon
,12894568,areas under the serum concentration-time curve,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[ng] / [min·ml],"14,093",28186,DB00386,Alseroxylon
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.146,28187,DB00386,Alseroxylon
,12894568,total clearances,"The mean peak concentrations of vinorelbine were 274.2 ng/ml (Standard Deviation or SD: 90) and 458 ng/ml (SD: 448), the mean areas under the serum concentration-time curve were 8,344 ng.min.ml-1 (SD: 2,604) and 14,093 ng/ml.min-1 (SD: 10,000) and the total clearances were 1.146 l/min (SD: 0.333) and 1.003 l/min (SD: 0.714) when the Catharanthus alkaloid was given alone or was combined with rifampin, respectively.",The effect of rifampin on the pharmacokinetics of vinorelbine in the micropig. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12894568/),[l] / [min],1.003,28188,DB00386,Alseroxylon
,25687617,peak serum concentration,Ibogaine was confirmed in his urine and serum with a peak serum concentration of 377 ng/mL.,"Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25687617/),[ng] / [ml],377,28805,DB00386,Alseroxylon
,1797198,Bioavailability,"Bioavailability (i.v./po) estimated from RIA and RA data averaged 40.6 and 93.0%, respectively.",Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797198/),%,40.6,29273,DB00386,Alseroxylon
,1797198,Bioavailability,"Bioavailability (i.v./po) estimated from RIA and RA data averaged 40.6 and 93.0%, respectively.",Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797198/),%,93.0,29274,DB00386,Alseroxylon
,11843245,MTD,"The MTD was 100 mg/m2/week due to the occurrence of dose-limiting neutropenia, nausea/vomiting and constipation in five of six patients.",Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),[mg] / [m2·week],100,30068,DB00386,Alseroxylon
,11843245,maximum blood concentration (Cmax),Vinorelbine was rapidly absorbed with maximum blood concentration (Cmax) of 103.8 +/- 41.6 ng x ml(-1) observed 1.2 +/- 0.8 hours (Tmax) after administration of 80 mg/m2.,Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),[ng] / [ml],103.8,30069,DB00386,Alseroxylon
,11843245,Tmax,Vinorelbine was rapidly absorbed with maximum blood concentration (Cmax) of 103.8 +/- 41.6 ng x ml(-1) observed 1.2 +/- 0.8 hours (Tmax) after administration of 80 mg/m2.,Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11843245/),h,1.2,30070,DB00386,Alseroxylon
,28611009,circulation half-life,"Increase in PEG coverage prolonged nanoparticle circulation half-life up to ~20h in rats and ~10h in mice and decreased retention in liver, spleen and lungs.",Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28611009/),h,20,30600,DB00386,Alseroxylon
,28611009,circulation half-life,"Increase in PEG coverage prolonged nanoparticle circulation half-life up to ~20h in rats and ~10h in mice and decreased retention in liver, spleen and lungs.",Comprehensive study of the drug delivery properties of poly(l-lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28611009/),h,10,30601,DB00386,Alseroxylon
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,1.63,31180,DB00386,Alseroxylon
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,1.67,31181,DB00386,Alseroxylon
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,2.48,31182,DB00386,Alseroxylon
,12357302,time to maximum concentration (T(max)),"The mean time to maximum concentration (T(max)) was shorter in fasted patients (1.63+/-0.98 h in blood, 1.67+/-0.96 h in plasma) than in fed patients (2.48+/-1.40 h in blood, 2.56+/-1.65 h in plasma) but these differences are not likely to modify the safety and/or efficacy of oral vinorelbine.",The effects of food on the pharmacokinetic profile of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12357302/),h,2.56,31183,DB00386,Alseroxylon
∼,21749385,circulation t½,"The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h).",Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749385/),h,9.47,31192,DB00386,Alseroxylon
,21749385,circulation t½,"The resulting vinorelbine circulation t½ was ∼ 9.47 h, which was greater than that of non-pegylated liposomes (∼ 5.55 h).",Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749385/),h,5.55,31193,DB00386,Alseroxylon
,546899,sensitivity,The sensitivity is 2 microgram in a 1-ml sample (amount applied 30 ng) for sulpiride and related compounds and about the same for vincamine.,"[Quantitative determination of drugs by in situ spectrophotometry of chromatograms for pharmacokinetic studies. I. Sulpiride and other benzamides, vincamine, naftazone (author's transl)]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/546899/),μg,2,32423,DB00386,Alseroxylon
≥,27037980,recoveries,The recoveries from spiked control samples were ≥86.16% for all analytes and IS.,"Validated liquid chromatography-tandem mass spectrometry method for simultaneous determination of clopamide, reserpine and dihydroergotoxine: Application to pharmacokinetics in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27037980/),%,86.16,32966,DB00386,Alseroxylon
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,7,32967,DB00386,Alseroxylon
,16419071,progression-free survival,Median progression-free survival was 7 months with VAD alone and 4.9 months with valspodar (P = 0.50).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,4.9,32968,DB00386,Alseroxylon
,16419071,Subjective response,Subjective response was 19% with VAD alone and 17% with valspodar (P = 1.0).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),,19,32969,DB00386,Alseroxylon
,16419071,survival,Median survival with VAD alone was 18.5 months and 15.3 with the addition of valspodar (P = 0.055).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),month,18.,32970,DB00386,Alseroxylon
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,89,32971,DB00386,Alseroxylon
,16419071,Toxicity,Toxicity of Grade 3 or greater was higher (P < 0.0001) in the valspodar arm (89%) compared with the VAD-alone arm (58%).,"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16419071/),%,58,32972,DB00386,Alseroxylon
,20950351,Peak plasma concentrations,"Peak plasma concentrations were 106.0 ± 28.9, 156.7 ± 34.3, and 223.0 ± 44.5 ng/mL for doses of 0.1, 0.2, and 0.4 mg/kg, respectively.",Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950351/),[ng] / [ml],106.0,33161,DB00386,Alseroxylon
,20950351,Peak plasma concentrations,"Peak plasma concentrations were 106.0 ± 28.9, 156.7 ± 34.3, and 223.0 ± 44.5 ng/mL for doses of 0.1, 0.2, and 0.4 mg/kg, respectively.",Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950351/),[ng] / [ml],156.7,33162,DB00386,Alseroxylon
,20950351,Peak plasma concentrations,"Peak plasma concentrations were 106.0 ± 28.9, 156.7 ± 34.3, and 223.0 ± 44.5 ng/mL for doses of 0.1, 0.2, and 0.4 mg/kg, respectively.",Pharmacokinetics and pharmacodynamics of three intravenous doses of yohimbine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20950351/),[ng] / [ml],223.0,33163,DB00386,Alseroxylon
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],2260,34190,DB00386,Alseroxylon
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],891,34191,DB00386,Alseroxylon
,9523729,maximum observed concentration,"The mean maximum observed concentration values were significantly greater for patients receiving VSLI at 2.8 mg/m2 (2260 +/- 212 ng/ml, n = 2) than for those receiving 2.0 mg/m2 and 2.4 mg/m2 (891 +/- 671 ng/ml, n = 6; 679 +/- 634 ng/ml, n = 6, respectively).",Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523729/),[ng] / [ml],679,34192,DB00386,Alseroxylon
,19640235,heart rate,"Two hours after admission, vital signs were blood pressure 259/107 mmHg and heart rate 140 beats/min.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),[beats] / [min],140,34374,DB00386,Alseroxylon
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,"1,530",34375,DB00386,Alseroxylon
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,865,34376,DB00386,Alseroxylon
,19640235,half-life,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),h,2,34377,DB00386,Alseroxylon
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,4.6,36048,DB00386,Alseroxylon
,17947225,progression-free survival (PFS),"Median progression-free survival (PFS) was 4.6 months in arm A and 5.0 months in arm B, with PFS rates at 12 months of 0% and 15%, respectively.",Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,5.0,36049,DB00386,Alseroxylon
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,7.3,36050,DB00386,Alseroxylon
,17947225,survival,Median survival was 7.3 months in arm A and 8.3 months in arm B.,Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17947225/),month,8.3,36051,DB00386,Alseroxylon
,25520304,flow rate,"The analyte was extracted from urine samples using liquid-liquid extraction after addition of vinblastine (VBL, used as internal standard) and chromatographed on an Acquity UPLC HSS T3 column with a gradient mobile phase at a flow rate of 0.4 mL/min.",Validation of an UPLC-MS-MS Method for Quantitative Analysis of Vincristine in Human Urine After Intravenous Administration of Vincristine Sulfate Liposome Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25520304/),[ml] / [min],0.4,36607,DB00386,Alseroxylon
,30646543,half-life t1/2α,"After intravenous (i.v.) dosing of 10-dehydroxyl-12-demethoxy-conophylline at different levels (4, 8, and 12 mg/kg), the half-life t1/2α of intravenous administration was about 7 min and the t1/2β was about 68 min.","Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),min,7,36728,DB00386,Alseroxylon
,30646543,t1/2β,"After intravenous (i.v.) dosing of 10-dehydroxyl-12-demethoxy-conophylline at different levels (4, 8, and 12 mg/kg), the half-life t1/2α of intravenous administration was about 7 min and the t1/2β was about 68 min.","Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),min,68,36729,DB00386,Alseroxylon
,30646543,AUC0→∞,The AUC0→∞ increased in a dose-proportional manner from 68.478 μg/L·min for 4 mg/kg to 305.616 mg/L·min for 12 mg/kg.,"Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),[μg] / [l·min],68.478,36730,DB00386,Alseroxylon
,30646543,AUC0→∞,The AUC0→∞ increased in a dose-proportional manner from 68.478 μg/L·min for 4 mg/kg to 305.616 mg/L·min for 12 mg/kg.,"Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),[mg] / [l·min],305.616,36731,DB00386,Alseroxylon
,30646543,absolute oral bioavailability,10-dehydroxyl-12-demethoxy-conophyllinea absolute oral bioavailability was only 15.79%.,"Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),%,15.79,36732,DB00386,Alseroxylon
over,30646543,protein binding degree,"Results indicated a very high protein binding degree (over 80%), reducing substantially the free fraction of the compound.","Pharmacokinetics, Tissue Distribution, Plasma Protein Binding Studies of 10-Dehydroxyl-12-Demethoxy-Conophylline, a Novel Anti-Tumor Candidate, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30646543/),%,80,36733,DB00386,Alseroxylon
,3389507,retention time,The measurement of phentolamine in biological samples was accomplished using yohimbime as the internal standard; retention time for yohimbine was 3.0 min while phentolamine eluted at 4.75 min.,An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),min,3.0,36886,DB00386,Alseroxylon
,3389507,retention time,The measurement of phentolamine in biological samples was accomplished using yohimbime as the internal standard; retention time for yohimbine was 3.0 min while phentolamine eluted at 4.75 min.,An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),min,4.75,36887,DB00386,Alseroxylon
,3389507,extraction efficiency,The extraction efficiency for this method was 99.4% for phentolamine in serum and 59.3% in liver tissue.,An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),%,99.4,36888,DB00386,Alseroxylon
,3389507,extraction efficiency,The extraction efficiency for this method was 99.4% for phentolamine in serum and 59.3% in liver tissue.,An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),%,59.3,36889,DB00386,Alseroxylon
,3389507,detection limit,"The detection limit for phentolamine was 5 ng/ml for 1.0-ml serum samples, and was 10 ng/ml for 1.0-ml liver homogenate samples.",An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),[ng] / [ml],5,36890,DB00386,Alseroxylon
,3389507,detection limit,"The detection limit for phentolamine was 5 ng/ml for 1.0-ml serum samples, and was 10 ng/ml for 1.0-ml liver homogenate samples.",An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),[ng] / [ml],10,36891,DB00386,Alseroxylon
,3389507,elimination half-life,The elimination half-life of phentolamine in serum was approximately 50 min and was paralleled by disappearance of phentolamine in the liver.,An assay for phentolamine using high performance liquid chromatography with electrochemical detection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3389507/),min,50,36892,DB00386,Alseroxylon
,17545847,area under the curve (AUC),Chemotherapy-naïve patients with locally advanced or metastatic NSCLC were treated with carboplatin area under the curve (AUC) 6 mg/ml per minute intravenously on day 1 and vinorelbine 30 mg/m2 intravenously on days 1 and 8 every 3 weeks for four planned cycles.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),[mg] / [min·ml],6,36914,DB00386,Alseroxylon
,17545847,Overall response rate,Overall response rate was 27%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),%,27,36915,DB00386,Alseroxylon
,17545847,survival,Median survival was 9.4 months (95% confidence interval: 6.1-18.0) with a 3-year survival rate of 20%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),month,9,36916,DB00386,Alseroxylon
,11428656,availability,"The availability of ajmaline in control rats was 16.7%, whereas the availability was increased to 41.1% in rats with renal dysfunction.",Effect of experimental renal dysfunction on bioavailability of ajmaline in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11428656/),%,16.7,37669,DB00386,Alseroxylon
,11428656,availability,"The availability of ajmaline in control rats was 16.7%, whereas the availability was increased to 41.1% in rats with renal dysfunction.",Effect of experimental renal dysfunction on bioavailability of ajmaline in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11428656/),%,41.1,37670,DB00386,Alseroxylon
,9502163,Recovery,Recovery of VINC from plasma and VINC from plasma spiked with vincristine sulfate liposome injection ranged from 74.9-87.1%.,Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9502163/),%,74.9-87.1,37705,DB00386,Alseroxylon
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,67,38013,DB00386,Alseroxylon
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,0,38014,DB00386,Alseroxylon
,31892325,objective response rate,"The objective response rate (complete response [CR] plus partial response [PR]) in heavily pre-treated HER2-positive MBC patients at the recommended doses of epertinib combined with trastuzumab was 67% (N = 9), with trastuzumab plus vinorelbine was 0% (N = 5) and with trastuzumab plus capecitabine was 56% (N = 9).",A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31892325/),%,56,38015,DB00386,Alseroxylon
,19184019,t (1/2),"Nanoliposome formulations of vincristine and vinblastine demonstrated similar pharmacokinetic profiles for the liposomal carrier, but increased clearance for liposome encapsulated vinblastine (t (1/2) = 9.7 h) relative to vincristine (t (1/2) = 18.5 h).",Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19184019/),h,9.7,39594,DB00386,Alseroxylon
,19184019,t (1/2),"Nanoliposome formulations of vincristine and vinblastine demonstrated similar pharmacokinetic profiles for the liposomal carrier, but increased clearance for liposome encapsulated vinblastine (t (1/2) = 9.7 h) relative to vincristine (t (1/2) = 18.5 h).",Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19184019/),h,18.5,39595,DB00386,Alseroxylon
,8859183,duration of response,"Median duration of response was 9.8 months (range, 2-27 months).","Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859183/),month,9.8,40719,DB00386,Alseroxylon
,8859183,Overall median survival,"Overall median survival was 9.5 months (95% CI, 6.8-15.3 months).","Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859183/),month,9.5,40720,DB00386,Alseroxylon
,8859183,AUC,"The back calculation of carboplatin area under the curve (AUC) with Calvert's formula and with the Cockcroft-Gault glomerular filtration rate estimation, showed a median AUC value of 4 (range, 2-8).","Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859183/),,4,40721,DB00386,Alseroxylon
,8859183,AUC,"Using the more precise Chatelut formula, AUC was again 4 (range, 2-7).","Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8859183/),,4,40722,DB00386,Alseroxylon
,34080039,area under the concentration-time curve [AUC] ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,1.8,41785,DB00386,Alseroxylon
,34080039,AUC ratio,"Extrapolation of the vincristine mechanistic PBPK model to other P-gp substrates further suggested DDI risk when ibrutinib (area under the concentration-time curve [AUC] ratio: 1.8), but not acalabrutinib (AUC ratio: 0.92), was given orally with venetoclax or digoxin.",Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34080039/),,0.92,41786,DB00386,Alseroxylon
,20561830,run time,Chromatographic separation was achieved in a run time of 3.5 min on a C(18) column under isocratic conditions.,"Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),min,3.5,43373,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,351.4,43374,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,280.2,43375,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,323.2,43376,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,280.2,43377,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,256.2,43378,DB00386,Alseroxylon
,20561830,m/z,"The protonated precursor to product ion transitions monitored for VP, AVA and IS were m/z 351.4-->280.2, 323.2-->280.2 and 256.2-->167.3 respectively.","Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561830/),,167.3,43379,DB00386,Alseroxylon
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],3.0,44601,DB00386,Alseroxylon
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],0.5,44602,DB00386,Alseroxylon
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],36,44603,DB00386,Alseroxylon
,10348798,biliary excretion clearance,"One-tenth milligram per kilogram PSC 833 was sufficient to significantly reduce the biliary excretion clearance of DGX from 3.0 ml/min/kg to 0.5 ml/min/kg, whereas 3 mg/kg PSC 833 was needed to significantly reduce the biliary excretion clearance of VCR from 36 ml/min/kg to 9 ml/min/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),[ml] / [kg·min],9,44604,DB00386,Alseroxylon
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44605,DB00386,Alseroxylon
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44606,DB00386,Alseroxylon
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44607,DB00386,Alseroxylon
,10348798,tissue-to-plasma,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44608,DB00386,Alseroxylon
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,0.34,44609,DB00386,Alseroxylon
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.64,44610,DB00386,Alseroxylon
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.07,44611,DB00386,Alseroxylon
,10348798,concentration ratio,"The tissue-to-plasma DGX concentration ratio in the brain at 6 h after administration (0.34 versus 1.64), but not that of VCR at 2 h (1.07 versus 1.37), was significantly increased by PSC 833, 3 mg/kg.","Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348798/),,1.37,44612,DB00386,Alseroxylon
,3723649,T 1/2,This declined with T 1/2 [corrected] of 10 hours over a period of 50 hours.,Strychnine poisoning: clinical and toxicological observations on a non-fatal case. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3723649/),h,10,44757,DB00386,Alseroxylon
,15371983,elimination half-life,"When haplotypes were assigned, haplotype 1/1 carriers (3435C/2677G) showed a longer elimination half-life than noncarriers (1156 versus 805 minutes, P =.038).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,1156,44763,DB00386,Alseroxylon
,15371983,elimination half-life,"When haplotypes were assigned, haplotype 1/1 carriers (3435C/2677G) showed a longer elimination half-life than noncarriers (1156 versus 805 minutes, P =.038).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,805,44764,DB00386,Alseroxylon
,15371983,elimination half-life,"In contrast, haplotype 1/2 carriers (3435T/2677G) had a shorter elimination half-life than noncarriers (805 versus 1180 minutes, P =.044).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,805,44765,DB00386,Alseroxylon
,15371983,elimination half-life,"In contrast, haplotype 1/2 carriers (3435T/2677G) had a shorter elimination half-life than noncarriers (805 versus 1180 minutes, P =.044).",Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15371983/),min,1180,44766,DB00386,Alseroxylon
,18537965,total plasma clearance,"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[min·ml] / [m(2],429,45156,DB00386,Alseroxylon
,18537965,total plasma clearance,"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[min·ml] / [m(2],331,45157,DB00386,Alseroxylon
,18537965,area under the plasma concentration-time curve (AUC),"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[mg] / [l·min],4.49,45158,DB00386,Alseroxylon
,18537965,area under the plasma concentration-time curve (AUC),"The median total plasma clearance was 429 and 331 ml/min per m(2) and the area under the plasma concentration-time curve (AUC) was 4.49 and 5.40 mg/l x min in relapse and non-relapse patients, respectively (not significant).",Vincristine pharmacokinetics is related to clinical outcome in children with standard risk acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18537965/),[mg] / [l·min],5.40,45159,DB00386,Alseroxylon
,11504822,half-life,"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),h,1.36,47492,DB00386,Alseroxylon
,11504822,plasma area under the plasma concentration-time curve (AUC),"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[h·μg] / [ml],0.59,47493,DB00386,Alseroxylon
,11504822,volume of distribution,"Vincristine elimination from the circulation after injection of conventional, aqueous formulated vincristine (C-VINC) was characterized by a short half-life (1.36 h), low plasma area under the plasma concentration-time curve (AUC) (0.59 microg x h/ml), and large volume of distribution (145 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),ml,145,47494,DB00386,Alseroxylon
,11504822,half-life,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),h,6.6,47495,DB00386,Alseroxylon
,11504822,plasma AUC,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[h·μg] / [ml],213,47496,DB00386,Alseroxylon
,11504822,volume of distribution,"Total drug elimination from the circulation after liposomal vincristine injection using SM/Chol liposomes was characterized by a prolonged half-life (6.6 h), increased plasma AUC (213 microg x h/ml) and small volume of distribution (2.0 ml).",Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),ml,2.0,47497,DB00386,Alseroxylon
,11504822,Plasma concentrations,Plasma concentrations of free drug remained between 0.025 and 0.05 microg/ml over 4 h of postinjection for both liposomal formulations.,Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11504822/),[μg] / [ml],0.025 and 0.05,47498,DB00386,Alseroxylon
,16203787,C(max),"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),[μM] / [l],12.5,48703,DB00386,Alseroxylon
,16203787,elimination half-life,"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),h,19.2,48704,DB00386,Alseroxylon
,16203787,total area under the curve,"Pharmacokinetics following single i.v. administration of ixabepilone at its MTD (10 mg/kg) were biexponential with C(max) of 12.5 micromol/L, elimination half-life of 19.2 hours, and total area under the curve of 5.8 micromol/L-h.","In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203787/),[μM] / [l-h],5.8,48705,DB00386,Alseroxylon
,16460899,flow rate,"The mobile phase consisted of methanol-10 mM ammonium acetate buffer (80:20, v/v) with the flow rate of 1.0 ml/min.",Determination of vinflunine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16460899/),[ml] / [min],1.0,49332,DB00386,Alseroxylon
,16460899,m/z,LC-MS was performed in the selected ion monitoring (SIM) mode using target ions at m/z: 817.3 for vinflunine and m/z: 373.2 for finasteride (IS).,Determination of vinflunine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16460899/),,817.3,49333,DB00386,Alseroxylon
,16460899,m/z,LC-MS was performed in the selected ion monitoring (SIM) mode using target ions at m/z: 817.3 for vinflunine and m/z: 373.2 for finasteride (IS).,Determination of vinflunine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry for a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16460899/),,373.2,49334,DB00386,Alseroxylon
,17551300,time-to-disease-progression,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,16.6,50554,DB00386,Alseroxylon
,17551300,time-to-disease-progression,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,23.9,50555,DB00386,Alseroxylon
,17551300,survival,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,26,50556,DB00386,Alseroxylon
,17551300,survival,"Median time-to-disease-progression was 16.6 weeks (PO) versus 23.9 weeks (IV), and the median survival was 26 weeks (PO) versus 40.9 weeks IV vinorelbine.",Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,40.9,50557,DB00386,Alseroxylon
,17551300,survival,Median survival on PO vinorelbine for patients with KPS 60-70 was 8.3 weeks versus 43 weeks (IV).,Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,8.3,50558,DB00386,Alseroxylon
,17551300,survival,Median survival on PO vinorelbine for patients with KPS 60-70 was 8.3 weeks versus 43 weeks (IV).,Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17551300/),weeks,43,50559,DB00386,Alseroxylon
,29883892,brain-blood,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.098,51174,DB00386,Alseroxylon
,29883892,brain-blood,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.44,51175,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.098,51176,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.44,51177,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.40,51178,DB00386,Alseroxylon
,29883892,brain-blood,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.20,51179,DB00386,Alseroxylon
,29883892,brain-blood,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,1.25,51180,DB00386,Alseroxylon
,29883892,brain-blood,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,2.06,51181,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,0.20,51182,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,1.25,51183,DB00386,Alseroxylon
,29883892,AUC ratios,"The dialysate brain-blood AUC ratios of brucine were 0.098, 0.44 and 0.40 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC, and the dialysate brain-blood AUC ratios of strychnine were 0.20, 1.25 and 2.06 respectively at 0.4, 0.8 and 1.6 g kg-1 doses of BQC.",Microdialysis combined with RRLC-MS/MS for the pharmacokinetics of two major alkaloids of Bi qi capsule and the potential roles of P-gp and BCRP on their penetration. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29883892/),,2.06,51184,DB00386,Alseroxylon
,22471295,absolute bioavailability,"The mean absolute bioavailability was high, at 58.3 ± 14.4% (SLCaps) and 57.3 ± 11% (HPCaps), with limited inter-individual variability (coefficient of variation = 25% and 19% for SLCaps and HPCaps, respectively).",Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471295/),%,58.3,53910,DB00386,Alseroxylon
,22471295,absolute bioavailability,"The mean absolute bioavailability was high, at 58.3 ± 14.4% (SLCaps) and 57.3 ± 11% (HPCaps), with limited inter-individual variability (coefficient of variation = 25% and 19% for SLCaps and HPCaps, respectively).",Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22471295/),%,57.3,53911,DB00386,Alseroxylon
,29115708,maximum dose,Patients received IV VCR 2 mg/m2 /dose with a maximum dose of 2.5 mg as part of standard treatment protocols.,CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),mg,2.5,54901,DB00386,Alseroxylon
,29115708,dose,"CYP3A5 low-expresser genotype subjects had a significantly higher dose and body surface area normalized area under the curve than CYP3A5 high-expresser genotype subjects (0.28 ± 0.15 hr·m2 /l vs. 0.15 ± 0.011 hr·m2 /l, P = 0.027).",CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),[h·m2] / [l],0.28,54902,DB00386,Alseroxylon
,29115708,body surface area normalized area under the curve,"CYP3A5 low-expresser genotype subjects had a significantly higher dose and body surface area normalized area under the curve than CYP3A5 high-expresser genotype subjects (0.28 ± 0.15 hr·m2 /l vs. 0.15 ± 0.011 hr·m2 /l, P = 0.027).",CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29115708/),[h·m2] / [l],0.15,54903,DB00386,Alseroxylon
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),min,4.75,55225,DB00386,Alseroxylon
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,0.822,55226,DB00386,Alseroxylon
,6891324,half-lives,"The three successive half-lives presented little individual variations and were 4.75 min, 0.822 hr and 18.9 hr.",Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),h,18.9,55227,DB00386,Alseroxylon
,6891324,total plasma clearance,The total plasma clearance of the parent drug ranged from 28.3 to 98.7 1/hr.,Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891324/),[1] / [h],28.3 to 98.7,55228,DB00386,Alseroxylon
,26838484,z,The results show that the spherical nanoparticles obtained were negatively charged with a zeta potential of about -23.4 mV and characterized ∼110 nm with a narrow size distribution.,Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838484/),m,23.4,55574,DB00386,Alseroxylon
,26838484,encapsulation efficiency,"The encapsulation efficiency and drug loading of prepared NPs were 76.4 ± 6.3 and 9.2 ± 2.2% (n=5), respectively.",Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838484/),%,76.4,55575,DB00386,Alseroxylon
,26838484,drug loading,"The encapsulation efficiency and drug loading of prepared NPs were 76.4 ± 6.3 and 9.2 ± 2.2% (n=5), respectively.",Development and evaluation of nanoparticles based on mPEG-PLA for controlled delivery of vinpocetine: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838484/),%,9.2,55576,DB00386,Alseroxylon
,26711181,overall,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,68,56026,DB00386,Alseroxylon
,26711181,complete response rates,"The overall and complete response rates were 68% and 37%, respectively.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),%,37,56027,DB00386,Alseroxylon
,26711181,trough levels,"Highest day 1 alemtuzumab trough levels were achieved at 60 mg (1973 ng/mL), but with significant inter- and intradose variability.",Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26711181/),[ng] / [ml],1973,56028,DB00386,Alseroxylon
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB00386,Alseroxylon
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB00386,Alseroxylon
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],-,56447,DB00386,Alseroxylon
,25645830,kill rate,"We indexed the efficacy of the standard combination regimen, which was a kill rate of -0.08 ± 0.05 log10 CFU/ml/day (r(2) = 0.99).",Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[cfu] / [d·ml],0.08,56448,DB00386,Alseroxylon
,25645830,half-life,We next performed moxifloxacin dose-effect and dose-scheduling studies at a half-life of 11.1 ± 6.47 h.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),h,11.1,56449,DB00386,Alseroxylon
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,317,56450,DB00386,Alseroxylon
,25645830,AUC0-24/MIC,The moxifloxacin exposure associated with 80% of maximal kill (EC80) was an AUC0-24/MIC of 317 (the non-protein-bound moxifloxacin AUC0-24/MIC was 158.5).,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),,158.5,56451,DB00386,Alseroxylon
,25645830,MIC susceptibility breakpoint,The MIC susceptibility breakpoint at this dose was 0.25 mg/liter.,Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25645830/),[mg] / [l],0.25,56452,DB00386,Alseroxylon
,8042515,elimination half-lives,"kg-1 vinpocetine in rats, the elimination of the drug from plasma accorded with linear kinetics and the elimination half-lives were shown to be 1.76 +/- 0.27 h.",[Pharmacokinetics and disposition of vinpocetine in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8042515/),h,1.76,56701,DB00386,Alseroxylon
,8042515,volumes of distribution,The volumes of distribution were 7.30 +/- 0.49 L.kg-1 (5 mg.kg-1) and 6.07 +/- 0.67 L.kg-1 (10 mg.kg-1) respectively.,[Pharmacokinetics and disposition of vinpocetine in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8042515/),[l] / [kg],7.30,56702,DB00386,Alseroxylon
,8042515,volumes of distribution,The volumes of distribution were 7.30 +/- 0.49 L.kg-1 (5 mg.kg-1) and 6.07 +/- 0.67 L.kg-1 (10 mg.kg-1) respectively.,[Pharmacokinetics and disposition of vinpocetine in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8042515/),[l] / [kg],6.07,56703,DB00386,Alseroxylon
,8042515,bioavailability,The bioavailability of vinpocetine after ig administration was 54.54% in rats.,[Pharmacokinetics and disposition of vinpocetine in rats]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8042515/),%,54.54,56704,DB00386,Alseroxylon
,31424307,absolute bioavailability (F),"In comparison with intravenous administration, after intraocular administration of vinpocetine alone, the absolute bioavailability (F) of vinpocetine was 43.82% for the plasma, and the drug target index (DTI) was 1.05 for the brain.",Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),%,43.82,57216,DB00386,Alseroxylon
,31424307,drug target index (DTI),"In comparison with intravenous administration, after intraocular administration of vinpocetine alone, the absolute bioavailability (F) of vinpocetine was 43.82% for the plasma, and the drug target index (DTI) was 1.05 for the brain.",Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),,1.05,57217,DB00386,Alseroxylon
,31424307,relative bioavailability (Fr),The relative bioavailability (Fr) of vinpocetine in the brain was improved (147.19-225.36%).,Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),%,147.19-225.36,57218,DB00386,Alseroxylon
,31424307,DTI,"The DTI was 1.12, 1.18, and 1.21 for 5, 10, and 20 mg/kg of borneol, respectively.",Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),,1.12,57219,DB00386,Alseroxylon
,31424307,DTI,"The DTI was 1.12, 1.18, and 1.21 for 5, 10, and 20 mg/kg of borneol, respectively.",Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),,1.18,57220,DB00386,Alseroxylon
,31424307,DTI,"The DTI was 1.12, 1.18, and 1.21 for 5, 10, and 20 mg/kg of borneol, respectively.",Effect of different doses of borneol on the pharmacokinetics of vinpocetine in rat plasma and brain after intraocular administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31424307/),,1.21,57221,DB00386,Alseroxylon
,17221920,flow rate,"The separation system consisted of a C18 column heated to 35 degrees C, a methanol-water (80:20, v/v) mobile phase, a flow rate of 0.8 mL/min and detection in the ultraviolet at 225 nm.",A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221920/),[ml] / [min],0.8,57926,DB00386,Alseroxylon
,17221920,retention time,"Mitragynine, with a retention time of 10.09 min, was well resolved from any interferences in human serum and the internal standard peak.",A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221920/),min,10.09,57927,DB00386,Alseroxylon
>,17221920,recovery,Extraction of mitragy-nine from alkalinized serum using diethyl ether gave a high recovery (>or=85%).,A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221920/),%,85,57928,DB00386,Alseroxylon
,17221920,limit of detection,The limit of detection was 0.03 microg/mL and the lower limit of quantification was 0.1 microg/mL.,A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17221920/),[μg] / [ml],0.03,57929,DB00386,Alseroxylon
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],23.18,57930,DB00386,Alseroxylon
,25537545,Area under the concentration time curve (AUC48-∝),"Area under the concentration time curve (AUC48-∝) of MTX significantly increased in variant group [(23.18±19.91) vs.(5.66±2.01) h·µmol/L] (t=4.025, P=0.001).",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[h·μM] / [l],5.66,57931,DB00386,Alseroxylon
>,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57932,DB00386,Alseroxylon
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57933,DB00386,Alseroxylon
,25537545,Time above the,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57934,DB00386,Alseroxylon
>,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57935,DB00386,Alseroxylon
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57936,DB00386,Alseroxylon
,25537545,safety threshold (,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57937,DB00386,Alseroxylon
>,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),[μM] / [l],0.1,57938,DB00386,Alseroxylon
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,95.3,57939,DB00386,Alseroxylon
,25537545,TC,"Time above the MTX safety threshold (TC>0.1 µmol/L) increased significantly in variant group [(95.3±22.0) vs.(67.1±7.5) h, t=5.880, P<0.001].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),h,67.1,57940,DB00386,Alseroxylon
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.95,57941,DB00386,Alseroxylon
,25537545,Hospital stay,"Hospital stay of variant group was significantly longer than that of wild-type [(4.95±1.43) vs. (4.05±0.22) d, t=2.881, P=0.009].",[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537545/),d,4.05,57942,DB00386,Alseroxylon
,18594220,Time to progression,"Time to progression was 361 days, with 75.0% of liver metastases and 60% of lung metastases responding to this treatment.",Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18594220/),d,361,58428,DB00386,Alseroxylon
,6144760,peak concentration,Quinidine induced a marked increase to give a mean peak concentration of ajmaline which increased from 0.018 micrograms ml-1 after a single administration to 0.141 micrograms ml-1 in combination with quinidine.,Quinidine-induced rise in ajmaline plasma concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144760/),[μg] / [ml],0.018,59095,DB00386,Alseroxylon
,6144760,peak concentration,Quinidine induced a marked increase to give a mean peak concentration of ajmaline which increased from 0.018 micrograms ml-1 after a single administration to 0.141 micrograms ml-1 in combination with quinidine.,Quinidine-induced rise in ajmaline plasma concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6144760/),[μg] / [ml],0.141,59096,DB00386,Alseroxylon
,9808549,area under the plasma concentration-time curve (AUC),"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.63 to 12,59168,DB00386,Alseroxylon
,9808549,AUC,"The area under the plasma concentration-time curve (AUC) of methotrexate ranged from 0.63 to 12 micromol*h/L, and the AUC of mercaptopurine ranged from 0.11 to 8 micromol*h/L.",Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9808549/),[h·μM] / [l],0.11 to 8,59169,DB00386,Alseroxylon
,19834427,clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),[l] / [h],23.1,59323,DB00386,Alseroxylon
,19834427,central,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59324,DB00386,Alseroxylon
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,35.4,59325,DB00386,Alseroxylon
,19834427,peripheral volume of distribution,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,1090,59326,DB00386,Alseroxylon
,19834427,intercompartmental clearance,"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),l,27.3,59327,DB00386,Alseroxylon
,19834427,mean transit time (tau),"Mean PK estimates and the corresponding interindividual variabilities (%) were clearance 23.1 L/h (34%), central and peripheral volume of distribution 35.4 and 1090 L, respectively, intercompartmental clearance 27.3 L (34%), endogenous Mn concentrations 15.8 nmol/L, slope-relating effect to concentration 141 nmol x L(-1) x s(-1) (52%), and mean transit time (tau) 3.8 days (34%).",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,3.8,59328,DB00386,Alseroxylon
,19834427,tau,"When patients had an early decrease in bilirubin at day 7, tau increased to 28.2 days.",Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19834427/),d,28.2,59329,DB00386,Alseroxylon
,23542494,maximum plasma curcumin concentration,"Although the nanosuspension appeared to exhibit slower clearance from the injection site after i.m. injection, compared to microsuspension (~5 μm), a significantly higher maximum plasma curcumin concentration (69.0 ng/ml) was observed for the former than that for the latter (18.5 ng/ml).","Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: preparation, characterization and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542494/),[ng] / [ml],69.0,59456,DB00386,Alseroxylon
,23542494,maximum plasma curcumin concentration,"Although the nanosuspension appeared to exhibit slower clearance from the injection site after i.m. injection, compared to microsuspension (~5 μm), a significantly higher maximum plasma curcumin concentration (69.0 ng/ml) was observed for the former than that for the latter (18.5 ng/ml).","Oily nanosuspension for long-acting intramuscular delivery of curcumin didecanoate prodrug: preparation, characterization and in vivo evaluation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23542494/),[ng] / [ml],18.5,59457,DB00386,Alseroxylon
,18948499,half-life in circulation,"The release rate of vinorelbine from the liposomal carrier was affected by both the chemical nature of the trapping agent and the resulting drug-to-lipid ratio, with liposomes prepared using sucrose octasulfate displaying the longest half-life in circulation (9.4 h) and in vivo retention in the nanoparticle (t(1/2) = 27.2 h).",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),h,9.4,59765,DB00386,Alseroxylon
,18948499,t(1/2),"The release rate of vinorelbine from the liposomal carrier was affected by both the chemical nature of the trapping agent and the resulting drug-to-lipid ratio, with liposomes prepared using sucrose octasulfate displaying the longest half-life in circulation (9.4 h) and in vivo retention in the nanoparticle (t(1/2) = 27.2 h).",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),h,27.2,59766,DB00386,Alseroxylon
,18948499,maximum tolerated dose,"Acute toxicity of the drug in immunocompetent mice slightly decreased upon encapsulation in liposomes, with a maximum tolerated dose of 17.5 mg VRL/kg for free vinorelbine and 23.8 mg VRL/kg for nanoliposomal vinorelbine.",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),mg,17.5,59767,DB00386,Alseroxylon
,18948499,maximum tolerated dose,"Acute toxicity of the drug in immunocompetent mice slightly decreased upon encapsulation in liposomes, with a maximum tolerated dose of 17.5 mg VRL/kg for free vinorelbine and 23.8 mg VRL/kg for nanoliposomal vinorelbine.",Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18948499/),mg,23.8,59768,DB00386,Alseroxylon
,11334329,limits of quantitation,The limits of quantitation (LOQ) reached 0.5 ng/ml for both VNB and VNO and 1 ng/ml for DAV.,Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),[ng] / [ml],0.5,59950,DB00386,Alseroxylon
,11334329,limits of quantitation,The limits of quantitation (LOQ) reached 0.5 ng/ml for both VNB and VNO and 1 ng/ml for DAV.,Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),[ng] / [ml],1,59951,DB00386,Alseroxylon
,11334329,extraction recovery,"The method was proved linear in the range of LOQs up to 1000 ng/ml, and extraction recovery was 80% on average for the three compounds.",Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334329/),%,80,59952,DB00386,Alseroxylon
,23320365,AUC0-1,"The AUC0-1 values were 7.24 +/- 0.61, 16.02 +/- 2.34 and 54.84 +/- 26.59 microg x h/mL after administration of 30, 60 and 180 mg/kg brucine hydrogel patch, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[h·μg] / [ml],7.24,62146,DB00386,Alseroxylon
,23320365,AUC0-1,"The AUC0-1 values were 7.24 +/- 0.61, 16.02 +/- 2.34 and 54.84 +/- 26.59 microg x h/mL after administration of 30, 60 and 180 mg/kg brucine hydrogel patch, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[h·μg] / [ml],16.02,62147,DB00386,Alseroxylon
,23320365,AUC0-1,"The AUC0-1 values were 7.24 +/- 0.61, 16.02 +/- 2.34 and 54.84 +/- 26.59 microg x h/mL after administration of 30, 60 and 180 mg/kg brucine hydrogel patch, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[h·μg] / [ml],54.84,62148,DB00386,Alseroxylon
,23320365,C(max),"The corresponding C(max) values were 0.73 +/- 0.23, 1.45 +/- 0.28 and 4.59 +/- 1.85 microg/mL, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[μg] / [ml],0.73,62149,DB00386,Alseroxylon
,23320365,C(max),"The corresponding C(max) values were 0.73 +/- 0.23, 1.45 +/- 0.28 and 4.59 +/- 1.85 microg/mL, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[μg] / [ml],1.45,62150,DB00386,Alseroxylon
,23320365,C(max),"The corresponding C(max) values were 0.73 +/- 0.23, 1.45 +/- 0.28 and 4.59 +/- 1.85 microg/mL, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),[μg] / [ml],4.59,62151,DB00386,Alseroxylon
,23320365,T(max),"And the corresponding T(max) values were 8.67 +/- 2.07, 11.67 +/- 2.66 and 8.33 +/- 2.65 h, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),h,8.67,62152,DB00386,Alseroxylon
,23320365,T(max),"And the corresponding T(max) values were 8.67 +/- 2.07, 11.67 +/- 2.66 and 8.33 +/- 2.65 h, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),h,11.67,62153,DB00386,Alseroxylon
,23320365,T(max),"And the corresponding T(max) values were 8.67 +/- 2.07, 11.67 +/- 2.66 and 8.33 +/- 2.65 h, respectively.",[Preparation and pharmacokinetics of brucine hydrogel patch]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23320365/),h,8.33,62154,DB00386,Alseroxylon
,8722343,clearance rate,The mean VP-16 clearance rate was 17.3 ml/min/m2 with continuous infusion.,Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[ml] / [m2·min],17.3,62274,DB00386,Alseroxylon
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],24.2,62275,DB00386,Alseroxylon
,8722343,steady-state plasma concentration,"A mean steady-state plasma concentration of 24.2 micrograms/ml (s.d. = 2) and 28.3 micrograms/ml (s.d. = 1.9) was achieved at the 1800 mg/ml and 2100 mg/m2 dose levels, respectively, GI toxicity is dose limiting when VP-16 at 2400 mg/m2/72 h, is associated with HDM.",Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8722343/),[μg] / [ml],28.3,62276,DB00386,Alseroxylon
,7973765,terminal phase half-life,"There is a prolonged terminal phase due to relatively slow efflux of the drug from peripheral compartments, which results in a long terminal phase half-life, with average values ranging from 27.7 to 43.6 hours.",The clinical pharmacokinetics of vinorelbine (Navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),h,27.7 to 43.6,62420,DB00386,Alseroxylon
,7973765,absolute bioavailability,The absolute bioavailability of vinorelbine from this dosage form was 27% when intravenous doses of 30 mg/m2 were compared with oral doses of 100 mg/m2.,The clinical pharmacokinetics of vinorelbine (Navelbine). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7973765/),%,27,62421,DB00386,Alseroxylon
,3691609,half-life,Vinpocetine was eliminated with a mean half-life of 2.12 +/- 0.51 h.,Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691609/),h,2.12,63419,DB00386,Alseroxylon
,3691609,Total plasma clearance (CL),"Total plasma clearance (CL) and distribution coefficient (delta) of the parent drug were 2.2 +/- 0.9 l.kg-1.h-1 and 6.7 +/- 3.7 l.kg-1, respectively.",Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691609/),[l] / [h·kg],2.2,63420,DB00386,Alseroxylon
,3691609,distribution coefficient (delta),"Total plasma clearance (CL) and distribution coefficient (delta) of the parent drug were 2.2 +/- 0.9 l.kg-1.h-1 and 6.7 +/- 3.7 l.kg-1, respectively.",Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691609/),[l] / [kg],6.7,63421,DB00386,Alseroxylon
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00386,Alseroxylon
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],4.81,65240,DB00386,Alseroxylon
,2924068,steady state distribution volume,The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats.,Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2924068/),[l] / [kg],3.80,65241,DB00386,Alseroxylon
,12084857,total body clearance,"In this group of children pharmacokinetic factors were highly variable: median (25th and 75th percentiles) total body clearance, 228 (128-360) mL.min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],228,65835,DB00386,Alseroxylon
,12084857,elimination half-life,"m(-2); elimination half-life, 1001 (737-1325) min; apparent volume of distribution at steady state 262 (158-469) L/m(2).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),min,1001,65836,DB00386,Alseroxylon
,12084857,apparent volume of distribution at steady state,"m(-2); elimination half-life, 1001 (737-1325) min; apparent volume of distribution at steady state 262 (158-469) L/m(2).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[l] / [m(2],262,65837,DB00386,Alseroxylon
,12084857,clearance,"Vincristine clearance was substantially slower than has been reported previously for children receiving vincristine in combination with steroids as part of combination chemotherapy (median clearance, 228 mL.min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],228,65838,DB00386,Alseroxylon
,12084857,clearance,"m(-2) versus mean clearance, 381 and 482 mL. min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],381,65839,DB00386,Alseroxylon
,12084857,clearance,"m(-2) versus mean clearance, 381 and 482 mL. min(-1).",Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12084857/),[ml] / [min],482,65840,DB00386,Alseroxylon
,2088769,terminal half-lives,"The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),h,14.3,66564,DB00386,Alseroxylon
,2088769,terminal half-lives,"The average terminal half-lives of VLB and VCR were 14.3 h and 7.5 h, respectively.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),h,7.5,66565,DB00386,Alseroxylon
,2088769,systemic clearance,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [h·kg],1.49,66566,DB00386,Alseroxylon
,2088769,systemic clearance,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [h·kg],0.12,66567,DB00386,Alseroxylon
,2088769,apparent distribution volume,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [kg],11.46,66568,DB00386,Alseroxylon
,2088769,apparent distribution volume,"The systemic clearance and apparent distribution volume for VLB, respectively 1.49 l/h/kg and 11.46 l/kg, were significantly greater than those of VCR, 0.12 l/h/kg and 0.41 l/kg.",In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[l] / [kg],0.41,66569,DB00386,Alseroxylon
,2088769,drug accumulation site,The highest drug accumulation site was the intestine (122.0 ng/g wet tissue at 24 h).,In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. Vinblastine and vincristine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2088769/),[ng] / [g],122.0,66570,DB00386,Alseroxylon
,27992451,response rate,The response rate was 30%.,Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27992451/),%,30,67410,DB00386,Alseroxylon
,17031408,duration of response,"The median duration of response was 4.8 months (95% CI: 4.2-7.2), median progression-free survival was 3.7 months (95% CI: 2.8-4.2) and median overall survival was 14.3 months (95% CI: 9.2-19.6).",Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031408/),month,4.8,67848,DB00386,Alseroxylon
,17031408,progression-free survival,"The median duration of response was 4.8 months (95% CI: 4.2-7.2), median progression-free survival was 3.7 months (95% CI: 2.8-4.2) and median overall survival was 14.3 months (95% CI: 9.2-19.6).",Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031408/),month,3.7,67849,DB00386,Alseroxylon
,17031408,overall survival,"The median duration of response was 4.8 months (95% CI: 4.2-7.2), median progression-free survival was 3.7 months (95% CI: 2.8-4.2) and median overall survival was 14.3 months (95% CI: 9.2-19.6).",Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031408/),month,14.3,67850,DB00386,Alseroxylon
,882146,t0.5alpha,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,3.0,67998,DB00386,Alseroxylon
,882146,t0.5alpha,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,2.5,67999,DB00386,Alseroxylon
,882146,t0.5beta,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,16,68000,DB00386,Alseroxylon
,882146,t0.5beta,A rapid distribution phase with a t0.5alpha of 3.0 min for ajmaline and 2.5 min for quindine was followed by a disposition phase with a t0.5beta of 16 min for ajmaline and 20 min for quinidine.,The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),min,20,68001,DB00386,Alseroxylon
,882146,volume of distribution Vdbeta,"High tissue accumulation of both alkaloids was found in lung, liver, and heart and this is also reflected by the volume of distribution Vdbeta, which was 136 ml for ajmaline and 116 ml for quinidine (body weight of the mice = 31 g).",The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),ml,136,68002,DB00386,Alseroxylon
,882146,volume of distribution Vdbeta,"High tissue accumulation of both alkaloids was found in lung, liver, and heart and this is also reflected by the volume of distribution Vdbeta, which was 136 ml for ajmaline and 116 ml for quinidine (body weight of the mice = 31 g).",The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/882146/),ml,116,68003,DB00386,Alseroxylon
,8406379,peak plasma levels,The plasma pharmacokinetics were described by a one-compartment open model with peak plasma levels of 6.9 +/- 2.5 micrograms/ml.,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),[μg] / [ml],6.9,69689,DB00386,Alseroxylon
,8406379,relative oral bioavailability,Mean relative oral bioavailability was generally high (91 +/- 27 per cent).,Pharmacokinetics of high dose methylprednisolone and use in hematological malignancies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8406379/),%,91,69690,DB00386,Alseroxylon
,23032618,MTD,The MTD of EC145 was 2.5 mg when administered as either a bolus injection or 1-hour infusion.,Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23032618/),mg,2.5,70296,DB00386,Alseroxylon
,31099166,IC50 concentration,"In vitro, the IC50 concentration of entinostat ranged from 280 to 1300 nM.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),nM,280 to 1300,72304,DB00386,Alseroxylon
,31099166,Cmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),[ng] / [ml],569.4,72305,DB00386,Alseroxylon
,31099166,Cmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),μM,1.51,72306,DB00386,Alseroxylon
,31099166,Tmax,"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),min,15,72307,DB00386,Alseroxylon
,31099166,total exposure (AUC0-12 h ),"Pharmacokinetic studies showed the average Cmax was 569.4 ng/mL (1.51 μM) with Tmax at 15 minutes, and total exposure (AUC0-12 h ) was 435.6 h × ng/mL.",Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31099166/),[h·ng] / [ml],435.6,72308,DB00386,Alseroxylon
,6891926,"apparent volume of distribution for the central compartment, V1","The mean apparent volume of distribution for the central compartment, V1, is 2.8 l, the total plasma clearance is 971 ml/min, with a renal clearance of 127 ml/min.",Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),l,2.8,73731,DB00386,Alseroxylon
,6891926,total plasma clearance,"The mean apparent volume of distribution for the central compartment, V1, is 2.8 l, the total plasma clearance is 971 ml/min, with a renal clearance of 127 ml/min.",Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),[ml] / [min],971,73732,DB00386,Alseroxylon
,6891926,renal clearance,"The mean apparent volume of distribution for the central compartment, V1, is 2.8 l, the total plasma clearance is 971 ml/min, with a renal clearance of 127 ml/min.",Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),[ml] / [min],127,73733,DB00386,Alseroxylon
,6891926,"elimination half-life, t1/2, z","The mean elimination half-life, t1/2, z, is 23.7 hr, but shows a large interindividual variation.",Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),h,23.7,73734,DB00386,Alseroxylon
,6891926,Urinary elimination,"Urinary elimination is quite low (16%), with the main part (12%) excreted in the first 24 hr.",Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),%,16,73735,DB00386,Alseroxylon
,6891926,plasma protein binding,In vitro plasma protein binding (78%) was found to be independent of the concentration (0.1-5.0 micrograms/ml).,Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891926/),%,78,73736,DB00386,Alseroxylon
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74807,DB00386,Alseroxylon
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74808,DB00386,Alseroxylon
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74809,DB00386,Alseroxylon
,7260915,half-lives,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74810,DB00386,Alseroxylon
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74811,DB00386,Alseroxylon
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74812,DB00386,Alseroxylon
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74813,DB00386,Alseroxylon
,7260915,beta,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74814,DB00386,Alseroxylon
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1.9,74815,DB00386,Alseroxylon
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,19.2,74816,DB00386,Alseroxylon
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min,1359,74817,DB00386,Alseroxylon
,7260915,gamma,"The mean half-lives of the triphasic decay curves alpha, beta, and gamma were 1.9, 19.2, and 1359 min (22.6 hr), respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),h,22.6,74818,DB00386,Alseroxylon
,7260915,apparent volume of the central compartment,"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,4.1,74819,DB00386,Alseroxylon
,7260915,volume of distribution at steady state (Vdss),"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,4.1,74820,DB00386,Alseroxylon
,7260915,volume of distribution at steady state (Vdss),"The apparent volume of the central compartment and the volume of distribution at steady state (Vdss) per 1.73 sq m body surface area were 4.1 and 167.6 liters, respectively.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),l,167.6,74821,DB00386,Alseroxylon
,7260915,plasma clearance,"The plasma clearance was 141.9 ml/min/1.73 sq m, and the area under the concentration X time curve from 0 to infinity (AUC0 infinity) for 2 mg vincristine was 21,689 nM.min.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),[ml] / [1.73·m·min·sq],141.9,74822,DB00386,Alseroxylon
,7260915,area under the concentration X time curve from 0 to infinity (AUC0 infinity),"The plasma clearance was 141.9 ml/min/1.73 sq m, and the area under the concentration X time curve from 0 to infinity (AUC0 infinity) for 2 mg vincristine was 21,689 nM.min.",Pharmacokinetics of vincristine sulfate in adult cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7260915/),min·nM,"21,689",74823,DB00386,Alseroxylon
,15160284,total clearance,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),[l] / [h·kg],0.6,76620,DB00386,Alseroxylon
,15160284,steady state volume of distribution,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),[l] / [h·kg],13,76621,DB00386,Alseroxylon
,15160284,elimination half-life,"In blood, the drug total clearance was about 0.6 l/h/kg, with minor contribution of renal clearance, steady state volume of distribution close to 13 l/h/kg, and elimination half-life at about 40 h.",Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15160284/),h,40,76622,DB00386,Alseroxylon
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,0.85,76758,DB00386,Alseroxylon
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,7.4,76759,DB00386,Alseroxylon
,902455,half-life t1/2,"Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min.",The pharmacokinetics of [3H]-vincristine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902455/),min,164,76760,DB00386,Alseroxylon
,20471464,encapsulation efficiency,The average encapsulation efficiency was 94.9+/-0.4%.,Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20471464/),%,94.9,78382,DB00386,Alseroxylon
,20471464,relative bioavailability,The relative bioavailability of VIN-NLC was 322% compared with VIN suspension.,Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20471464/),%,322,78383,DB00386,Alseroxylon
,20809205,MTD,The MTD was 18.5 mg/m(2).,A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20809205/),[mg] / [m(2],18.5,79239,DB00386,Alseroxylon
,10738641,relative bioavailability,"The relative bioavailability based on Cmax and AUC0-12 were found to be 83.15% and 84.15%, respectively.",In vitro-in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10738641/),%,83.15,79957,DB00386,Alseroxylon
,10738641,relative bioavailability,"The relative bioavailability based on Cmax and AUC0-12 were found to be 83.15% and 84.15%, respectively.",In vitro-in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10738641/),%,84.15,79958,DB00386,Alseroxylon
,1742851,Tmax,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),h,0.9-1.75,80851,DB00386,Alseroxylon
,1742851,cmax,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[ng] / [ml],70.9-832.6,80852,DB00386,Alseroxylon
,1742851,absorption constants,"Absorption of navelbine was very rapid after oral administration: maximal drug concentrations were reached within the first 1 or 2 h (Tmax, 0.9-1.75 h; cmax, 70.9-832.6 ng/ml), with absorption constants ranging from 0.85 to 2.42 l/h.",Pharmacokinetics of navelbine after oral administration in cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[l] / [h],0.85 to 2.42,80853,DB00386,Alseroxylon
,1742851,oral clearance,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[1] / [h·kg],0.43-1.45,80854,DB00386,Alseroxylon
,1742851,apparent volume of distribution,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),[1] / [kg],27.4-45.9,80855,DB00386,Alseroxylon
,1742851,terminal half-life,"The navelbine pharmacokinetic parameters obtained following oral administration were similar to those observed after i.v. bolus injection and were characterised by high oral clearance (0.43-1.45 1 h-1 kg-1), a large apparent volume of distribution (27.4-45.9 1/kg), and a long terminal half-life (24.2-56.5 h).",Pharmacokinetics of navelbine after oral administration in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1742851/),h,24.2-56.5,80856,DB00386,Alseroxylon
,8083697,central volume of distribution,"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [kg],0.66,81481,DB00386,Alseroxylon
,8083697,steady-state volume of distribution (Vss),"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [kg],20.02,81482,DB00386,Alseroxylon
,8083697,terminal half-life (t1/2),"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),h,18,81483,DB00386,Alseroxylon
,8083697,clearance (CI) rate,"Mean central volume of distribution and steady-state volume of distribution (Vss) were large (0.66 +/- 0.46 L/kg and 20.02 +/- 8.55 L/kg, respectively); the mean harmonic terminal half-life (t1/2) was long (18 hours); and the high mean clearance (CI) rate (0.80 +/- 0.68 L/h/kg) approached hepatic blood flow.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[l] / [h·kg],0.80,81484,DB00386,Alseroxylon
,8083697,F,"F was low (0.27 +/- 12), and absorption was rapid (mean time of maximum plasma concentration [Tmax], 0.91 +/- 0.22 hours).","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.27,81485,DB00386,Alseroxylon
,8083697,time of maximum plasma concentration [Tmax],"F was low (0.27 +/- 12), and absorption was rapid (mean time of maximum plasma concentration [Tmax], 0.91 +/- 0.22 hours).","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),h,0.91,81486,DB00386,Alseroxylon
,8083697,F,"Absorption parameters after the first and second oral doses were similar, with mean F values of 0.27 +/- 0.14 and 0.25 +/- 0.11, respectively.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.27,81487,DB00386,Alseroxylon
,8083697,F,"Absorption parameters after the first and second oral doses were similar, with mean F values of 0.27 +/- 0.14 and 0.25 +/- 0.11, respectively.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),,0.25,81488,DB00386,Alseroxylon
,8083697,nominal oral dose,"The mean nominal oral dose was 82 mg/m2, and the mean percentage of intended dose that was received was 92%.","Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083697/),[mg] / [m2],82,81489,DB00386,Alseroxylon
,22180371,T(max),The mean T(max) in both regimens was estimated for 1.5 h.,Omeprazole does not change the oral bioavailability or pharmacokinetics of vinpocetine in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180371/),h,1.5,82468,DB00386,Alseroxylon
,3216038,toxicity score,"The mean toxicity score for all patients was 7.11 and for groups (A and B) it was 4.0 and 9.6, respectively (P = .02).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),,7.11,83492,DB00386,Alseroxylon
,3216038,toxicity score,"The mean toxicity score for all patients was 7.11 and for groups (A and B) it was 4.0 and 9.6, respectively (P = .02).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),,4.0,83493,DB00386,Alseroxylon
,3216038,toxicity score,"The mean toxicity score for all patients was 7.11 and for groups (A and B) it was 4.0 and 9.6, respectively (P = .02).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),,9.6,83494,DB00386,Alseroxylon
,3216038,steady-state vinblastine concentration,"Steady-state vinblastine concentration for each patient was compared with toxicity where the mean steady-state vinblastine concentration was 7.3 ng/mL for all patients, and 5.8 ng/mL and 8.5 ng/mL for groups A and B, respectively (P = .01).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),[ng] / [ml],7.3,83495,DB00386,Alseroxylon
,3216038,steady-state vinblastine concentration,"Steady-state vinblastine concentration for each patient was compared with toxicity where the mean steady-state vinblastine concentration was 7.3 ng/mL for all patients, and 5.8 ng/mL and 8.5 ng/mL for groups A and B, respectively (P = .01).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),[ng] / [ml],5.8,83496,DB00386,Alseroxylon
,3216038,steady-state vinblastine concentration,"Steady-state vinblastine concentration for each patient was compared with toxicity where the mean steady-state vinblastine concentration was 7.3 ng/mL for all patients, and 5.8 ng/mL and 8.5 ng/mL for groups A and B, respectively (P = .01).",The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216038/),[ng] / [ml],8.5,83497,DB00386,Alseroxylon
,18520083,absolute bioavailability,"The absolute bioavailability of vinpocetine in the microparticles was 27.6% in rats, which suggested that PLGA in situ microparticles were a valuable system for the delivery of vinpocetine.",Optimized preparation of in situ forming microparticles for the parenteral delivery of vinpocetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18520083/),%,27.6,84898,DB00386,Alseroxylon
,19694580,stability,The in vitro stability in human plasma at 37 degrees C for 72 hours was 83% +/- 3.5%.,Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19694580/),%,83,85124,DB00386,Alseroxylon
,12926122,overall response rate,The overall response rate was 25% which included 1 of 24 complete responses (4%) and 4 of 24 partial responses (21%).,Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),%,25,85985,DB00386,Alseroxylon
,12926122,response duration,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,5.5,85986,DB00386,Alseroxylon
,12926122,overall median survival,"The median response duration was 5.5 months (2-16 months) and the overall median survival was 9 months (range, 2-25+).",Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12926122/),month,9,85987,DB00386,Alseroxylon
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,30,86057,DB00386,Alseroxylon
,11304769,complete response rates,"The complete response rates were 30% and 48% among patients who received mCHOP and full-dose CHOP combined with HAART, respectively.",Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304769/),%,48,86058,DB00386,Alseroxylon
,20382523,logClearance,"Mean vincristine logClearance was lower in Malawian as compared to UK patients (2.2 versus 2.6 ml/min, p=0.001).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[ml] / [min],2.2,86488,DB00386,Alseroxylon
,20382523,logClearance,"Mean vincristine logClearance was lower in Malawian as compared to UK patients (2.2 versus 2.6 ml/min, p=0.001).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[ml] / [min],2.6,86489,DB00386,Alseroxylon
,20382523,logAUC,"Mean logAUC values were higher in Malawian than in UK patients (3.8 versus 3.5 microg/mlmin, p=0.003).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[μg] / [mlmin],3.8,86490,DB00386,Alseroxylon
,20382523,logAUC,"Mean logAUC values were higher in Malawian than in UK patients (3.8 versus 3.5 microg/mlmin, p=0.003).",Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382523/),[μg] / [mlmin],3.5,86491,DB00386,Alseroxylon
,11985336,bioavailabilities,"These differences can explain the differences in bioavailabilities of vinpocetine in the three species (52% in rats, 21.5+/-19.3% in dogs and 6.2+/-1.9% in humans).",In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985336/),%,52,86792,DB00386,Alseroxylon
,11985336,bioavailabilities,"These differences can explain the differences in bioavailabilities of vinpocetine in the three species (52% in rats, 21.5+/-19.3% in dogs and 6.2+/-1.9% in humans).",In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985336/),%,21.5,86793,DB00386,Alseroxylon
,11985336,bioavailabilities,"These differences can explain the differences in bioavailabilities of vinpocetine in the three species (52% in rats, 21.5+/-19.3% in dogs and 6.2+/-1.9% in humans).",In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11985336/),%,6.2,86794,DB00386,Alseroxylon
,10849889,alpha,"The plasma time course in 5 of 7 animals demonstrated an excellent fit to a two-compartment pharmacokinetic model, with alpha and beta half-lives of 7.3 min and 3.3 h, respectively.",Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849889/),min,7.3,87456,DB00386,Alseroxylon
,10849889,beta half-lives,"The plasma time course in 5 of 7 animals demonstrated an excellent fit to a two-compartment pharmacokinetic model, with alpha and beta half-lives of 7.3 min and 3.3 h, respectively.",Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849889/),h,3.3,87457,DB00386,Alseroxylon
,10849889,Drug clearance,Drug clearance was estimated to be 5.9 l/h (n = 7).,Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10849889/),[l] / [h],5.9,87458,DB00386,Alseroxylon
,32737470,minimum optimal C1-trough,"The first cycle trough concentration (C1-trough) of rituximab was a significant independent risk factor for achieving CR in matched-pair logistic regression analysis, rather than the concentrations in later cycles; the recommendatory minimum optimal C1-trough was 13.60 μg/mL.",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],13.60,88213,DB00386,Alseroxylon
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],12.21,88214,DB00386,Alseroxylon
,32737470,C1-trough,"Patients with grade 1/2 had significantly lower C1-trough compared with grade 3 (12.21 μg/mL vs. 23.45 μg/mL, P < 0.001), only 30% patients with grade 1/2 could reach 13.60 μg/mL, compared with 91.67% in patients with grade 3, which was in accord with its unsatisfactory CR rates (43.33% vs. 76.32%).",Low initial trough concentration of rituximab is associated with unsatisfactory response of first-line R-CHOP treatment in patients with follicular lymphoma with grade 1/2. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737470/),[μg] / [ml],23.45,88215,DB00386,Alseroxylon
,20454783,limits of detection,"The method had limits of detection and quantification of 0.025 and 0.050 microg/mL, respectively.","Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20454783/),[μg] / [ml],0.025,89582,DB00386,Alseroxylon
,20454783,limits of detection,"The method had limits of detection and quantification of 0.025 and 0.050 microg/mL, respectively.","Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20454783/),[μg] / [ml],0.050,89583,DB00386,Alseroxylon
,20454783,absolute oral bioavailability,"Oral absorption of the drug was slow, prolonged and was incomplete, with a calculated absolute oral bioavailability value of 3.03%.","Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20454783/),%,3.03,89584,DB00386,Alseroxylon
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,44,91127,DB00386,Alseroxylon
,7710633,absolute bioavailability,"Cinchonine demonstrates a greater absolute bioavailability than quinine (44% versus 30%, respectively).",Cinchonine per os: efficient circumvention of P-glycoprotein-mediated multidrug resistance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7710633/),%,30,91128,DB00386,Alseroxylon
,32956837,bioavailability,"Vinpocetine (VPN) displays poor bioavailability (~7%) and short half-life (2-3 h) justifying the frequent dosing requirement of currently marketed oral tablets (thrice daily) and thus, posing a great challenge to patient compliance.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),%,7,93923,DB00386,Alseroxylon
,32956837,half-life,"Vinpocetine (VPN) displays poor bioavailability (~7%) and short half-life (2-3 h) justifying the frequent dosing requirement of currently marketed oral tablets (thrice daily) and thus, posing a great challenge to patient compliance.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),h,2-3,93924,DB00386,Alseroxylon
,32956837,vesicle size,"Fractional factorial design followed by combined D-optimal design were applied to identify critical material attributes and obtain their statistically verified optimum levels (Phospholipon 90G, 15.17 mM; Phospholipon 90H, 4.83 mM; sodium deoxycholate, 15 mol% and Vinpocetine, 5 mol%) showing mean vesicle size of 75.65 nm and mean drug entrapment of 87.44%.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),nm,75.65,93925,DB00386,Alseroxylon
,32956837,entrapment,"Fractional factorial design followed by combined D-optimal design were applied to identify critical material attributes and obtain their statistically verified optimum levels (Phospholipon 90G, 15.17 mM; Phospholipon 90H, 4.83 mM; sodium deoxycholate, 15 mol% and Vinpocetine, 5 mol%) showing mean vesicle size of 75.65 nm and mean drug entrapment of 87.44%.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),%,87.44,93926,DB00386,Alseroxylon
,32956837,steady state flux,Ex vivo permeation across full thickness pig ear skin revealed a steady state flux of 11.091 μg/cm2/h via VPN UDL MNP with around 9-fold enhancement when compared to flux value achieved through VPN suspension.,Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),[μg] / [cm2·h],11.091,93927,DB00386,Alseroxylon
,32956837,half-life,"In addition, half-life of 14 h and MRT of 21 h further confirmed the controlled release behavior of UDL MNP for prolonged period of time.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),h,14,93928,DB00386,Alseroxylon
,32956837,MRT,"In addition, half-life of 14 h and MRT of 21 h further confirmed the controlled release behavior of UDL MNP for prolonged period of time.",Vinpocetine loaded ultradeformable liposomes as fast dissolving microneedle patch: Tackling treatment challenges of dementia. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32956837/),h,21,93929,DB00386,Alseroxylon
,23893615,flow rate,"Following a single-step liquid-liquid extraction of plasma samples using chloroform, 7-hydroxymitragynine and the internal standard (tryptoline) were separated on an Acquity UPLC(TM) BEH C18 (1.7 µm, 2.1 × 50 mm) column using an isocratic elution at a flow rate of 0.2 mL/min.","Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ-opioid agonist, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893615/),[ml] / [min],0.2,94084,DB00386,Alseroxylon
,23893615,run time,The run time was 2.5 min.,"Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ-opioid agonist, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893615/),min,2.5,94085,DB00386,Alseroxylon
,23893615,extraction recoveries,"The extraction recoveries ranged from 62.0 to 67.3% at concentrations of 20, 600 and 3200 ng/mL).","Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ-opioid agonist, in rat plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23893615/),%,62.0 to 67.3,94086,DB00386,Alseroxylon
,9556164,maximum CSF concentration,The maximum CSF concentration of THP was 0.97% of plasma in patient A and 0.89% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),,0,95277,DB00386,Alseroxylon
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,28.4,95278,DB00386,Alseroxylon
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,13.1,95279,DB00386,Alseroxylon
,8826613,peak plasma concentrations (Cmax),Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],8.9,96648,DB00386,Alseroxylon
,8826613,terminal half-life,Pharmacokinetic evaluations performed i.v. at the highest non-toxic dosage in mice bearing P03 tumors revealed CPT-11 peak plasma concentrations (Cmax) of 8.9 micrograms/ml and a terminal half-life of 0.6 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,0.6,96649,DB00386,Alseroxylon
,8826613,Cmax,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),[μg] / [ml],1.6,96650,DB00386,Alseroxylon
,8826613,terminal half-life,The metabolite SN-38 plasma concentrations presented a Cmax of 1.6 micrograms/ml and a terminal half-life of 7.4 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,7.4,96651,DB00386,Alseroxylon
,8826613,half-life,"Although the CPT-11 tumor levels were similar to the plasma concentrations for early time points, drug levels decreased more slowly in the tumor compared to plasma (half-life, 5.0 h).",Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,5.0,96652,DB00386,Alseroxylon
,8826613,half-life,SN-38 tumor levels reached concentrations in the range of 0.32-0.34 micrograms/g and decayed with a half-life of 6.9 h.,Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8826613/),h,6.9,96653,DB00386,Alseroxylon
,10506711,overall response rate,The overall response rate was 16% (2 patients achieved a complete response and 5 patients achieved a partial response).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),%,16,97318,DB00386,Alseroxylon
,10506711,duration of response,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4.3,97319,DB00386,Alseroxylon
,10506711,overall survival,The median duration of response was 4.3 months and the median overall survival was 8.6 months.,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.6,97320,DB00386,Alseroxylon
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,3.1,97321,DB00386,Alseroxylon
,10506711,durations of response,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,4. 9,97322,DB00386,Alseroxylon
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,8.1,97323,DB00386,Alseroxylon
,10506711,overall survival,Patients with visceral metastases and/or multiple sites of involvement had shorter durations of response than patients with only soft tissue disease or single-site metastasis (3.1 months vs. 4. 9 months) and shorter overall survival (8.1 months vs. 12 months).,Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10506711/),month,12,97324,DB00386,Alseroxylon
,25290813,Entrapment efficiency,"Entrapment efficiency, particle size, polydispersity index and zeta potential of the optimized formula were 50.74 ± 3.26%, 161.50 ± 7.39 nm, 0.21 ± 0.03 and -22.42 ± 1.72 mV, respectively.","Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25290813/),%,50.74,98045,DB00386,Alseroxylon
,25290813,particle size,"Entrapment efficiency, particle size, polydispersity index and zeta potential of the optimized formula were 50.74 ± 3.26%, 161.50 ± 7.39 nm, 0.21 ± 0.03 and -22.42 ± 1.72 mV, respectively.","Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25290813/),nm,161.50,98046,DB00386,Alseroxylon
,25290813,polydispersity index,"Entrapment efficiency, particle size, polydispersity index and zeta potential of the optimized formula were 50.74 ± 3.26%, 161.50 ± 7.39 nm, 0.21 ± 0.03 and -22.42 ± 1.72 mV, respectively.","Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25290813/),nm,161.50,98047,DB00386,Alseroxylon
,25290813,zeta potential,"Entrapment efficiency, particle size, polydispersity index and zeta potential of the optimized formula were 50.74 ± 3.26%, 161.50 ± 7.39 nm, 0.21 ± 0.03 and -22.42 ± 1.72 mV, respectively.","Optimization of long circulating mixed polymeric micelles containing vinpocetine using simple lattice mixture design, in vitro and in vivo characterization. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25290813/),mv,22.42,98048,DB00386,Alseroxylon
,8896693,elimination half-life,"Peak plasma concentrations were observed after 5 hours, and the elimination half-life was long (about 24 hours).",Toxicity and kinetics of amitraz in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8896693/),h,24,100861,DB00386,Alseroxylon
,25995615,time to reach the maximum plasma concentration,"From data of nine subjects, the pharmacokinetic parameters established were time to reach the maximum plasma concentration (0.83±0.35 hour), terminal half-life (23.24±16.07 hours), and the apparent volume of distribution (38.04±24.32 L/kg).",Pharmacokinetics of mitragynine in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25995615/),h,0.83,101381,DB00386,Alseroxylon
,25995615,terminal half-life,"From data of nine subjects, the pharmacokinetic parameters established were time to reach the maximum plasma concentration (0.83±0.35 hour), terminal half-life (23.24±16.07 hours), and the apparent volume of distribution (38.04±24.32 L/kg).",Pharmacokinetics of mitragynine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25995615/),h,23.24,101382,DB00386,Alseroxylon
,25995615,apparent volume of distribution,"From data of nine subjects, the pharmacokinetic parameters established were time to reach the maximum plasma concentration (0.83±0.35 hour), terminal half-life (23.24±16.07 hours), and the apparent volume of distribution (38.04±24.32 L/kg).",Pharmacokinetics of mitragynine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25995615/),[l] / [kg],38.04,101383,DB00386,Alseroxylon
,25995615,urine excretion of unchanged form,The urine excretion of unchanged form was 0.14%.,Pharmacokinetics of mitragynine in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25995615/),%,0.14,101384,DB00386,Alseroxylon
,25995615,terminal half-life,"This was the first pharmacokinetic study in humans, which demonstrated linearity and was consistent with the oral two-compartment model with a terminal half-life of about 1 day.",Pharmacokinetics of mitragynine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25995615/),d,1,101385,DB00386,Alseroxylon
,32259532,BTE%,"The potential of both formulae to deliver vinpocetine to the brain directly through the intranasal route was confirmed by the high BTE% of 370.97% and 480.70% and the high DTP% of 73.04% and 79.19% for the dispersion and in situ gel, respectively.",In Situ Hexosomal Gel as a Promising Tool to Ameliorate the Transnasal Brain Delivery of Vinpocetine: Central Composite Optimization and In Vivo Biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32259532/),%,370.97,101663,DB00386,Alseroxylon
,32259532,BTE%,"The potential of both formulae to deliver vinpocetine to the brain directly through the intranasal route was confirmed by the high BTE% of 370.97% and 480.70% and the high DTP% of 73.04% and 79.19% for the dispersion and in situ gel, respectively.",In Situ Hexosomal Gel as a Promising Tool to Ameliorate the Transnasal Brain Delivery of Vinpocetine: Central Composite Optimization and In Vivo Biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32259532/),%,480.70,101664,DB00386,Alseroxylon
,32259532,DTP%,"The potential of both formulae to deliver vinpocetine to the brain directly through the intranasal route was confirmed by the high BTE% of 370.97% and 480.70% and the high DTP% of 73.04% and 79.19% for the dispersion and in situ gel, respectively.",In Situ Hexosomal Gel as a Promising Tool to Ameliorate the Transnasal Brain Delivery of Vinpocetine: Central Composite Optimization and In Vivo Biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32259532/),%,73.04,101665,DB00386,Alseroxylon
,32259532,DTP%,"The potential of both formulae to deliver vinpocetine to the brain directly through the intranasal route was confirmed by the high BTE% of 370.97% and 480.70% and the high DTP% of 73.04% and 79.19% for the dispersion and in situ gel, respectively.",In Situ Hexosomal Gel as a Promising Tool to Ameliorate the Transnasal Brain Delivery of Vinpocetine: Central Composite Optimization and In Vivo Biodistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32259532/),%,79.19,101666,DB00386,Alseroxylon
,9705120,Tmax,"In the control group, Tmax was 31 min and this decreased significantly (P < 0.05) following the administration of metoclopramide.",Acetaminophen as a marker of gastric emptying in ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9705120/),min,31,102516,DB00386,Alseroxylon
,17321495,half-time for LN clearance (Tc(1/2)),"For example, the half-time for LN clearance (Tc(1/2)) at a low lipid dose (15 micromol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for DHSM/Chol LN.",Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17321495/),h,3.8,104521,DB00386,Alseroxylon
,17321495,half-time for LN clearance (Tc(1/2)),"For example, the half-time for LN clearance (Tc(1/2)) at a low lipid dose (15 micromol lipid/kg, corresponding to 8 mg lipid/kg body weight) in mice was 3.8 h for ESM/Chol LN compared to 6 h for DHSM/Chol LN.",Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17321495/),h,6,104522,DB00386,Alseroxylon
,9862762,ED50,The total brain concentration (25 microM) of drug at the ED50 value (approximately 3 mg/kg) for protection against MES seizures was consistent with the reported affinity of AR-R 15896AR at the N-methyl-D- aspartic acid binding site (IC50 value = 1.3 microM).,"[S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862762/),[mg] / [kg],3,104817,DB00386,Alseroxylon
,9862762,IC50,The total brain concentration (25 microM) of drug at the ED50 value (approximately 3 mg/kg) for protection against MES seizures was consistent with the reported affinity of AR-R 15896AR at the N-methyl-D- aspartic acid binding site (IC50 value = 1.3 microM).,"[S]-AR-R 15896AR-A novel anticonvulsant: acute safety, pharmacokinetic and pharmacodynamic properties. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862762/),μM,1.3,104818,DB00386,Alseroxylon
,26696583,elimination half-life,The median MTX elimination half-life was 21.7 h (range 9.4-204.4).,The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26696583/),h,21.7,105605,DB00386,Alseroxylon
,7747714,peak whole-blood CsA level,"Mean peak whole-blood CsA level at the highest CsA dose level was 919 ng/ml (range: 414-1,827) with a trough prior to Vbl injection of 451 ng/ml (range: 128-1,229).",Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7747714/),[ng] / [ml],919,105670,DB00386,Alseroxylon
,7747714,trough prior to Vbl injection,"Mean peak whole-blood CsA level at the highest CsA dose level was 919 ng/ml (range: 414-1,827) with a trough prior to Vbl injection of 451 ng/ml (range: 128-1,229).",Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7747714/),[ng] / [ml],451,105671,DB00386,Alseroxylon
,12451472,Hill constant,"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),,4.38,106375,DB00386,Alseroxylon
,12451472,EC(50),"In contrast, there was a highly significant relationship between the mean VRB AUC (days 1-5) and the absolute neutrophil count decrease (Emax model, Hill constant=4.38+/-2.59, EC(50)=508+/-53.2 micro g.h/l, r=0.75, P=0.0013).",The raltitrexed-vinorelbine combination: a phase I pharmacokinetic and pharmacodynamic trial in advanced breast cancer. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451472/),[h·μg] / [l],508,106376,DB00386,Alseroxylon
,21219345,Peak plasma concentration,Peak plasma concentration was 114.5 + 31.8 ng/mL and occurred at 0.09 + 0.03 h.,Pharmacokinetics of yohimbine following intravenous administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),[ng] / [ml],114.5,107340,DB00386,Alseroxylon
,21219345,systemic clearance (Cls),Mean ± SD systemic clearance (Cls) and steady-state volume of distribution (Vdss) were 13.5 + 2.1 mL/min/kg and 3.3 + 1.3 L/kg following noncompartmental analysis.,Pharmacokinetics of yohimbine following intravenous administration to horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),[ml] / [kg·min],13.5,107341,DB00386,Alseroxylon
,21219345,steady-state volume of distribution (Vdss),Mean ± SD systemic clearance (Cls) and steady-state volume of distribution (Vdss) were 13.5 + 2.1 mL/min/kg and 3.3 + 1.3 L/kg following noncompartmental analysis.,Pharmacokinetics of yohimbine following intravenous administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),[l] / [kg],3.3,107342,DB00386,Alseroxylon
,21219345,Cls,"Mean ± SD Cls and Vdss of yohimbine were 13.6 ± 2.0 mL/min/kg and 3.2 ± 1.1 L/kg, respectively.",Pharmacokinetics of yohimbine following intravenous administration to horses. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),[ml] / [kg·min],13.6,107343,DB00386,Alseroxylon
,21219345,Vdss,"Mean ± SD Cls and Vdss of yohimbine were 13.6 ± 2.0 mL/min/kg and 3.2 ± 1.1 L/kg, respectively.",Pharmacokinetics of yohimbine following intravenous administration to horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),[l] / [kg],3.2,107344,DB00386,Alseroxylon
,21219345,terminal elimination half-life,Mean ± SD terminal elimination half-life was 4.4 ± 0.9 h following noncompartmental analysis.,Pharmacokinetics of yohimbine following intravenous administration to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219345/),h,4.4,107345,DB00386,Alseroxylon
,2380017,terminal half-life,The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours.,A phase I and pharmacokinetic study of intravenous vinzolidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2380017/),h,23,107494,DB00386,Alseroxylon
,1653559,maximum concentration (Cmax),The maximum concentration (Cmax) of VDS was 6.9 ng/ml and the area under the curve (AUC) was 803 ng.hr/ml.,[Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653559/),[ng] / [ml],6.9,108739,DB00386,Alseroxylon
,1653559,area under the curve (AUC),The maximum concentration (Cmax) of VDS was 6.9 ng/ml and the area under the curve (AUC) was 803 ng.hr/ml.,[Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1653559/),[h·ng] / [ml],803,108740,DB00386,Alseroxylon
,32693425,volume of distribution (Vd,"Following intravenous administration, mitragynine showed a large volume of distribution (Vd, 6.3 ± 0.6 L/kg) and high clearance (Cl, 1.8 ± 0.4 L/h/kg).",Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),[l] / [kg],6.3,109353,DB00386,Alseroxylon
,32693425,clearance (Cl,"Following intravenous administration, mitragynine showed a large volume of distribution (Vd, 6.3 ± 0.6 L/kg) and high clearance (Cl, 1.8 ± 0.4 L/h/kg).",Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),[l] / [h·kg],1.8,109354,DB00386,Alseroxylon
,32693425,first peak plasma (Cmax,"Following oral mitragynine dosing, first peak plasma (Cmax, 278.0 ± 47.4 ng/mL) concentrations were observed within 0.5 h.",Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),[ng] / [ml],278.0,109355,DB00386,Alseroxylon
,32693425,Cmax,"A potent mu-opioid receptor agonist and active metabolite of mitragynine, 7-hydroxymitragynine, was also observed with a Cmax of 31.5 ± 3.3 ng/mL and a Tmax of 1.7 ± 0.6 h in orally dosed dogs while its plasma concentrations were below the lower limit of quantification (1 ng/mL) for the intravenous study.",Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),[ng] / [ml],31.5,109356,DB00386,Alseroxylon
,32693425,Tmax,"A potent mu-opioid receptor agonist and active metabolite of mitragynine, 7-hydroxymitragynine, was also observed with a Cmax of 31.5 ± 3.3 ng/mL and a Tmax of 1.7 ± 0.6 h in orally dosed dogs while its plasma concentrations were below the lower limit of quantification (1 ng/mL) for the intravenous study.",Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),h,1.7,109357,DB00386,Alseroxylon
,32693425,absolute oral bioavailability,The absolute oral bioavailability of mitragynine was 69.6%.,Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32693425/),%,69.6,109358,DB00386,Alseroxylon
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],299,110190,DB00386,Alseroxylon
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],384,110191,DB00386,Alseroxylon
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],245,110192,DB00386,Alseroxylon
,23802659,peak levels,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),[μg] / [ml],321,110193,DB00386,Alseroxylon
,23802659,troughs,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110194,DB00386,Alseroxylon
,23802659,t½,Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t½ of 26-29 d.,Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802659/),d,26-29,110195,DB00386,Alseroxylon
,2076728,t1/2 beta,The drug was rapidly eliminated (t1/2 beta 0.58 h orally and t1/2 beta 0.68 h intravenously).,Yohimbine bioavailability in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),h,0.58,110351,DB00386,Alseroxylon
,2076728,t1/2 beta,The drug was rapidly eliminated (t1/2 beta 0.58 h orally and t1/2 beta 0.68 h intravenously).,Yohimbine bioavailability in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),h,0.68,110352,DB00386,Alseroxylon
,2076728,t1/2a,"Following intravenous administration the data fit a two-compartment pharmacokinetic model, with a very rapid distribution phase (t1/2a was approximately 6 min).",Yohimbine bioavailability in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),min,6,110353,DB00386,Alseroxylon
,2076728,oral clearance,Both the oral and the intravenous yohimbine clearance values were high but oral clearance values were much higher (mean 9.77 ml.min-1.kg-1 intravenous versus 55.9 ml.min-1.kg-1 oral).,Yohimbine bioavailability in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),[ml] / [kg·min],9.77,110354,DB00386,Alseroxylon
,2076728,oral clearance,Both the oral and the intravenous yohimbine clearance values were high but oral clearance values were much higher (mean 9.77 ml.min-1.kg-1 intravenous versus 55.9 ml.min-1.kg-1 oral).,Yohimbine bioavailability in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),[ml] / [kg·min],55.9,110355,DB00386,Alseroxylon
,2076728,oral bioavailability,"The oral bioavailability showed great variability, ranging from 7% to 87% (mean value was 33%).",Yohimbine bioavailability in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),%,87,110356,DB00386,Alseroxylon
,2076728,oral bioavailability,"The oral bioavailability showed great variability, ranging from 7% to 87% (mean value was 33%).",Yohimbine bioavailability in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076728/),%,33,110357,DB00386,Alseroxylon
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,34,113744,DB00386,Alseroxylon
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,3,113745,DB00386,Alseroxylon
,9055138,absolute bioavailability,The absolute bioavailability of PSC 833 was 34% but ranged from 3% to 58% of the administered dose.,"Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9055138/),%,58,113746,DB00386,Alseroxylon
,25144346,bioavailability,The median bioavailability on i.p. administration was 76% for cyclophosphamide and 100% for vincristine.,Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),%,76,113888,DB00386,Alseroxylon
,25144346,bioavailability,The median bioavailability on i.p. administration was 76% for cyclophosphamide and 100% for vincristine.,Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),%,100,113889,DB00386,Alseroxylon
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],11.4,113890,DB00386,Alseroxylon
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.0,113891,DB00386,Alseroxylon
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.7,113892,DB00386,Alseroxylon
,25144346,areas under the curve,"Median areas under the curve for i.p. and intravenous administration were 11.4 and 16.0 ng h/ml for cyclophosphamide and 16.7 and 16.5 ng h/ml for vincristine, respectively.",Bioavailability of cyclophosphamide and vincristine after intraperitoneal administration in cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25144346/),[h·ng] / [ml],16.5,113893,DB00386,Alseroxylon
,29337963,PFS,"Median PFS was 14.6 and 15.9 weeks for patients treated at the MTDA and MTDB, including dose-escalation and expansion cohorts.",Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29337963/),weeks,14.6,114006,DB00386,Alseroxylon
,29337963,PFS,"Median PFS was 14.6 and 15.9 weeks for patients treated at the MTDA and MTDB, including dose-escalation and expansion cohorts.",Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29337963/),weeks,15.9,114007,DB00386,Alseroxylon
,31103789,half maximal inhibitory concentration,"The antitumor activity was characterized by 3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide assay, and half maximal inhibitory concentration values of VCR-liposomes spray-dried powder were 24.42 ± 1.88 nM and 55.28 ± 4.76 nM in MCF-7 and A549 cells, respectively.",Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103789/),nM,24.42,115381,DB00386,Alseroxylon
,31103789,half maximal inhibitory concentration,"The antitumor activity was characterized by 3-(4, 5-dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide assay, and half maximal inhibitory concentration values of VCR-liposomes spray-dried powder were 24.42 ± 1.88 nM and 55.28 ± 4.76 nM in MCF-7 and A549 cells, respectively.",Formulation and Characterization of Spray-Dried Powders Containing Vincristine-Liposomes for Pulmonary Delivery and Its Pharmacokinetic Evaluation From In Vitro and In Vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31103789/),nM,55.28,115382,DB00386,Alseroxylon
,580746,apparent half-life,Ajmaline was eliminated from serum with an apparent half-life of approximately 1 h and NPA with one of approximately 4 h.,Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),h,1,115501,DB00386,Alseroxylon
,580746,apparent half-life,Ajmaline was eliminated from serum with an apparent half-life of approximately 1 h and NPA with one of approximately 4 h.,Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),h,4,115502,DB00386,Alseroxylon
,580746,bioavailability,"The bioavailability of oral ajmaline, calculated from the area under the serum concentration/time curves, was about 90%.",Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),%,90,115503,DB00386,Alseroxylon
,580746,peak serum concentrations,"The peak serum concentrations of ajmaline and NPA after a single oral dose of 50 mg of ajmaline and NPAB were about 1.4 microgram/ml and 0.6 microgram/ml, respectively, the latter calculated as its bitartrate, with about the same peak time: 1 h.",Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),[μg] / [ml],1.4,115504,DB00386,Alseroxylon
,580746,peak serum concentrations,"The peak serum concentrations of ajmaline and NPA after a single oral dose of 50 mg of ajmaline and NPAB were about 1.4 microgram/ml and 0.6 microgram/ml, respectively, the latter calculated as its bitartrate, with about the same peak time: 1 h.",Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),[μg] / [ml],0.6,115505,DB00386,Alseroxylon
,580746,peak time,"The peak serum concentrations of ajmaline and NPA after a single oral dose of 50 mg of ajmaline and NPAB were about 1.4 microgram/ml and 0.6 microgram/ml, respectively, the latter calculated as its bitartrate, with about the same peak time: 1 h.",Pharmacokinetic studies of the antiarrhythmic drugs ajmaline and N-propylajmaline bitartrate in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580746/),h,1,115506,DB00386,Alseroxylon
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],24,117533,DB00386,Alseroxylon
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],522,117534,DB00386,Alseroxylon
,12663724,area under concentration-time curve (AUC),"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117535,DB00386,Alseroxylon
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],14,117536,DB00386,Alseroxylon
,12663724,cumulative AUC,"Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively).",Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663724/),[μmol] / [h·l],303,117537,DB00386,Alseroxylon
,2319463,half-lives (T1/2),"The biphasic elimination of radioactivity in rats was characterized by half-lives (T1/2) of 10 and 143 hr, whereas the elimination of radioactivity in monkeys was characterized by T1/2 values of 11 and 66 hr.",Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,10,117965,DB00386,Alseroxylon
,2319463,half-lives (T1/2),"The biphasic elimination of radioactivity in rats was characterized by half-lives (T1/2) of 10 and 143 hr, whereas the elimination of radioactivity in monkeys was characterized by T1/2 values of 11 and 66 hr.",Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,143,117966,DB00386,Alseroxylon
,2319463,T1/2,"The biphasic elimination of radioactivity in rats was characterized by half-lives (T1/2) of 10 and 143 hr, whereas the elimination of radioactivity in monkeys was characterized by T1/2 values of 11 and 66 hr.",Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,11,117967,DB00386,Alseroxylon
,2319463,T1/2,"The biphasic elimination of radioactivity in rats was characterized by half-lives (T1/2) of 10 and 143 hr, whereas the elimination of radioactivity in monkeys was characterized by T1/2 values of 11 and 66 hr.",Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,66,117968,DB00386,Alseroxylon
,2319463,T1/2,The T1/2 of free DAVLB-hyd in plasma of LY203725 dosed monkeys was 16 hr.,Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,16,117969,DB00386,Alseroxylon
,2319463,T1/2,Administration of DAVLB-hyd to rats resulted in a rapid initial decrease in plasma DAVLB-hyd followed by a slower (T1/2 = 1.4 hr) elimination rate.,Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2319463/),h,1.4,117970,DB00386,Alseroxylon
,22045498,response rate,"Objective partial responses were reported in 7 patients, yielding a response rate of 43.8% in the all-treated population according to the investigator assessment.",A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22045498/),%,43.8,118154,DB00386,Alseroxylon
,16366040,Cmax,The mean values for the Cmax were 49.5 (+/- 16) ng/ml for test and 51.4 (+/- 14) ng/ml for the reference product.,Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16366040/),[ng] / [ml],49.5,119218,DB00386,Alseroxylon
,16366040,Cmax,The mean values for the Cmax were 49.5 (+/- 16) ng/ml for test and 51.4 (+/- 14) ng/ml for the reference product.,Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16366040/),[ng] / [ml],51.4,119219,DB00386,Alseroxylon
,16366040,AUC0-infinity,"The mean values for the AUC0-infinity were 95 (+/- 29) ng/ml x h for test and 96.9 (+/- 26) ng/ml x h for reference, respectively.",Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16366040/),[ng] / [h·ml],95,119220,DB00386,Alseroxylon
,16366040,AUC0-infinity,"The mean values for the AUC0-infinity were 95 (+/- 29) ng/ml x h for test and 96.9 (+/- 26) ng/ml x h for reference, respectively.",Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16366040/),[ng] / [h·ml],96.9,119221,DB00386,Alseroxylon
,3653227,absorption half-time,The drug was rapidly absorbed (absorption half-time 0.17 +/- 0.11 h) and rapidly eliminated from the plasma (elimination half-life 0.60 +/- 0.26 h).,The pharmacokinetics of yohimbine in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653227/),h,0.17,121819,DB00386,Alseroxylon
,3653227,elimination half-life,The drug was rapidly absorbed (absorption half-time 0.17 +/- 0.11 h) and rapidly eliminated from the plasma (elimination half-life 0.60 +/- 0.26 h).,The pharmacokinetics of yohimbine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653227/),h,0.60,121820,DB00386,Alseroxylon
,8738192,relative recovery,"Each chromatographic separation was completed in 14 min and the results showed a relative recovery which varied between 95.9 and 116%, a good overall precision (relative standard deviation, 7.00%) and sensitivity over a linear range of 5.00-300 ng ml-1 (R = 0.999) for AVA in plasma.",Determination of apovincaminic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738192/),%,95.9,122014,DB00386,Alseroxylon
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,1.3,122794,DB00386,Alseroxylon
,16651648,Fractional survival,Fractional survival of neutrophils ranged from 1.3% to 100% and was significantly correlated with vinorelbine clearance (P < .01).,Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16651648/),%,100,122795,DB00386,Alseroxylon
,12839283,distribution half-life,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),min,6.4,122866,DB00386,Alseroxylon
,12839283,elimination half-life,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),min,1014,122867,DB00386,Alseroxylon
,12839283,volume of distribution,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),[l] / [m2],445,122868,DB00386,Alseroxylon
,12839283,total body clearance,"The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553).",Vincristine in childhood leukaemia: no pharmacokinetic rationale for dose reduction in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839283/),[ml] / [m2·min],362,122869,DB00386,Alseroxylon
,15726371,area under the plasma concentration-time curve (AUC),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[h·μg] / [l],566,125229,DB00386,Alseroxylon
,15726371,maximum plasma concentration (c(max)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[μg] / [l],599,125230,DB00386,Alseroxylon
,15726371,elimination half-life (t(1/2)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),h,30.8,125231,DB00386,Alseroxylon
,15726371,clearance,"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],61.8,125232,DB00386,Alseroxylon
,15726371,intercompartmental clearance (Q),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],112,125233,DB00386,Alseroxylon
,15726371,volume of the central compartment (V(1)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,23.3,125234,DB00386,Alseroxylon
,15726371,volume of the peripheral compartment (V(2)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,"1,130",125235,DB00386,Alseroxylon
,23847961,absolute bioavailability,"After transdermal administration, the absolute bioavailability was calculated to be 18.72%.",[Optimization and application of method to determine plasma concentration of brucine]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23847961/),%,18.72,125245,DB00386,Alseroxylon
,3855472,half-life (t 1/2),[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),min,30,126941,DB00386,Alseroxylon
,3855472,terminal phase (t 1/2,[3H]VBL exhibited two phases of elimination: a rapid early phase [half-life (t 1/2) of approximately equal to 30 min] and a prolonged terminal phase (t 1/2 of approximately equal to 17 hr).,Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3855472/),h,17,126942,DB00386,Alseroxylon
,16130744,flow rate,"Samples were eluted with a mobile phase containing methanol-1% diethylamine (pH 7.15) in water (75:25, v/v) and the flow rate of the mobile phase was 0.7 ml/min.",Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130744/),[ml] / [min],0.7,127286,DB00386,Alseroxylon
,12506167,overall response rate,"Four patients (6.9%) had complete responses, and 14 (24.1%) had partial responses, for an overall response rate of 31% (95% CI, 19% to 43%).",Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506167/),%,31,127727,DB00386,Alseroxylon
,12506167,progression-free survival,Median progression-free survival was 17.4 weeks.,Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506167/),weeks,17.4,127728,DB00386,Alseroxylon
,6359081,terminal half-life,Pharmacokinetic studies indicate that vindesine exhibits a triphasic elimination pattern with a terminal half-life of 24.2 hours.,"Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6359081/),h,24.2,128127,DB00386,Alseroxylon
,23956145,trough concentration,"Sirolimus was administered daily by mouth or nasogastric (NG) tube, with doses adjusted to achieve a target trough concentration of 10-15 ng/ml, with weekly intravenous vinblastine (dose escalated 4-6 mg/m(2)/dose according to 3 + 3 phase I design).",Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [ml],10-15,128738,DB00386,Alseroxylon
,23956145,trough concentrations,Dose-adjusted sirolimus trough concentrations were significantly lower in patients receiving drug via NG tube (1.50 ± 0.75 ng/ml/mg vs. 2.25 ± 1.07 ng/ml/mg for oral administration).,Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [mg·ml],1.50,128739,DB00386,Alseroxylon
,23956145,trough concentrations,Dose-adjusted sirolimus trough concentrations were significantly lower in patients receiving drug via NG tube (1.50 ± 0.75 ng/ml/mg vs. 2.25 ± 1.07 ng/ml/mg for oral administration).,Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23956145/),[ng] / [mg·ml],2.25,128740,DB00386,Alseroxylon
,16163538,oral bioavailability,The oral bioavailability in wild-type was 16.0+/-1.4% (mean+/-SE) and was not significantly higher in mdr1a/1b (-/-) mice (17.9+/-0.7%).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,16.0,129278,DB00386,Alseroxylon
,16163538,oral bioavailability,The oral bioavailability in wild-type was 16.0+/-1.4% (mean+/-SE) and was not significantly higher in mdr1a/1b (-/-) mice (17.9+/-0.7%).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,17.9,129279,DB00386,Alseroxylon
,16163538,oral bioavailability,Because RTV increased the AUC of oral VRL by 83% the oral bioavailability was increased to 22.5+/-2.3% (p = 0.016).,The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16163538/),%,22.5,129280,DB00386,Alseroxylon
,2015726,maximal increase,"Twelve milligrams of yohimbine moderately but significantly accelerated supine heart rate (mean maximal increase, 7 +/- 3 beats/min).",The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015726/),[beats] / [min],7,131264,DB00386,Alseroxylon
,3224160,Total clearance,Total clearance was 7.69 +/- 3.53 1.hr-1 for CPH administered alone and 6.76 +/- 1.63 1.hr-1 for CPH administered with vindesin.,Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224160/),[1] / [h],7.69,134288,DB00386,Alseroxylon
,3224160,Total clearance,Total clearance was 7.69 +/- 3.53 1.hr-1 for CPH administered alone and 6.76 +/- 1.63 1.hr-1 for CPH administered with vindesin.,Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224160/),[1] / [h],6.76,134289,DB00386,Alseroxylon
,3224160,Biological half-life,Biological half-life was 4.3 +/- 1.5 hr (CPH alone) and 5.1 +/- 2.2 hr (CPH + VDS).,Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224160/),h,4.3,134290,DB00386,Alseroxylon
,3224160,Biological half-life,Biological half-life was 4.3 +/- 1.5 hr (CPH alone) and 5.1 +/- 2.2 hr (CPH + VDS).,Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224160/),h,5.1,134291,DB00386,Alseroxylon
,12402426,Peak peritoneal concentration,Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml.,[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),[μg] / [ml],40.0,137388,DB00386,Alseroxylon
,12402426,peritoneal concentration at 24 hours,Peak peritoneal concentration was 40.0 +/- 14.5 micrograms/ml and peritoneal concentration at 24 hours after drug administration was 4.3 +/- 3.9 micrograms/ml.,[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),[μg] / [ml],4.3,137389,DB00386,Alseroxylon
,12402426,AUC peritoneal/AUC plasma,"The median pharmacokinetic advantage (AUC peritoneal/AUC plasma) was 515 (range 22-1, 770).",[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination]. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402426/),,515,137390,DB00386,Alseroxylon
,33095287,maximum tolerated dose (MTD),"In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS.","Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33095287/),mg,165,138074,DB00386,Alseroxylon
,1336784,areas under the curve,"In addition, the areas under the curve calculated from 1 hour (beginning of CDDP administration) to 72 hours were 414 ng.hour/mL (standard deviation [SD]: 94) (group NVB alone) and 407.1 ng.hour/mL (SD: 32.9) (group NVB + CDDP).",Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336784/),[h·ng] / [ml],414,141056,DB00386,Alseroxylon
,1336784,areas under the curve,"In addition, the areas under the curve calculated from 1 hour (beginning of CDDP administration) to 72 hours were 414 ng.hour/mL (standard deviation [SD]: 94) (group NVB alone) and 407.1 ng.hour/mL (SD: 32.9) (group NVB + CDDP).",Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1336784/),[h·ng] / [ml],407.1,141057,DB00386,Alseroxylon
,8310715,terminal half-life,"2. In man, the pharmacokinetics of NVB are best characterized by a three-compartment model with a terminal half-life of 42 h and a large volume of distribution (75 l/kg).","Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),h,42,141475,DB00386,Alseroxylon
,8310715,volume of distribution,"2. In man, the pharmacokinetics of NVB are best characterized by a three-compartment model with a terminal half-life of 42 h and a large volume of distribution (75 l/kg).","Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),[l] / [kg],75,141476,DB00386,Alseroxylon
,8310715,total clearance,The total clearance was 1.26 lh-1 kg-1 and about 11% of the dose was eliminated by the kidneys.,"Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310715/),1/[kg·lh],1.26,141477,DB00386,Alseroxylon
,1815520,relative bioavailability,The relative bioavailability of prajmalium bitartrate from the tablet amounted to 112%.,Pharmacokinetics and relative bioavailability of prajmalium bitartrate after single oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815520/),%,112,141834,DB00386,Alseroxylon
,12006542,time required to reach the maximum plasma drug concentration (t(max)),"Our findings indicate that LFM-A13 is quickly absorbed, with the time required to reach the maximum plasma drug concentration (t(max)) being 10-18 min after i.p. administration with nearly complete bioavailability.","In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,10-18,143386,DB00386,Alseroxylon
,12006542,elimination half-life,LFM-A13 had an elimination half-life of 17-32 min after i.p. administration at dose levels of 10-50 mg/kg.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),min,17-32,143387,DB00386,Alseroxylon
,12006542,survival time,LFM-A13 prolonged the median survival time of VPL-treated mice from 37 to 58 days.,"In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006542/),d,37 to 58,143388,DB00386,Alseroxylon
,22102379,flow-rate,The reconstituted solution was injected into an HPLC system and was subjected to reverse-phase HPLC on a 5 µm ODS-3 column at a flow-rate of 0.2 mL/min.,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),[ml] / [min],0.2,144009,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,817.4,144010,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,160.1,144011,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,142.3,144012,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,447.2,144013,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,128.3,144014,DB00386,Alseroxylon
,22102379,m/z,Vinflunine was detected in the single ion monitoring mode using target ions at m/z 817.4/160.1/142.3 for vinflunine and m/z 447.2/128.3/112.1 for gefitinib (internal standard).,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),,112.1,144015,DB00386,Alseroxylon
more,22102379,extraction recovery,The extraction recovery of vinflunine was more than 80%.,A validated LC-MS/MS method for the determination of vinflunine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22102379/),%,80,144016,DB00386,Alseroxylon
,21372831,overall response rate (ORR),"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,45.5,147623,DB00386,Alseroxylon
,21372831,CR rate,"The overall response rate (ORR) was 45.5%, and the CR rate was 27.3%.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),%,27,147624,DB00386,Alseroxylon
,21372831,progression-free survival (PFS) rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,6.5,147625,DB00386,Alseroxylon
,21372831,survival rate,"The 1-year overall survival rate was 45.5%, and the median progression-free survival (PFS) rate was 6.5 [95% confidence interval (95% CI) 3.17-19.02] with a survival rate of 11.5 months (95% CI 6.65-16.36).",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),,11,147626,DB00386,Alseroxylon
,21372831,plasma concentration,The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg·L(-1) after administration of the CCOP regimen (0-168 h).,Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [l],1.7036 to 9.2207,147627,DB00386,Alseroxylon
,21372831,AUC(0-∞),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[mg] / [h·l],910.76,147628,DB00386,Alseroxylon
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147629,DB00386,Alseroxylon
,21372831,CL,"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147630,DB00386,Alseroxylon
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [(m)^2·h],0.043,147631,DB00386,Alseroxylon
,21372831,t(1/2),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),h,68.40,147632,DB00386,Alseroxylon
,21372831,V(d),"The pharmacokinetic parameters AUC(0-∞), CL, t(1/2), and V(d) were 910.76 mg/L·h, 0.043 L·h(-1)·m(-2), 68.40 h, and 3.56 L/m(2), respectively.",Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21372831/),[l] / [m(2],3.56,147633,DB00386,Alseroxylon
,12655441,clearance,"The pharmacokinetics of AVLB were linear, and well characterized by a two-compartment model, with a mean clearance of 26.4 l/h per m(2) and median terminal half-life of 18 h.",Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655441/),[h·l] / [m(2],26.4,147918,DB00386,Alseroxylon
,12655441,terminal half-life,"The pharmacokinetics of AVLB were linear, and well characterized by a two-compartment model, with a mean clearance of 26.4 l/h per m(2) and median terminal half-life of 18 h.",Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12655441/),h,18,147919,DB00386,Alseroxylon
,1607002,terminal half-life,The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1).,Pharmacokinetics of vinorelbine in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),h,44.7,148319,DB00386,Alseroxylon
,1607002,volume of distribution (Vz,The plasma concentration-time curves showed a tri-exponential decay with a long terminal half-life (44.7 h) and a high volume of distribution (Vz = 75.61.kg-1).,Pharmacokinetics of vinorelbine in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),1/[kg],75.61,148320,DB00386,Alseroxylon
,1607002,CL,"The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h).",Pharmacokinetics of vinorelbine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),[l] / [h·kg],1.28,148321,DB00386,Alseroxylon
,1607002,AUC,"The concentrations after the 8th infusion were significantly lower than after the 1st infusion, but without significant modification of CL (1.28 l.h-1.kg-1) or AUC (0.80 mg.l-1.h).",Pharmacokinetics of vinorelbine in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607002/),[h·mg] / [l],0.80,148322,DB00386,Alseroxylon
,14513809,flow rate,Hypersil BDS C18 column was used and the mobile phase consisted of acetonitrile-water at the flow rate of 0.8 mL.min-1.,[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[ml] / [min],0.8,148347,DB00386,Alseroxylon
,14513809,T1/2 alpha,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,8,148348,DB00386,Alseroxylon
,14513809,T1/2 alpha,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,4,148349,DB00386,Alseroxylon
,14513809,T1/2 alpha,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,6.2,148350,DB00386,Alseroxylon
,14513809,T1/2 alpha,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,3.0,148351,DB00386,Alseroxylon
,14513809,T1/2 beta,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,262,148352,DB00386,Alseroxylon
,14513809,T1/2 beta,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,416,148353,DB00386,Alseroxylon
,14513809,T1/2 beta,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,285,148354,DB00386,Alseroxylon
,14513809,T1/2 beta,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),min,342,148355,DB00386,Alseroxylon
,14513809,CL,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[ml] / [min],17,148356,DB00386,Alseroxylon
,14513809,CL,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[ml] / [min],21,148357,DB00386,Alseroxylon
,14513809,CL,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[ml] / [min],1.9,148358,DB00386,Alseroxylon
,14513809,CL,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[ml] / [min],2.8,148359,DB00386,Alseroxylon
,14513809,Vc,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],1.4,148360,DB00386,Alseroxylon
,14513809,Vc,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],1.7,148361,DB00386,Alseroxylon
,14513809,Vc,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],0.24,148362,DB00386,Alseroxylon
,14513809,Vc,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],0.23,148363,DB00386,Alseroxylon
,14513809,Vd,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],6.0,148364,DB00386,Alseroxylon
,14513809,Vd,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],12,148365,DB00386,Alseroxylon
,14513809,Vd,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],0.8,148366,DB00386,Alseroxylon
,14513809,Vd,"Their parameters were as follows: T1/2 alpha were (8 +/- 5), (4 +/- 3), (6.2 +/- 1.7) and (3.0 +/- 0.8) min, T1/2 beta were (262 +/- 125), (416 +/- 131), (285 +/- 50) and (342 +/- 141) min, CL were (17 +/- 4), (21 +/- 12), (1.9 +/- 1.8) and (2.8 +/- 1.1) mL.min-1, Vc were (1.4 +/- 0.5), (1.7 +/- 1.1), (0.24 +/- 0.16) and (0.23 +/- 0.06) L.kg-1, Vd were (6.0 +/- 1.2), (12 +/- 7), (0.8 +/- 0.6) and (1.5 +/- 0.6) L.kg-1, AUC were (57,578 +/- 25,578), (35,240 +/- 15,616), (93,088 +/- 22,375) and (177,712 +/- 120,110) h.microgram.",[Pharmacokinetics of the alkaloids from the processed seeds of Strychnos nux-vomica in rats]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14513809/),[l] / [kg],1.5,148367,DB00386,Alseroxylon
more,34219092,serum half-life,"The pharmacokinetics of rituximab differs substantially among individuals and its serum half-life is approximately more than 500 hours; therefore, the peak concentration increases cumulatively by weekly infusion.",[Optimization of rituximab dosing schedule in R-CHOP therapy for diffuse large B-cell lymphoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34219092/),h,500,148482,DB00386,Alseroxylon
,7888700,CED,The CED of NVB was provisionally decided to be 4.8 mg/kg based on the comparison of AUC values at 24-infinity h between human patients and nude mice.,Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7888700/),[mg] / [kg],4.8,149596,DB00386,Alseroxylon
,889590,t1/2,"The data were consistent with a three-compartment open model system with the following values, alpha phase: t1/2=3.90+/-1.46 min; Vc=16.8+/-7.1 liters.",Pharmacokinetics and metabolism of vinblastine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),min,3.90,150133,DB00386,Alseroxylon
,889590,Vc,"The data were consistent with a three-compartment open model system with the following values, alpha phase: t1/2=3.90+/-1.46 min; Vc=16.8+/-7.1 liters.",Pharmacokinetics and metabolism of vinblastine in humans. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),l,16.8,150134,DB00386,Alseroxylon
,889590,t1/2,beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters.,Pharmacokinetics and metabolism of vinblastine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),min,53.0,150135,DB00386,Alseroxylon
,889590,Vbeta,beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters.,Pharmacokinetics and metabolism of vinblastine in humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),l,79.0,150136,DB00386,Alseroxylon
,889590,t1/2,beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters.,Pharmacokinetics and metabolism of vinblastine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),min,1173.0,150137,DB00386,Alseroxylon
,889590,Vgamma,beta phase:t1/2=53.0+/-13.0 min; Vbeta=79.0+/-52.0 liters; gamma phase:t1/2=1173.0+/-65.0 min; Vgamma=1656.0+/-717.0 liters.,Pharmacokinetics and metabolism of vinblastine in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/889590/),l,1656.0,150138,DB00386,Alseroxylon
,2549204,overall response rate,"In the 24-hour arm, two patients achieved a partial remission, resulting in an overall response rate of 10%.",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,10,151311,DB00386,Alseroxylon
,2549204,overall response rate,"In the 5-day schedule, 16 patients had a partial response and one had a complete remission, producing an overall response rate of 89%, which was significantly superior to that in the 24-hour arm (P less than .001).",A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,89,151312,DB00386,Alseroxylon
,2549204,duration of remission,The median duration of remission to etoposide in the 5-day arm was 4.5 months.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),month,4.5,151313,DB00386,Alseroxylon
excess,2549204,response rate,The response rate to single-agent etoposide using an efficacious schedule in extensive small-cell lung cancer has been determined to be in excess of 80%.,A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2549204/),%,80,151314,DB00386,Alseroxylon
,20199976,tumor response rate,Treatment of 53 patients at this recommended dose demonstrated a tumor response rate of 32.1% in the intent-to-treat population; disease control was achieved in 79.2% of the patients.,Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20199976/),%,32.1,152225,DB00386,Alseroxylon
,16912527,response rate,The response rate was 25.0% (3 PR/12).,[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16912527/),%,25.0,152993,DB00386,Alseroxylon
,23802438,encapsulation capacities,Ethosome was found to be a more efficient delivery carrier with high encapsulation capacities (79.5% +/- 1.8%) and nanometric size (180.7 +/- 1.5 nm).,Ethosomes as delivery system for transdermal administration of vinpocetine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802438/),%,79.5,153516,DB00386,Alseroxylon
,23802438,transdermal fluxes,"The vinpocetine transdermal fluxes from ethosome gel (3.56 +/- 0.13 microg/cm2/h) were 6.72 and 3.10 times higher than that of vinpocetine gel solution and vinpocetine aueous solution, respectively.",Ethosomes as delivery system for transdermal administration of vinpocetine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802438/),[μg] / [cm2·h],3.56,153517,DB00386,Alseroxylon
,6825110,plasma half-life,"In four patients who achieved partial remission, the average plasma half-life of VLB during the terminal phase was 29.4 +/- 14.6 days, with a total clearance of 36 +/- 8 ml/kg/hr, and a steady-state apparent volume of distribution of 28.1 +/- 8.5 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),d,29.4,154417,DB00386,Alseroxylon
,6825110,total clearance,"In four patients who achieved partial remission, the average plasma half-life of VLB during the terminal phase was 29.4 +/- 14.6 days, with a total clearance of 36 +/- 8 ml/kg/hr, and a steady-state apparent volume of distribution of 28.1 +/- 8.5 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),[ml] / [h·kg],36,154418,DB00386,Alseroxylon
,6825110,steady-state apparent volume of distribution,"In four patients who achieved partial remission, the average plasma half-life of VLB during the terminal phase was 29.4 +/- 14.6 days, with a total clearance of 36 +/- 8 ml/kg/hr, and a steady-state apparent volume of distribution of 28.1 +/- 8.5 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),[l] / [kg],28.1,154419,DB00386,Alseroxylon
,6825110,plasma half-life,"However, in three patients whose disease merely stabilized, the plasma half-life was 6.4 +/- 1.6 days, the total clearance was 137 +/- 2.9 ml/kg/hr, and the volume of distribution was 33.0 +/- 11.6 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),d,6.4,154420,DB00386,Alseroxylon
,6825110,total clearance,"However, in three patients whose disease merely stabilized, the plasma half-life was 6.4 +/- 1.6 days, the total clearance was 137 +/- 2.9 ml/kg/hr, and the volume of distribution was 33.0 +/- 11.6 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),[ml] / [h·kg],137,154421,DB00386,Alseroxylon
,6825110,volume of distribution,"However, in three patients whose disease merely stabilized, the plasma half-life was 6.4 +/- 1.6 days, the total clearance was 137 +/- 2.9 ml/kg/hr, and the volume of distribution was 33.0 +/- 11.6 liters/kg.",Clinical pharmacokinetics of vinblastine by continuous intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6825110/),[l] / [kg],33.0,154422,DB00386,Alseroxylon
,8137220,survival time,"Median duration of CR was 10 months (range, 4-27 months), and median survival time for patients achieving complete response was 30.5 months (range, 28-33 months).","Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8137220/),month,30.5,154539,DB00386,Alseroxylon
,582791,T1/2 alpha,There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h.,Pharmacokinetics of vinpocetine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),h,0.136,154671,DB00386,Alseroxylon
,582791,T1/2 beta,There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h.,Pharmacokinetics of vinpocetine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),h,4.83,154672,DB00386,Alseroxylon
,582791,Vdss,The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins.,Pharmacokinetics of vinpocetine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),[l] / [kg],2.1,154673,DB00386,Alseroxylon
,582791,clearance rate of elimination,The clearance rate of elimination was 0.366 l/h/kg.,Pharmacokinetics of vinpocetine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),[l] / [h·kg],0.366,154674,DB00386,Alseroxylon
,582791,maximum plasma concentration,Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml.,Pharmacokinetics of vinpocetine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),[ng] / [ml],20,154675,DB00386,Alseroxylon
,582791,bioavailability,The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9%.,Pharmacokinetics of vinpocetine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582791/),%,56.6,154676,DB00386,Alseroxylon
,1618961,flow-rate,"This assay was performed using a LiChrosorb Si 60 column and a mobile phase consisting of 0.02 M sodium acetate (pH 5)-methanol (5:95, v/v) at a flow-rate of 1 ml/min.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),[ml] / [min],1,155084,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,91.8,155085,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,45.3,155086,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,17.8,155087,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,3.8,155088,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,1.4,155089,DB00386,Alseroxylon
,1618961,extraction yields,"The extraction yields of YO, 10-OHYO and 11-OHYO from plasma were 91.8, 45.3 and 17.8%, respectively, and their respective within-day reproducibilities were 3.8, 1.4 and 5.9%.",Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1618961/),%,5.9,155090,DB00386,Alseroxylon
,2820763,IC50,"In vitro, tabernanthine inhibited specific flunitrazepam binding in a competitive manner with an affinity (IC50 150 microM) in the same range as harmane.",Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820763/),μM,150,155188,DB00386,Alseroxylon
,2820763,half-life,"In vivo, the time course of tremorigenic activity was related to the tabernanthine concentration in brain (half-life = 2 h).",Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820763/),h,2,155189,DB00386,Alseroxylon
,19837906,clearance,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),[l] / [h],56.1,155334,DB00386,Alseroxylon
,19837906,steady-state volume of distribution,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),l,26.1,155335,DB00386,Alseroxylon
,19837906,steady-state volume of distribution,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),min,6,155336,DB00386,Alseroxylon
,19837906,distribution,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),l,26.1,155337,DB00386,Alseroxylon
,19837906,distribution,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),min,6,155338,DB00386,Alseroxylon
,19837906,elimination half-lives,"Population estimates for the clearance, steady-state volume of distribution, distribution, and elimination half-lives were 56.1 L/h, 26.1 L, 6 minutes, and 26 minutes, respectively.",Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19837906/),min,26,155339,DB00386,Alseroxylon
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,2.7,155899,DB00386,Alseroxylon
,3152911,First-phase elimination half-lives (t1/2(alpha)),First-phase elimination half-lives (t1/2(alpha)) of MTX and 7-hydroxy-methotrexate (7-OH-MTX) after 21 infusions were 2.7 +/- 0.4 h and 6.5 +/- 1.8 h (mean +/- SD).,High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,6.5,155900,DB00386,Alseroxylon
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,4.2,155901,DB00386,Alseroxylon
,3152911,first-phase elimination half-lives (t1/2(alpha],"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,9.9,155902,DB00386,Alseroxylon
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,43,155903,DB00386,Alseroxylon
,3152911,second-phase elimination half-lives (t1/2(beta)),"In one course (4.5%) there was delayed systemic MTX elimination, with first-phase elimination half-lives (t1/2(alpha] for MTX and 7-OH-MTX of 4.2 and 9.9 h, respectively, and second-phase elimination half-lives (t1/2(beta)) of 43 and 58 h.",High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3152911/),h,58,155904,DB00386,Alseroxylon
,3494841,terminal plasma half-lives,"Although the plasma pharmacokinetics were similar between LY256787 and DAVLB (terminal plasma half-lives of 62 and 83 hr, respectively), substantial differences in the volumes of distribution and initial redistribution-elimination phases were found.",Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3494841/),h,62,156335,DB00386,Alseroxylon
,3494841,terminal plasma half-lives,"Although the plasma pharmacokinetics were similar between LY256787 and DAVLB (terminal plasma half-lives of 62 and 83 hr, respectively), substantial differences in the volumes of distribution and initial redistribution-elimination phases were found.",Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3494841/),h,83,156336,DB00386,Alseroxylon
,3494841,terminal half-lives,No sex-related differences in the plasma pharmacokinetics were found (terminal half-lives of 90 and 84 hr in males and females).,Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3494841/),h,90,156337,DB00386,Alseroxylon
,3494841,terminal half-lives,No sex-related differences in the plasma pharmacokinetics were found (terminal half-lives of 90 and 84 hr in males and females).,Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3494841/),h,84,156338,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,28.0,156443,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,5.1,156444,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,9.9,156445,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,2.8,156446,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22. 9,156447,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,14.7,156448,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,22.3,156449,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,11.1,156450,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,39.6,156451,DB00386,Alseroxylon
,10227700,net efflux (B-A/A-B,"While both apical-to-basal (A-B) and basal-to-apical (B-A) fluxes of all CYP3A/P-gp substrates tested were increased in the presence of GJ, the resulting net efflux (B-A/A-B) was in all cases significantly greater with GJ than control (Vin, 28.0 vs. 5.1; CsA, 9.9 vs. 2.8; Dig, 22. 9 vs. 14.7, Fex, 22.3 vs. 11.1, Los, 39.6 vs. 26).",Grapefruit juice activates P-glycoprotein-mediated drug transport. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10227700/),,26,156452,DB00386,Alseroxylon
,630051,Sensitivity,Sensitivity is 30 pg ml plasma.,Determination of vincamine in plasma by selected ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/630051/),ml·pg·plasma,30,159057,DB00386,Alseroxylon
less,17719191,cumulative distribution,"The VRL-loaded LMs had a particle size of 180.5+/-35.2nm with a 90% cumulative distribution less than 244.1nm, while the drug entrapment efficiency was 96.8%, and it remained stable for 12 months at 6+/-2 degrees C.","A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17719191/),n,244,159067,DB00386,Alseroxylon
,17719191,entrapment efficiency,"The VRL-loaded LMs had a particle size of 180.5+/-35.2nm with a 90% cumulative distribution less than 244.1nm, while the drug entrapment efficiency was 96.8%, and it remained stable for 12 months at 6+/-2 degrees C.","A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17719191/),%,96.8,159068,DB00386,Alseroxylon
,34111732,flow rate,"A gradient elution of mobile phase A (methanol-0.2 % formic acid in water, 20:80 v/v) and mobile phase B (methanol-0.2 % formic acid in water, 80:20 v/v) was used with a flow rate of 0.4 mL/min and a total run time of 5 min.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),[ml] / [min],0.4,159313,DB00386,Alseroxylon
,34111732,total run time,"A gradient elution of mobile phase A (methanol-0.2 % formic acid in water, 20:80 v/v) and mobile phase B (methanol-0.2 % formic acid in water, 80:20 v/v) was used with a flow rate of 0.4 mL/min and a total run time of 5 min.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),min,5,159314,DB00386,Alseroxylon
,34111732,extraction recovery,"The extraction recovery of VCR from DBS paper was 35.3-39.4 % and 10.4-13.4 % for M1, with no carryover observed for both analytes.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),%,35.3-39.4,159315,DB00386,Alseroxylon
,34111732,extraction recovery,"The extraction recovery of VCR from DBS paper was 35.3-39.4 % and 10.4-13.4 % for M1, with no carryover observed for both analytes.",Simultaneous quantification of vincristine and its major M1 metabolite from dried blood spot samples of Kenyan pediatric cancer patients by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34111732/),%,10.4-13.4,159316,DB00386,Alseroxylon
,10602901,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,40,159547,DB00386,Alseroxylon
,10602901,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,50,159548,DB00386,Alseroxylon
,10602901,overall response rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,36.5,159549,DB00386,Alseroxylon
,10602901,CR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,4.8,159550,DB00386,Alseroxylon
,10602901,PR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),%,31.7,159551,DB00386,Alseroxylon
,10602901,response duration,The median response duration was 7.0 months (range 2-13 months).,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10602901/),month,7.0,159552,DB00386,Alseroxylon
,16111453,elimination half-life,Oral vinorelbine is rapidly absorbed (1.5-3 hours) with an elimination half-life of approximately 40 hours.,Oral versus intravenous vinorelbine: clinical safety profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),h,40,161157,DB00386,Alseroxylon
,16111453,absolute bioavailability,"It shows a low level of binding to plasma proteins (13%), is highly bound to platelets (78%) and has a hepatic metabolism and an absolute bioavailability of 40% with a moderate and similar interpatient variability for the two forms.",Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161158,DB00386,Alseroxylon
,16111453,absolute bioavailability,The absolute bioavailability is close to 38% in elderly whereas it is close to 40% in younger patients.,Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,38,161159,DB00386,Alseroxylon
,16111453,absolute bioavailability,The absolute bioavailability is close to 38% in elderly whereas it is close to 40% in younger patients.,Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161160,DB00386,Alseroxylon
,16111453,absolute bioavailability,"As compared to the intravenous drug, oral vinorelbine demonstrated linear pharmacokinetics as well an absolute bioavailability of approximately 40%, and a reliable dose-correspondence of 80 mg/m2 oral form --> 30 mg/m2 i.v. and 60 mg/m2 oral --> 25 mg/m2 i.v.",Oral versus intravenous vinorelbine: clinical safety profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16111453/),%,40,161161,DB00386,Alseroxylon
,30689002,CL,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],3.58,161752,DB00386,Alseroxylon
,30689002,Vmale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,32.2,161753,DB00386,Alseroxylon
,30689002,Vfemale,"The population PK parameters for CP were: CL = 3.58 L/h, Vmale = 32.2 L, and Vfemale = 28.7 L.",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,28.7,161754,DB00386,Alseroxylon
,30689002,CL,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],51.1,161755,DB00386,Alseroxylon
,30689002,Q,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),[l] / [h],49.6,161756,DB00386,Alseroxylon
,30689002,V1,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161757,DB00386,Alseroxylon
,30689002,V2,"The population PK parameters for DOXO obtained for the structural model were: CL = 51.1 L/h, Q = 49.6 L/h, V1 = 29.4 L, V2 = 1,130 L (clearances: CL, Q, volumes of distribution: V1, V2).",Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,"1,130",161758,DB00386,Alseroxylon
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,29.4,161759,DB00386,Alseroxylon
,30689002,V1,VCR increases DOXO V1 from 29.4 L to 57.5 L (p = 0.02).,Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30689002/),l,57.5,161760,DB00386,Alseroxylon
,3476358,area under the curve (AUC) 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [ml],0.06-0.37,162790,DB00386,Alseroxylon
,3476358,AUC 0-24 h,A large variability was observed with respect to (1) the plasma area under the curve (AUC) 0-24 h (range: 0.06-0.37 nmol X h/ml); (2) the white cell AUC 0-24 h (range: 0-441 nmol X h/10(9) cells); and (3) the 1 h bone marrow concentration (range: 0-27 nmol/10(9) cells).,Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3476358/),[h·nM] / [10(9)·cells],0-441,162791,DB00386,Alseroxylon
,32222808,volume of distribution,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [kg],57.3 to 95.6,163246,DB00386,Alseroxylon
,32222808,clearance,"Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively.",Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),[ml] / [d·kg],12.7 to 18.2,163247,DB00386,Alseroxylon
,32222808,elimination half-life,acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week).,Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32222808/),week,1,163248,DB00386,Alseroxylon
,580205,invasion half-life,After GC analysis of the vincamine-serum concentration the following pharmacokinetic profile could be established: The substance appears in the streaming blood with an invasion half-life of 53 min.,[Pharmacokinetics of multilayer vincamine dragees. Study of normal subjects]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580205/),min,53,163374,DB00386,Alseroxylon
,580205,apparent elimination half-life,The apparent elimination half-life caused by the sustained release from of the multi-layer dragee was 9.13 h.,[Pharmacokinetics of multilayer vincamine dragees. Study of normal subjects]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/580205/),h,9.13,163375,DB00386,Alseroxylon
,580205,serum concentration,24 h after application there was still a mean serum concentration of 5.74 ng/ml to be detected.,[Pharmacokinetics of multilayer vincamine dragees. Study of normal subjects]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/580205/),[ng] / [ml],5.74,163376,DB00386,Alseroxylon
,8995494,time of maximum plasma concentration (Tmax),"The mean time of maximum plasma concentration (Tmax) increased from 1.3 +/- 1.6 h in the fasting state to 2.5 +/- 1.6 h in the fed state, although this difference was not statistically significant.",The effects of food and divided dosing on the bioavailability of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995494/),h,1.3,164461,DB00386,Alseroxylon
,8995494,time of maximum plasma concentration (Tmax),"The mean time of maximum plasma concentration (Tmax) increased from 1.3 +/- 1.6 h in the fasting state to 2.5 +/- 1.6 h in the fed state, although this difference was not statistically significant.",The effects of food and divided dosing on the bioavailability of oral vinorelbine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8995494/),h,2.5,164462,DB00386,Alseroxylon
,33684722,flow rate,Separation of vincristine and the internal standard [2H3]-vincristine was achieved on an Accucore aQ column with a gradient mobile phase delivered at a flow rate of 0.4 mL/min and a run time of 2.2 min.,Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),[ml] / [min],0.4,164756,DB00386,Alseroxylon
,33684722,run time,Separation of vincristine and the internal standard [2H3]-vincristine was achieved on an Accucore aQ column with a gradient mobile phase delivered at a flow rate of 0.4 mL/min and a run time of 2.2 min.,Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),min,2.2,164757,DB00386,Alseroxylon
,33684722,matrix effect,"The matrix effect and extraction recovery for vincristine were ranging 108-110% and 88.4-107%, respectively.",Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),%,108-110,164758,DB00386,Alseroxylon
,33684722,extraction recovery,"The matrix effect and extraction recovery for vincristine were ranging 108-110% and 88.4-107%, respectively.",Rapid quantification of vincristine in mouse plasma using ESI-LC-MS/MS: Application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33684722/),%,88.4-107,164759,DB00386,Alseroxylon
,2376823,detection limit,"The analytical recoveries (99.3-110.4%), reproducibilities (within-run, C.V. less than 2.27%), and detection limit (0.80 ng/ml, S/N = 3) indicate that this system is suited for determination of Yoh.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),[ng] / [ml],0.80,164916,DB00386,Alseroxylon
,2376823,S/N,"The analytical recoveries (99.3-110.4%), reproducibilities (within-run, C.V. less than 2.27%), and detection limit (0.80 ng/ml, S/N = 3) indicate that this system is suited for determination of Yoh.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),,3,164917,DB00386,Alseroxylon
,2376823,maximal serum concentration,"The average of the maximal serum concentration and the area under the curve (AUC) from 0 to 4 h were 10.3 +/- 0.88 ng/ml and 19.70 +/- 0.87 ng.h.ml-1, respectively.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),[ng] / [ml],10.3,164918,DB00386,Alseroxylon
,2376823,area under the curve (AUC) from 0 to 4 h,"The average of the maximal serum concentration and the area under the curve (AUC) from 0 to 4 h were 10.3 +/- 0.88 ng/ml and 19.70 +/- 0.87 ng.h.ml-1, respectively.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),[h·ng] / [ml],19.70,164919,DB00386,Alseroxylon
,2376823,elimination rate constant (Kc1),"The elimination rate constant (Kc1) was 0.52 +/- 0.03 h, and biological half-life (t1/2el) was 1.32 +/- 0.12 h.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),h,0.52,164920,DB00386,Alseroxylon
,2376823,biological half-life (t1/2el),"The elimination rate constant (Kc1) was 0.52 +/- 0.03 h, and biological half-life (t1/2el) was 1.32 +/- 0.12 h.",[Determination of yohimbine in serum by high performance liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376823/),h,1.32,164921,DB00386,Alseroxylon
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00386,Alseroxylon
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00386,Alseroxylon
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00386,Alseroxylon
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],4 to 8,167513,DB00386,Alseroxylon
,12510869,ED50,"Aminophylline (50-100 mg/kg) and strychnine (0.125-0.5 mg/kg) significantly raised the ED50 values of LY 300164 against maximal electroshock in mice, from 4 to 8 mg/kg (aminophylline 100 mg/kg) and from 3.6 to 11.5 mg/kg (strychnine 0.5 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],3.6 to 11.5,167514,DB00386,Alseroxylon
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5,167515,DB00386,Alseroxylon
,12510869,ED50,"Also, aminophylline (25-50 mg/kg) and strychnine (0.125-0.25 mg/kg) increased the ED50 value of lamotrigine in this test, for instance from 5.5 to 8.0 mg/kg (aminophylline 50 mg/kg) and from 5.2 to 8.9 mg/kg (strychnine 0.25 mg/kg).","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],5.2 to 8.9,167516,DB00386,Alseroxylon
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],79.9,167517,DB00386,Alseroxylon
,12510869,ED50S,"Moreover, the ED50S values of aminophylline and strychnine for the reduction of the anticonvulsant effect of LY 300164 (7 mg/kg, the dose equal to its ED97 value against maximal electroshock) were 79.9 and 0.2 mg/kg, respectively.","Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167518,DB00386,Alseroxylon
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],40.9,167519,DB00386,Alseroxylon
,12510869,ED50,The respective ED50 values for the inhibition of the antiseizure action of lamotrigine were 40.9 and 0.2 mg/kg.,"Influence of several convulsants on the protective activity of a non-competitive AMPA/kainate antagonist, LY 300164, and lamotrigine against maximal electroshock in mice. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12510869/),[mg] / [kg],0.2,167520,DB00386,Alseroxylon
,25279818,half-life,"The drug was slowly eliminated, with mean half-life estimates of 28-49 hours across dose groups.","Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25279818/),h,28-49,167639,DB00386,Alseroxylon
,25279818,Apparent volume of distribution,Apparent volume of distribution was high (mean 1417-3086 L across dose groups).,"Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25279818/),l,1417-3086,167640,DB00386,Alseroxylon
,16001165,Total body clearance,Total body clearance calculated from the intravenous dose was 43.65 L/h (+/-10.9) and the terminal half-life was estimated to be 49 h.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),[l] / [h],43.65,169108,DB00386,Alseroxylon
,16001165,terminal half-life,Total body clearance calculated from the intravenous dose was 43.65 L/h (+/-10.9) and the terminal half-life was estimated to be 49 h.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),h,49,169109,DB00386,Alseroxylon
,16001165,absolute bioavailability,"Using complete data from the remaining 19 subjects, the mean absolute bioavailability of the oral dosage formulation of vinorelbine was calculated to be 33% (+/-18%).",The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),%,33,169110,DB00386,Alseroxylon
,16001165,oral bioavailability,In conclusion we have characterized the pharmacokinetics of both orally administered and intravenous vinorelbine over 7 days after administration and have determined the mean oral bioavailability of this oral formulation to be 33%.,The absolute bioavailability of oral vinorelbine in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001165/),%,33,169111,DB00386,Alseroxylon
,4085521,half-lives,Mean plasma concentrations of 3H reached a peak (1900 ng equiv./ml) at 1 h after dosing and declined biphasically with half-lives of 5 h and 11 h which were similar to half-lives for urinary excretion of 3H.,The metabolic fate of 11-bromo[15-3H]vincamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085521/),h,5,169363,DB00386,Alseroxylon
,4085521,half-lives,Mean plasma concentrations of 3H reached a peak (1900 ng equiv./ml) at 1 h after dosing and declined biphasically with half-lives of 5 h and 11 h which were similar to half-lives for urinary excretion of 3H.,The metabolic fate of 11-bromo[15-3H]vincamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085521/),h,11,169364,DB00386,Alseroxylon
,4085521,half-lives,Mean plasma concentrations of 11-bromovincamine reached a peak (620 ng/ml) at 0.75 h and declined biphasically with half-lives of about 1 h and 5 h.,The metabolic fate of 11-bromo[15-3H]vincamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085521/),h,1,169365,DB00386,Alseroxylon
,4085521,half-lives,Mean plasma concentrations of 11-bromovincamine reached a peak (620 ng/ml) at 0.75 h and declined biphasically with half-lives of about 1 h and 5 h.,The metabolic fate of 11-bromo[15-3H]vincamine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4085521/),h,5,169366,DB00386,Alseroxylon
,7735488,sensitivity,"This method used a new internal standard, teniposide, that permitted a good compromise between sensitivity and retention times (10.6 and 15.5 min for teniposide and vinorelbine, respectively).",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),min,10.6,169602,DB00386,Alseroxylon
,7735488,retention times,"This method used a new internal standard, teniposide, that permitted a good compromise between sensitivity and retention times (10.6 and 15.5 min for teniposide and vinorelbine, respectively).",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),min,15.5,169603,DB00386,Alseroxylon
,7735488,extraction efficiency,The extraction efficiency was approximately 80% for both vinorelbine and the internal standard.,Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),%,80,169604,DB00386,Alseroxylon
,7735488,limit of detection,"Using coulometric detection, the limit of detection in plasma (400 microliters) was 1 ng/ml.",Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7735488/),[ng] / [ml],1,169605,DB00386,Alseroxylon
,3412496,t1/2 alpha,The serum concentration-time profile of yohimbine was biphasic with a rapid distribution phase (t1/2 alpha = 0.048 h) followed by a very slow elimination phase t1/2 beta = 16.3 h).,The pharmacokinetic properties of yohimbine in the conscious rat. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3412496/),h,0.048,170201,DB00386,Alseroxylon
,3412496,elimination phase t1/2 beta,The serum concentration-time profile of yohimbine was biphasic with a rapid distribution phase (t1/2 alpha = 0.048 h) followed by a very slow elimination phase t1/2 beta = 16.3 h).,The pharmacokinetic properties of yohimbine in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3412496/),h,16.3,170202,DB00386,Alseroxylon
,3412496,clearance,"The clearance of yohimbine was 11 ml/h.kg-1, and the volume of distribution was 259 ml/kg.",The pharmacokinetic properties of yohimbine in the conscious rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3412496/),[ml] / [h·kg],11,170203,DB00386,Alseroxylon
,3412496,volume of distribution,"The clearance of yohimbine was 11 ml/h.kg-1, and the volume of distribution was 259 ml/kg.",The pharmacokinetic properties of yohimbine in the conscious rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3412496/),[ml] / [kg],259,170204,DB00386,Alseroxylon
,3412496,t1/2 beta,"Yohimbine entered the brain rapidly (5,000 ng/g at 5 min after 1 mg/kg, i.v.) and disappeared from brain with a t1/2 beta of 7.7 h.",The pharmacokinetic properties of yohimbine in the conscious rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3412496/),h,7.7,170205,DB00386,Alseroxylon
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171231,DB00386,Alseroxylon
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171232,DB00386,Alseroxylon
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171233,DB00386,Alseroxylon
,7307229,half-lives,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171234,DB00386,Alseroxylon
,7307229,alpha,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171235,DB00386,Alseroxylon
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171236,DB00386,Alseroxylon
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171237,DB00386,Alseroxylon
,7307229,beta,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171238,DB00386,Alseroxylon
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,2.6,171239,DB00386,Alseroxylon
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,41,171240,DB00386,Alseroxylon
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min,"1,531",171241,DB00386,Alseroxylon
,7307229,gamma,"The half-lives of the triphasic decay curves alpha, beta, and gamma were 2.6, 41, and 1,531 min (25.5 h), respectively.",Pharmacokinetics of vincristine sulfate in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171242,DB00386,Alseroxylon
,7307229,apparent volume of the central compartment,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,3.25,171243,DB00386,Alseroxylon
,7307229,volume of distribution per,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,215.9,171244,DB00386,Alseroxylon
,7307229,body surface area at steady state,"The mean apparent volume of the central compartment was 3.25 l, and the the volume of distribution per 1.73 m2 body surface area at steady state was 215.9 l.",Pharmacokinetics of vincristine sulfate in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),l,215.9,171245,DB00386,Alseroxylon
,7307229,k12,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),1/[min],0.088,171246,DB00386,Alseroxylon
,7307229,k13,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.121,171247,DB00386,Alseroxylon
,7307229,k21,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.028,171248,DB00386,Alseroxylon
,7307229,k31,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.0026,171249,DB00386,Alseroxylon
,7307229,k10,"In a three-compartment open model, the first-order distribution and elimination rate constants (min-1) of vincristine were as follows: k12, 0.088; k13, 0.121; k21, 0.028; k31, 0.0026; k10, 0.045.",Pharmacokinetics of vincristine sulfate in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),,0.045,171250,DB00386,Alseroxylon
,7307229,plasma clearance,"The plasma clearance was 146.2 ml/min per 1.73 m2, while the AUC0 infinity was 27,816 nM . min.",Pharmacokinetics of vincristine sulfate in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),[ml] / [1.73·m2·min],146.2,171251,DB00386,Alseroxylon
,7307229,AUC0 infinity,"The plasma clearance was 146.2 ml/min per 1.73 m2, while the AUC0 infinity was 27,816 nM . min.",Pharmacokinetics of vincristine sulfate in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),min·nM,"27,816",171252,DB00386,Alseroxylon
,7307229,biological half-life,"The low elimination rate constant from poorly perfused tissues to blood plasma (k31), a large apparent volume of distribution, and a long biological half-life (25.5 h) indicate avid tissue binding from which a slow release of the drug from the body tissues occurs.",Pharmacokinetics of vincristine sulfate in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7307229/),h,25.5,171253,DB00386,Alseroxylon
,22633624,overall response rate (ORR),"In rhabdomyosarcoma (RMS) (n=50), the best overall response rate (ORR) was 36% with four complete (8%) and 14 partial responses (28%).",Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma--a report from the Société Française des Cancers et leucémies de l'Enfant et de l'adolescent (SFCE). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22633624/),%,36,171487,DB00386,Alseroxylon
,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],2,173364,DB00386,Alseroxylon
less,17273824,plasma peak concentration,The plasma peak concentration of Tet was about 2 micromol/L and not less than 1 micromol/L until 18 h following Tet administration (i.p.) at 30 mg/kg.,Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17273824/),[μM] / [l],1,173365,DB00386,Alseroxylon
,9626924,V1,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),l,21,173478,DB00386,Alseroxylon
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),1/[h],0.04,173479,DB00386,Alseroxylon
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),[l] / [h],57,173480,DB00386,Alseroxylon
,9626924,t1/2gamma,"The population mean values (CV%) of V1, k10, k12, k21, k13, k31, CL, t1/2gamma were respectively 21 l (55%), 3.2 h(-1) (29%), 7.7 h(-1) (74%), 1.3 h(-1) (67%), 4.7 h(-1) (53%), 0.04 h(-1) (20%), 57 l x h(-1) (31%) and 43 h (36%).",Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626924/),h,43,173481,DB00386,Alseroxylon
,21665557,flow rate,"Chromatographic separation of VCR and IS was achieved by a Dikma Dimonsil C₁₈ column (200 mm×4.6 mm) with the mobile phase consisting of 0.02 M sodium dihydrogen phosphate-methanol (36:64, v/v, pH=4.7) at a flow rate of 1.0 mL/min.",An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),[ml] / [min],1.0,173582,DB00386,Alseroxylon
over,21665557,method,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,83,173583,DB00386,Alseroxylon
over,21665557,recoveries,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,83,173584,DB00386,Alseroxylon
,21665557,extraction recoveries,The average method recoveries for vincristine from spiked plasma at all QC levels were over 83%; and extraction recoveries were between 66 and 70%.,An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA-PEG nanoparticle formulations after injection to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21665557/),%,66 and 70,173585,DB00386,Alseroxylon
,4010386,APC,"Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6% bound to erythrocytes.",Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),,2.05,173977,DB00386,Alseroxylon
,4010386,pKa,"Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6% bound to erythrocytes.",Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),,6.17,173978,DB00386,Alseroxylon
,4010386,terminal half-life,"The terminal half-life is about 1 hour, the apparent volume of distribution 2.9 L/kg, and the total clearance is about 33.3 ml/min/kg.",Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),h,1,173979,DB00386,Alseroxylon
,4010386,apparent volume of distribution,"The terminal half-life is about 1 hour, the apparent volume of distribution 2.9 L/kg, and the total clearance is about 33.3 ml/min/kg.",Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),[l] / [kg],2.9,173980,DB00386,Alseroxylon
,4010386,total clearance,"The terminal half-life is about 1 hour, the apparent volume of distribution 2.9 L/kg, and the total clearance is about 33.3 ml/min/kg.",Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),[ml] / [kg·min],33.3,173981,DB00386,Alseroxylon
,4010386,therapeutic steady state concentration,A therapeutic steady state concentration for effectiveness in gerbils has been estimated to be 0.02 mcg/ml.,Biopharmaceutic and pharmacokinetic aspects of vincamine HCl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010386/),[mcg] / [ml],0.02,173982,DB00386,Alseroxylon
,1493849,half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),min,0.4 and 18,174457,DB00386,Alseroxylon
,1493849,elimination half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,0.25 and 2.5,174458,DB00386,Alseroxylon
,1493849,volume of distribution (Vss),"The volume of distribution (Vss) was 74 l, (range 26 to 127 l).",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),l,74,174459,DB00386,Alseroxylon
,1493849,Total plasma clearance,"Total plasma clearance was 117 l.h-1, which exceeds the hepatic plasma flow.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),[l] / [h],117,174460,DB00386,Alseroxylon
,1493849,half life,"The data also suggested the existence of a slower elimination phase, with a half life of 13 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,13,174461,DB00386,Alseroxylon
,21519841,CL,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],24.9,174812,DB00386,Alseroxylon
,21519841,V1,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,8.48,174813,DB00386,Alseroxylon
,21519841,Q2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],50.7,174814,DB00386,Alseroxylon
,21519841,V2,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,"1,320",174815,DB00386,Alseroxylon
,21519841,Q3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],66.1,174816,DB00386,Alseroxylon
,21519841,V3,"The final parameter estimates were as follows: CL = 24.9 L/h, V1 = 8.48 L, Q2 = 50.7 L/h, V2 = 1,320 L, Q3 = 66.1 L/h, and V3 = 62.4 L (Qi and Vi denote inter-compartmental clearance and peripheral volume of distribution, respectively), normalized for a 70-kg patient according to BW allometric scaling (CL is normalized for a 250,000 platelet count).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,62.4,174817,DB00386,Alseroxylon
,21519841,CL,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),[l] / [h],27.7,174818,DB00386,Alseroxylon
,21519841,V,"The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),l,357,174819,DB00386,Alseroxylon
,21519841,"absorption constant, ka","The population pharmacokinetic parameters were CL = 27.7 L/h, V = 357 L, and the absorption constant, ka = 0.44 h(-1).",Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21519841/),1/[h],0.44,174820,DB00386,Alseroxylon
,10518192,concentration,"The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1).",Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518192/),[ng] / [ml],4.8,175223,DB00386,Alseroxylon
,10518192,concentration,"The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1).",Vinblastine pharmacokinetics in patients with non-small cell lung cancer given cisplatin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10518192/),[ng] / [ml],4.9,175224,DB00386,Alseroxylon
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],289,175451,DB00386,Alseroxylon
,8547077,maximum rhIL-3 serum concentration,Following s.c. injection on cycle day 2. the maximum rhIL-3 serum concentration ranged from 289 pg/ml (0.5 micrograms/kg) to 4690 pg/ml (10 micrograms/kg).,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[pg] / [ml],4690,175452,DB00386,Alseroxylon
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,160,175453,DB00386,Alseroxylon
,8547077,elimination half-life T1/2 beta,"The elimination half-life T1/2 beta was 160 min for 0.5 micrograms/kg and 134 min for 10 micrograms/kg, with no apparent dose relationship.",Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),min,134,175454,DB00386,Alseroxylon
,8547077,systemic clearance,The systemic clearance of 3.0-6.0 ml/min/kg was comparable at all dose levels.,Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8547077/),[ml] / [kg·min],3.0-6.0,175455,DB00386,Alseroxylon
,16809798,area under the plasma concentration-time curve from time zero to infinity,The area under the plasma concentration-time curve from time zero to infinity of total vincristine in plasma ranged from 4933 to 40495 h.ng/mL and total clearance ranged from 131 to 445 mL/h.,Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[h·ng] / [ml],4933 to 40495,175531,DB00386,Alseroxylon
,16809798,total clearance,The area under the plasma concentration-time curve from time zero to infinity of total vincristine in plasma ranged from 4933 to 40495 h.ng/mL and total clearance ranged from 131 to 445 mL/h.,Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[ml] / [h],131 to 445,175532,DB00386,Alseroxylon
,16809798,volume of distribution at steady state,"The volume of distribution at steady state was 2650 +/- 731 mL, indicating VSLI was mainly confined within the plasma.",Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),ml,2650,175533,DB00386,Alseroxylon
below,16809798,trough plasma levels,"The pharmacokinetic parameters were similar between cycles 1 and 3, and trough plasma levels of total vincristine were below the level of quantitation of 1 ng/mL.",Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16809798/),[ng] / [ml],1,175534,DB00386,Alseroxylon
,11855752,half-lives of,"The half-lives of the terminal part of the curves, determined from blood and plasma data, were of the same order of magnitude: 31-35 h.",Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),h,31-35,176031,DB00386,Alseroxylon
,11855752,total clearances,Mean total clearances were about 0.71 l/h/kg from plasma and 0.45 l/h/kg from blood.,Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),[l] / [h·kg],0.71,176032,DB00386,Alseroxylon
,11855752,total clearances,Mean total clearances were about 0.71 l/h/kg from plasma and 0.45 l/h/kg from blood.,Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),[l] / [h·kg],0.45,176033,DB00386,Alseroxylon
,11855752,ratio AUC(B)/AU,"The ratio AUC(B)/AUC(P) (AUC(B) and AUC(P) are the area under the concentration-time curve from blood and plasma data, respectively) averaged 1.7; it was comparable to the blood/plasma ratio of 1.6 that remained constant over the 72 h of the study.",Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855752/),,1.7,176034,DB00386,Alseroxylon
,33790554,zeta potential,"CoNP-lips had a spherical shape with uniform size distribution; the average particle size was 162.97±9.06 nm, and the average zeta potential was -13.02±0.22 mV.",Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33790554/),m,-,176425,DB00386,Alseroxylon
,33790554,zeta potential,"CoNP-lips had a spherical shape with uniform size distribution; the average particle size was 162.97±9.06 nm, and the average zeta potential was -13.02±0.22 mV.",Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33790554/),m,13.02,176426,DB00386,Alseroxylon
,1849042,Cmax,"NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 +/- 139 (SEM) ng/ml.",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[ng] / [ml],1130,176738,DB00386,Alseroxylon
,1849042,total body clearance,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [h·kg],1.26,176739,DB00386,Alseroxylon
,1849042,apparent volume of distribution,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [kg],75.6,176740,DB00386,Alseroxylon
,1849042,apparent volume of distribution,"The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2).",Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1849042/),[l] / [m2],2918.4,176741,DB00386,Alseroxylon
,32888086,Drug Targeting Index (DTI),"The Drug Targeting Index (DTI) was 1.06 and 1.26 for vinpocetine ointment and vinpocetine ISG, respectively, after ocular administration, showing that vinpocetine ISG had better distribution in rat brain.","Design, Characterization, and Application of a pH-Triggered In Situ Gel for Ocular Delivery of Vinpocetine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32888086/),,1.06,176881,DB00386,Alseroxylon
,32888086,Drug Targeting Index (DTI),"The Drug Targeting Index (DTI) was 1.06 and 1.26 for vinpocetine ointment and vinpocetine ISG, respectively, after ocular administration, showing that vinpocetine ISG had better distribution in rat brain.","Design, Characterization, and Application of a pH-Triggered In Situ Gel for Ocular Delivery of Vinpocetine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32888086/),,1.26,176882,DB00386,Alseroxylon
,23907766,CL,"In contrast to the rapid CL and wide tissue distribution of non-liposomal VCR, VSLI circulates in plasma for a prolonged period of time, with a slow CL of 345 mL/h and relatively small Vd of 3,570 mL.",Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907766/),[ml] / [h],345,177101,DB00386,Alseroxylon
,23907766,Vd,"In contrast to the rapid CL and wide tissue distribution of non-liposomal VCR, VSLI circulates in plasma for a prolonged period of time, with a slow CL of 345 mL/h and relatively small Vd of 3,570 mL.",Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23907766/),ml,"3,570",177102,DB00386,Alseroxylon
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],21.7,177346,DB00386,Alseroxylon
,20959500,clearance,"In 6 patients with cancer, vinblastine increased the median (95% CI) clearance of the CYP3A4 phenotyping probe midazolam from 21.7 L/h (12.6 to 28.1) to 32.3 L/h (17.3 to 53.9) (p = 0.0156, Wilcoxon signed-rank test).",Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20959500/),[l] / [h],32.3,177347,DB00386,Alseroxylon
,16283312,Response rate,"Response rate was 30%, and disease stabilization rate was 64% (all dose levels included).",Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16283312/),%,30,177794,DB00386,Alseroxylon
,7622296,distribution phase plasma half-life,Encapsulation of vincristine in sterically stabilized liposomes (SL-VCR) prolonged the drug's distribution phase plasma half-life in rats from 0.22 to 10.5 hr.,Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7622296/),h,0,178263,DB00386,Alseroxylon
,7622296,distribution phase plasma half-life,Encapsulation of vincristine in sterically stabilized liposomes (SL-VCR) prolonged the drug's distribution phase plasma half-life in rats from 0.22 to 10.5 hr.,Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7622296/),h,10,178264,DB00386,Alseroxylon
,18229621,entrapment ratio,The average particle size of VCR-T prepared was 63 nm with an entrapment ratio of 59%.,[Transdermal and lymph targeting transfersomes of vincristine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229621/),,59,178422,DB00386,Alseroxylon
,18229621,accumulation permeation percentage,"The in vitro transdermal research with modified Franz cell showed that VCR-T permeated through the skin in accordance with polynomial equation, and with an accumulation permeation percentage of 67.4% up to 12 h.",[Transdermal and lymph targeting transfersomes of vincristine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18229621/),%,67.4,178423,DB00386,Alseroxylon
,30088322,efflux ratio (B-A/A-B),"7-Hydroxymitragynine showed a tendency to efflux, with efflux ratio (B-A/A-B) of 1.39.",Rate and extent of mitragynine and 7-hydroxymitragynine blood-brain barrier transport and their intra-brain distribution: the missing link in pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30088322/),,1.39,178827,DB00386,Alseroxylon
,34023919,area under the concentration-time curve (AUC),"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[ng] / [h·ml],332,178967,DB00386,Alseroxylon
,34023919,clearance,"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[l] / [h·m2],4.6,178968,DB00386,Alseroxylon
,34023919,half-life,"The median (coefficient of variation, CV%) area under the concentration-time curve (AUC) was 332 ng/mL·h. (110%); clearance was 4.6 L/h/m2 (90%); half-life was 25 h (60%).",Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),h,25,178969,DB00386,Alseroxylon
,34023919,AUC,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[ng] / [h·ml],78,178970,DB00386,Alseroxylon
,34023919,clearance,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),[l] / [h·m2],17.2,178971,DB00386,Alseroxylon
,34023919,half-life,The median (CV%) AUC was 78 ng/mL·h (98%); clearance was 17.2 L/h/m2 (67%); half-life was 14.6 h (73%).,Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34023919/),h,14.6,178972,DB00386,Alseroxylon
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,335.2,179126,DB00386,Alseroxylon
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,184.2,179127,DB00386,Alseroxylon
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,199.1,179128,DB00386,Alseroxylon
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,171.1,179129,DB00386,Alseroxylon
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,78,179130,DB00386,Alseroxylon
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,102,179131,DB00386,Alseroxylon
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,95.2,179132,DB00386,Alseroxylon
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,106,179133,DB00386,Alseroxylon
,22715737,C(max),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[μg] / [l],26.20,179134,DB00386,Alseroxylon
,22715737,C(max),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[μg] / [l],12.50,179135,DB00386,Alseroxylon
,22715737,AUC(0-infinity),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[h·μg] / [l],193.75,179136,DB00386,Alseroxylon
,22715737,AUC(0-infinity),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[h·μg] / [l],98.25,179137,DB00386,Alseroxylon
,26661090,half-life (T1/2),"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),min,4.8,179351,DB00386,Alseroxylon
,26661090,terminal T1/2,"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),h,24.3,179352,DB00386,Alseroxylon
,26661090,T1/2,"In contrast to standard vincristine, which had a multi-exponential plasma disappearance curve with a median initial (EOI to 30 min post-infusion) half-life (T1/2) of 4.8 min (range, 4.4-5.0 min) and terminal T1/2 of 24.3 h, a near-monoexponential curve with a median T1/2 of 17.9 h (range, 13.9-21.5 h) hours was calculated with VSLI.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),h,17.9,179353,DB00386,Alseroxylon
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,300,179354,DB00386,Alseroxylon
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,463,179355,DB00386,Alseroxylon
,26661090,ratios Cl VCR:Cl VSLI,"The ratios Cl VCR:Cl VSLI for the individual NHP were 300, 463 and 477.","Plasma and cerebrospinal fluid pharmacokinetics of vincristine and vincristine sulfate liposomes injection (VSLI, marqibo®) after intravenous administration in Non-human primates. ",Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26661090/),,477,179356,DB00386,Alseroxylon
,6517534,steady state,"Pharmacokinetic studies in 4 patients showed that plasma levels increased rapidly after beginning the infusion with a steady state occurring in 10-48 hours at 2 ng/ml for 1.25 mg/m2, and 5-8 ng/ml for 2.0 mg/m2.",Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517534/),[ng] / [ml],2,179737,DB00386,Alseroxylon
,6517534,steady state,"Pharmacokinetic studies in 4 patients showed that plasma levels increased rapidly after beginning the infusion with a steady state occurring in 10-48 hours at 2 ng/ml for 1.25 mg/m2, and 5-8 ng/ml for 2.0 mg/m2.",Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517534/),[ng] / [ml],5-8,179738,DB00386,Alseroxylon
,6517534,T 1/2 b,The T 1/2 b after completion of the infusion was 19 hours.,Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6517534/),h,19,179739,DB00386,Alseroxylon
,20962707,Residual concentration,Residual concentration of AMD was 0.18 ± 0.02 ng/mL or 0.16% of the initial infusion concentration.,Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962707/),[ng] / [ml],0.18,179823,DB00386,Alseroxylon
,20962707,Residual concentration,Residual concentration of AMD was 0.18 ± 0.02 ng/mL or 0.16% of the initial infusion concentration.,Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20962707/),%,0.16,179824,DB00386,Alseroxylon
,3708225,total body blood clearance,Coronary occlusion induced a change in pharmacokinetics of ajmaline (2 mg kg-1) and its total body blood clearance was significantly decreased from 56.6 ml min-1 kg-1 in sham-operated rats to 43.1 ml min-1 kg-1 in rats after coronary occlusion.,Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708225/),[ml] / [kg·min],56.6,180019,DB00386,Alseroxylon
,3708225,total body blood clearance,Coronary occlusion induced a change in pharmacokinetics of ajmaline (2 mg kg-1) and its total body blood clearance was significantly decreased from 56.6 ml min-1 kg-1 in sham-operated rats to 43.1 ml min-1 kg-1 in rats after coronary occlusion.,Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708225/),[ml] / [kg·min],43.1,180020,DB00386,Alseroxylon
exceed,21855426,extraction recoveries,The extraction recoveries of both the two alkaloids exceed 81.9%.,Ultra-performance liquid chromatography-tandem mass spectrometric method for the determination of strychnine and brucine in mice plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21855426/),%,81.9,180342,DB00386,Alseroxylon
,7448826,half-life,"Pharmacokinetic studies in mice using either radioactivity measurements or selective extraction followed by spectrofluorometric quantitation have shown that blood levels drop very rapidly during the distribution phase followed by a much slower disposition phase, with a half-life of about 30 hours for the quaternary salt.",Metabolism and disposition studies of 9-hydroxyellipticine and 2-methyl-9-hydroxyellipticinium acetate in animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448826/),h,30,180722,DB00386,Alseroxylon
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,57,180748,DB00386,Alseroxylon
,12852694,Response rates,"Response rates in patients with visceral and liver metastases were 57% and 50%, respectively.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),%,50,180749,DB00386,Alseroxylon
,12852694,time to progression,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,8.5,180750,DB00386,Alseroxylon
,12852694,overall survival,"After a median follow-up of 24 months (13-36), median time to progression was 8.5 months and median overall survival 17 months.",Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852694/),month,17,180751,DB00386,Alseroxylon
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,189,181217,DB00386,Alseroxylon
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,152,181218,DB00386,Alseroxylon
,6690071,terminal half-lives,"The average terminal half-lives of vincristine, vinblastine, and vindesine in the serum were 189, 152, and 175 min, respectively.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min,175,181219,DB00386,Alseroxylon
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"26,572",181220,DB00386,Alseroxylon
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"16,745",181221,DB00386,Alseroxylon
,6690071,areas under the alkaloid concentration-time curve from 0 to infinity,"The areas under the alkaloid concentration-time curve from 0 to infinity for these drugs for a 1-mg dose were as follows: vincristine, 26,572 nM x min; vinblastine, 16,745 nM x min; and vindesine, 12,708 nM x min.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),min·nM,"12,708",181222,DB00386,Alseroxylon
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],4.8,181223,DB00386,Alseroxylon
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],7.0,181224,DB00386,Alseroxylon
,6690071,clearance rate,The clearance rate (ml/min/kg) for vincristine (4.8) was slightly lower than that for vinblastine (7.0) or vindesine (7.8).,"Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[ml] / [kg·min],7.8,181225,DB00386,Alseroxylon
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.3,181226,DB00386,Alseroxylon
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.5,181227,DB00386,Alseroxylon
,6690071,apparent volumes of distribution,"The apparent volumes of distribution for vincristine, vinblastine, and vindesine were, respectively, 1.3, 1.5, and 1.9 l/kg body weight.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),[l] / [body·kg·weight],1.9,181228,DB00386,Alseroxylon
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,36.7,181229,DB00386,Alseroxylon
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,18.2,181230,DB00386,Alseroxylon
,6690071,total average excretion,"The total average excretion of the alkaloids over a 4-day period in urine and feces for vincristine, vinblastine, and vindesine were, respectively, 36.7%, 18.2%, and 25.3% of the injected dose.","Pharmacokinetics of vincristine, vinblastine, and vindesine in rhesus monkeys. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6690071/),%,25.3,181231,DB00386,Alseroxylon
,3432163,apparent half-life of its formation,The apparent half-life of its formation was 0.56 +/- 0.23 h and that of the apparent elimination was 9.6 h which did not significantly differ from the elimination half-life of total radioactivity (8.16 +/- 1.77 h) and from the apparent elimination half-life of vinpocetine itself (8.9 +/- 2.87 h).,Pharmacokinetics of apovincaminic acid in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432163/),h,0.56,181319,DB00386,Alseroxylon
,3432163,apparent elimination,The apparent half-life of its formation was 0.56 +/- 0.23 h and that of the apparent elimination was 9.6 h which did not significantly differ from the elimination half-life of total radioactivity (8.16 +/- 1.77 h) and from the apparent elimination half-life of vinpocetine itself (8.9 +/- 2.87 h).,Pharmacokinetics of apovincaminic acid in dogs. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432163/),h,9.6,181320,DB00386,Alseroxylon
,3432163,elimination half-life,The apparent half-life of its formation was 0.56 +/- 0.23 h and that of the apparent elimination was 9.6 h which did not significantly differ from the elimination half-life of total radioactivity (8.16 +/- 1.77 h) and from the apparent elimination half-life of vinpocetine itself (8.9 +/- 2.87 h).,Pharmacokinetics of apovincaminic acid in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432163/),h,8.16,181321,DB00386,Alseroxylon
,3432163,apparent elimination half-life,The apparent half-life of its formation was 0.56 +/- 0.23 h and that of the apparent elimination was 9.6 h which did not significantly differ from the elimination half-life of total radioactivity (8.16 +/- 1.77 h) and from the apparent elimination half-life of vinpocetine itself (8.9 +/- 2.87 h).,Pharmacokinetics of apovincaminic acid in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432163/),h,8.9,181322,DB00386,Alseroxylon
,3432163,clearance,The volume of distribution of AVA was 2.3 times lower than that of vinpocetine and its clearance value (1.5 +/- 0.77 1 h-1 kg-1) was 2.8 times less than that of vinpocetine.,Pharmacokinetics of apovincaminic acid in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3432163/),[1] / [h·kg],1.5,181323,DB00386,Alseroxylon
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.19,181891,DB00386,Alseroxylon
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.41,181892,DB00386,Alseroxylon
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],1.4,181893,DB00386,Alseroxylon
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.3,181894,DB00386,Alseroxylon
,3698163,Clearance,"Clearance was found to parallel toxicity for all drugs: it increases from 0.19 1 h-1 kg-1 for vincristine to 0.41 for Na-formyl navelbine, 1.4 for vinblastine, 2.3 for navelbine, and 2.6 for deacetyl navelbine amide.",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],2.6,181895,DB00386,Alseroxylon
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,13,181896,DB00386,Alseroxylon
,3698163,Terminal half-lives,Terminal half-lives were longer for the Na-formyl-substituted alkaloids (around 13 h) than for the others (8-10 h).,Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,8-10,181897,DB00386,Alseroxylon
,3698163,clearance,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),[1] / [h·kg],0.92,181898,DB00386,Alseroxylon
,3698163,terminal half-life,"We have also studied navelbine kinetics in cancer patients entered in recent navelbine clinical trials and found that navelbine pharmacokinetics are characterized by fast and extensive distribution, high clearance (0.92 +/- 0.27 1 h-1 kg-1), and a relatively long terminal half-life (31.2 +/- 4.4 h).",Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3698163/),h,31.2,181899,DB00386,Alseroxylon
,18306910,drug,"These differences were not clinically significant, however the drug bioavailability, which was fixed to 0.35 in the simulation, might be highly variable among subjects contributing to a large extent to the observed variability in drug toxicity.",Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18306910/),,0.35,182398,DB00386,Alseroxylon
,18306910,bioavailability,"These differences were not clinically significant, however the drug bioavailability, which was fixed to 0.35 in the simulation, might be highly variable among subjects contributing to a large extent to the observed variability in drug toxicity.",Chemotherapy-induced myelosuppression by vinorelbine: a comparison between different dose schedules by simulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18306910/),,0.35,182399,DB00386,Alseroxylon
,22405129,maximum measured detomidine concentrations,"The maximum measured detomidine concentrations were 76.0 and 129.9 ng mL(-1) for the D and DY treatments, respectively.",The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],76.0,184500,DB00386,Alseroxylon
,22405129,maximum measured detomidine concentrations,"The maximum measured detomidine concentrations were 76.0 and 129.9 ng mL(-1) for the D and DY treatments, respectively.",The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],129.9,184501,DB00386,Alseroxylon
,22405129,maximum measured yohimbine plasma concentrations,There was a significant increase in the maximum measured yohimbine plasma concentrations from Y (173.9 ng mL(-1)) to DY (289.8 ng mL(-1)).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],173.9,184502,DB00386,Alseroxylon
,22405129,maximum measured yohimbine plasma concentrations,There was a significant increase in the maximum measured yohimbine plasma concentrations from Y (173.9 ng mL(-1)) to DY (289.8 ng mL(-1)).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],289.8,184503,DB00386,Alseroxylon
,22405129,Cl,Both the Cl and V(d) for yohimbine were significantly less (6.8 mL minute(-1) kg(-1) (Cl) and 1.7 L kg(-1) (V(d) )) for the DY as compared to the Y treatments (13.9 mL minute(-1) kg(-1) (Cl) and 2.7 L kg(-1) (V(d))).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ml] / [kg·minute],6.8,184504,DB00386,Alseroxylon
,22405129,V(d) ),Both the Cl and V(d) for yohimbine were significantly less (6.8 mL minute(-1) kg(-1) (Cl) and 1.7 L kg(-1) (V(d) )) for the DY as compared to the Y treatments (13.9 mL minute(-1) kg(-1) (Cl) and 2.7 L kg(-1) (V(d))).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[l] / [kg],1.7,184505,DB00386,Alseroxylon
,22405129,Cl,Both the Cl and V(d) for yohimbine were significantly less (6.8 mL minute(-1) kg(-1) (Cl) and 1.7 L kg(-1) (V(d) )) for the DY as compared to the Y treatments (13.9 mL minute(-1) kg(-1) (Cl) and 2.7 L kg(-1) (V(d))).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ml] / [kg·minute],13.9,184506,DB00386,Alseroxylon
,22405129,V(d)),Both the Cl and V(d) for yohimbine were significantly less (6.8 mL minute(-1) kg(-1) (Cl) and 1.7 L kg(-1) (V(d) )) for the DY as compared to the Y treatments (13.9 mL minute(-1) kg(-1) (Cl) and 2.7 L kg(-1) (V(d))).,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[l] / [kg],2.7,184507,DB00386,Alseroxylon
below,22405129,Plasma concentrations,Plasma concentrations were below the limit of quantitation (0.05 and 0.5 ng mL(-1)) by 18 hours for both detomidine and yohimbine.,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],0.05,184508,DB00386,Alseroxylon
,22405129,Plasma concentrations,Plasma concentrations were below the limit of quantitation (0.05 and 0.5 ng mL(-1)) by 18 hours for both detomidine and yohimbine.,The effects of yohimbine on the pharmacokinetic parameters of detomidine in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22405129/),[ng] / [ml],0.5,184509,DB00386,Alseroxylon
,29043863,oral bioavailability,"The oral bioavailability of self-emulsifying pH gradient release pellets was about 149.8% of commercial VIN tablets, and it was about 86% of liquid VIN SEDDS, but there were no significant difference between liquid SEDDS and self-emulsifying pH gradient release pellets.",Preparation and evaluation of Vinpocetine self-emulsifying pH gradient release pellets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043863/),%,149.8,184922,DB00386,Alseroxylon
,29043863,oral bioavailability,"The oral bioavailability of self-emulsifying pH gradient release pellets was about 149.8% of commercial VIN tablets, and it was about 86% of liquid VIN SEDDS, but there were no significant difference between liquid SEDDS and self-emulsifying pH gradient release pellets.",Preparation and evaluation of Vinpocetine self-emulsifying pH gradient release pellets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29043863/),%,86,184923,DB00386,Alseroxylon
,2954633,half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,40.76,186414,DB00386,Alseroxylon
,2954633,terminal half-life,"In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40.76 h and its in vivo terminal half-life of 0.52 h.",Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954633/),h,0.52,186415,DB00386,Alseroxylon
,12649112,MTD,The MTD of vinflunine was achieved at 400 mg/m(2) every 3 weeks.,Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12649112/),,400,187271,DB00386,Alseroxylon
,16428494,Cl(TB),"A higher mean i.v. Cl(TB) was observed (1.75 +/- 1.0 L/h/kg) compared with adult reports, with a mean t(1/2B) of 16.5 +/- 9.7 hours.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [h·kg],1.75,187914,DB00386,Alseroxylon
,16428494,t(1/2B),"A higher mean i.v. Cl(TB) was observed (1.75 +/- 1.0 L/h/kg) compared with adult reports, with a mean t(1/2B) of 16.5 +/- 9.7 hours.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),h,16.5,187915,DB00386,Alseroxylon
,16428494,oral bioavailability,Mean oral bioavailability was 28.5 +/- 22.5%.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),%,28.5,187916,DB00386,Alseroxylon
,16428494,apparent oral clearance,The apparent oral clearance (12.1 +/- 13.0 L/h/kg) and volume of distribution (69.4 +/- 30.6 L/kg) were substantially higher than in adults given similar oral doses.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [h·kg],12.1,187917,DB00386,Alseroxylon
,16428494,volume of distribution,The apparent oral clearance (12.1 +/- 13.0 L/h/kg) and volume of distribution (69.4 +/- 30.6 L/kg) were substantially higher than in adults given similar oral doses.,Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[l] / [kg],69.4,187918,DB00386,Alseroxylon
,16428494,maximum tolerated dose,"The maximum tolerated dose in children without bone marrow involvement was 30 mg/m(2), similar to that reported in adults, with myelosuppression being the dose-limiting toxicity.",Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428494/),[mg] / [m(2],30,187919,DB00386,Alseroxylon
,7987996,oral bioavailability,"Pharmacokinetic studies in BALB/c mice showed the oral bioavailability to be 20%, with 35% of the drug being excreted unchanged in the faeces over the first 24 h.","Preclinical pharmacology of 1069C85, a novel tubulin binder. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7987996/),%,20,188284,DB00386,Alseroxylon
<,33222021,oral bioavailability,Vinpocetine (VIN) tablets for cerebrovascular degenerative disorders ensued < 7% oral bioavailability.,"Patient-Friendly, Olfactory-Targeted, Stimuli-Responsive Hydrogels for Cerebral Degenerative Disorders Ensured > 400% Brain Targeting Efficiency in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33222021/),%,7,188438,DB00386,Alseroxylon
,6467494,terminal t1/2,"Serum concentrations were highest (5 X 10(-7) M) in patients receiving a bolus injection, but fell to nondetectable levels by 48 h in four of five patients (terminal t1/2 15.0 +/- 9.4 h).",Pharmacokinetics of vindesine bolus and infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467494/),h,15.0,190122,DB00386,Alseroxylon
,6467494,steady-state concentrations,Whereas steady-state concentrations (approximately 1 X 10(-8) M) were maintained throughout the infusion of 1.2 mg/m2/day progressively increasing serum levels were observed during the infusion of 2.0 mg/m2/day.,Pharmacokinetics of vindesine bolus and infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6467494/),M,1 X 10(-8),190123,DB00386,Alseroxylon
,1418055,areas under the plasma concentration-time curves (AUC),"The areas under the plasma concentration-time curves (AUC) amounted to 27.3 +/- 18.1 ng.h/ml (fasting) and 42.8 +/- 27.4 up to 54.3 +/- 38.4 ng.h/ml (non-fasting, intake before and after meal, resp.).",Bioavailability of vinpocetine and interference of the time of application with food intake. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418055/),[h·ng] / [ml],27.3,191226,DB00386,Alseroxylon
,1418055,areas under the plasma concentration-time curves (AUC),"The areas under the plasma concentration-time curves (AUC) amounted to 27.3 +/- 18.1 ng.h/ml (fasting) and 42.8 +/- 27.4 up to 54.3 +/- 38.4 ng.h/ml (non-fasting, intake before and after meal, resp.).",Bioavailability of vinpocetine and interference of the time of application with food intake. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418055/),[h·ng] / [ml],42.8,191227,DB00386,Alseroxylon
,1418055,areas under the plasma concentration-time curves (AUC),"The areas under the plasma concentration-time curves (AUC) amounted to 27.3 +/- 18.1 ng.h/ml (fasting) and 42.8 +/- 27.4 up to 54.3 +/- 38.4 ng.h/ml (non-fasting, intake before and after meal, resp.).",Bioavailability of vinpocetine and interference of the time of application with food intake. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1418055/),[h·ng] / [ml],54.3,191228,DB00386,Alseroxylon
,7166185,bioavailability,The bioavailability was 78%.,[Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7166185/),%,78,191487,DB00386,Alseroxylon
,7166185,terminal plasma elimination half-life (beta-phase),The terminal plasma elimination half-life (beta-phase) was in the range of 4 to 6 hours.,[Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7166185/),h,4 to 6,191488,DB00386,Alseroxylon
,11521794,overall response rate,"Activity was observed at all dose levels and at all metastatic sites, with an overall response rate of 71% (95% CI: 52.0%-85.8%).",Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),%,71,192822,DB00386,Alseroxylon
,11521794,time to progression,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),weeks,31.4,192823,DB00386,Alseroxylon
,11521794,survival,The median time to progression was 31.4 weeks (95% CI: 12-48 weeks) and median survival was 15.6 months (95% CI: 2.6-26.6 months).,Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11521794/),month,15.6,192824,DB00386,Alseroxylon
,29956056,overall survival,"Results Median treatment duration and overall survival were 15 (range 1.3-144) and 32.3 weeks, respectively; fourty-eight (60%) patients experienced clinical benefit.",Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29956056/),weeks,32.3,193972,DB00386,Alseroxylon
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,85,194070,DB00386,Alseroxylon
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,24,194071,DB00386,Alseroxylon
,7070351,terminal phase half-life,"However, vincristine had a longer and more variable terminal phase half-life (85 +/- 69 hr) than vindesine (24 +/- 10 hr) or vinblastine (25 +/- 7 hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),h,25,194072,DB00386,Alseroxylon
,7070351,serum,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.106,194073,DB00386,Alseroxylon
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.106,194074,DB00386,Alseroxylon
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.252,194075,DB00386,Alseroxylon
,7070351,body clearances,"The most important finding was the observation of differences in the serum or body clearances of these drugs (vincristine 0.106 liter/kg/hr, vindesine 0.252 liter/kg/hr, and vinblastine 0.740 liter/kg/hr).","The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7070351/),[l] / [h·kg],0.740,194076,DB00386,Alseroxylon
,21342795,flow-rate,"The chromatographic separation was achieved on a Spursil polar-modified C(18) column (50 mm×2.1 mm, 3 μm, Dikma Technologies) with an isocratic mobile phase of a 75:25 (v/v) acetonitrile-4 mmol/L ammonium formate (pH 3.0) mixture at a flow-rate of 0.4 mL/min.",Rapid and sensitive determination of vinorelbine in human plasma by liquid chromatography-tandem mass spectrometry and its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21342795/),[ml] / [min],0.4,194377,DB00386,Alseroxylon
,8877249,bioavailability,The bioavailability of a liquid filled gelatin capsule ranges between 12 and 59% with a mean value of 27% [standard deviation (SD) 12%].,Clinical pharmacokinetics of vinorelbine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,27,195585,DB00386,Alseroxylon
,8877249,unbound blood fraction,"In vitro, vinorelbine is mainly distributed into the blood cells, especially platelets (78%) and lymphocytes (4.8%) The unbound blood fraction is around 2%.",Clinical pharmacokinetics of vinorelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,2,195586,DB00386,Alseroxylon
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,33.9,195587,DB00386,Alseroxylon
,8877249,amount of radioactivity,"Faecal elimination has been demonstrated in 2 patients who were administered 3H-labelled vinorelbine; the amount of radioactivity recovered in the faeces was 33.9 and 58.4% for the 2 patients, respectively.",Clinical pharmacokinetics of vinorelbine. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),%,58.4,195588,DB00386,Alseroxylon
,8877249,terminal half-life (t1/2),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,20 and 40,195589,DB00386,Alseroxylon
,8877249,apparent volume of distribution (Vd),The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life (t1/2) that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg.,Clinical pharmacokinetics of vinorelbine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [kg],70,195590,DB00386,Alseroxylon
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],72.54 and 89.46,195591,DB00386,Alseroxylon
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [min],1209 and 1491,195592,DB00386,Alseroxylon
,8877249,Systemic clearance,Systemic clearance ranges between 72.54 and 89.46 L/h (1209 and 1491 ml/min) when determined by high performance liquid chromatography and is higher than that reported by radioimmunoassay [46.2 L/h (770 ml/min)].,Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h],46.2,195593,DB00386,Alseroxylon
,8877249,t1/2,"In children, vinorelbine seems to display a shorter t1/2 (14.7 hours) than that found in adults.",Clinical pharmacokinetics of vinorelbine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),h,14.7,195594,DB00386,Alseroxylon
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[l] / [h·m2],12 to 93.96,195595,DB00386,Alseroxylon
,8877249,systemic clearance,"In addition, the systemic clearance is highly variable [from 12 to 93.96 L/h/m2 (200 to 1566 ml/min/m2)].",Clinical pharmacokinetics of vinorelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877249/),[ml] / [m2·min],200 to 1566,195596,DB00386,Alseroxylon
,4016723,maximal tolerated dose,The maximal tolerated dose appears to be about 43 mg/m2.,Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[mg] / [m2],43,196957,DB00386,Alseroxylon
,4016723,elimination half-life,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),h,30,196958,DB00386,Alseroxylon
,4016723,plasma clearance,"Pharmacokinetics, studied with a radioimmunoassay (RIA) method, suggested an elimination half-life of 30 h and a plasma clearance of 75 l/h.",Phase I pharmacologic study of a new Vinca alkaloid: navelbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4016723/),[l] / [h],75,196959,DB00386,Alseroxylon
,20042378,flow rate,"Chromatographic separation was achieved on a C8 HPLC column (Phenomenex Luna 50 mm x 2.0 mm, 3.0 microm) with a mobile phase gradient at a flow rate of 0.2 ml/min.",Validation of an electrospray ionization LC/MS/MS method for quantitative analysis of vincristine in human plasma samples. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20042378/),[ml] / [min],0.2,197044,DB00386,Alseroxylon
,578452,maximum plasma levels,"At the end of the infusion, maximum plasma levels ranged between 607 and 999 ng/ml.",[Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/578452/),[ng] / [ml],607 and 999,197810,DB00386,Alseroxylon
,578452,half-life,The mean half-life for the beta-slope was 2 h.,[Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/578452/),h,2,197811,DB00386,Alseroxylon
,22967996,OR rate,The OR rate in assessable phase II patients was 41% (no prior lapatinib) and 8% (prior lapatinib).,Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967996/),%,41,198109,DB00386,Alseroxylon
,22967996,OR rate,The OR rate in assessable phase II patients was 41% (no prior lapatinib) and 8% (prior lapatinib).,Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22967996/),%,8,198110,DB00386,Alseroxylon
,23658485,particle,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),nm,157.6,198765,DB00386,Alseroxylon
,23658485,zeta potential,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,-,198766,DB00386,Alseroxylon
,23658485,zeta potential,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,26.5,198767,DB00386,Alseroxylon
,23658485,encapsulation efficiency,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),m,26.5,198768,DB00386,Alseroxylon
,23658485,encapsulation efficiency,"The mean particle size, zeta potential, and encapsulation efficiency were 157.6 ± 12.6 nm, -26.5 ± 5.0 mV and 78.64% ± 3.44%, respectively.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),%,78.64,198769,DB00386,Alseroxylon
,23658485,mean residence time [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),min,187.19,198770,DB00386,Alseroxylon
,23658485,mean residence time [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),min,227,198771,DB00386,Alseroxylon
,23658485,maximum concentration,"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[ng] / [ml],252.13,198772,DB00386,Alseroxylon
,23658485,maximum concentration,"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[ng] / [ml],533.34,198773,DB00386,Alseroxylon
,23658485,area under the curve (area under the curve [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[μg] / [l·min],"11,417.77",198774,DB00386,Alseroxylon
,23658485,area under the curve (area under the curve [0-∞],"Compared with VCR solution, the pharmacokinetic study of VCR-OA-SME showed relatively longer mean residence time (mean residence time [0-∞] increased from 187.19 to 227.56 minutes), higher maximum concentration (from 252.13 ng/mL to 533.34 ng/mL), and greater area under the curve (area under the curve [0-∞] from 11,417.77 μg/L/minute to 17,164.34 μg/L/minute.",A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23658485/),[μg] / [l·min],"17,164.34",198775,DB00386,Alseroxylon
,7849233,relative bioavailabilities,"The relative bioavailabilities (solution versus powder) were, respectively, 286.0% and 268.0% as estimated from experimental (0-72 h) and extrapolated (0-infinity) AUC.",Relative bioavailability of two oral formulations of navelbine in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849233/),%,286.0,200413,DB00386,Alseroxylon
,7849233,relative bioavailabilities,"The relative bioavailabilities (solution versus powder) were, respectively, 286.0% and 268.0% as estimated from experimental (0-72 h) and extrapolated (0-infinity) AUC.",Relative bioavailability of two oral formulations of navelbine in cancer patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849233/),%,268.0,200414,DB00386,Alseroxylon
,27329361,volume of distribution of central compartment,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),l,0.95,200467,DB00386,Alseroxylon
,27329361,clearance of Reditux™,"The volume of distribution of central compartment and clearance of Reditux™ were estimated at 0.95 L and 5.98 mL/h, respectively.","Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27329361/),[ml] / [h],5.98,200468,DB00386,Alseroxylon
,25649934,volume of distribution,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),[l] / [kg],0.660,200473,DB00386,Alseroxylon
,25649934,elimination half-life,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),min,21.5,200474,DB00386,Alseroxylon
,25649934,elimination half-life,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),min,47.6,200475,DB00386,Alseroxylon
,25649934,plasma clearance,"The volume of distribution, distribution half-life, elimination half-life and plasma clearance were 0.660 ± 0.210 l/kg, 21.5 ± 6.90 min, 47.6 ± 14.2 min and 0.010 ± 0.001 l/min/kg, respectively.",Clinical pharmacokinetics and effects of vincristine sulfate in dogs with transmissible venereal tumor (TVT). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25649934/),[l] / [kg·min],0.010,200476,DB00386,Alseroxylon
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,84,202921,DB00386,Alseroxylon
,27154915,overall response rate (ORR),"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),%,24,202922,DB00386,Alseroxylon
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,100,202923,DB00386,Alseroxylon
,27154915,ORR,"Among patients receiving the MTD (n = 38), the overall response rate (ORR) was 84% (n = 32), including 24% (n = 9) with complete response; the ORR was 100% for patients with indolent lymphoma (n = 27) and 57% for those with aggressive histology lymphoma (n = 21).",Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27154915/),,57,202924,DB00386,Alseroxylon
,10914711,Area under the plasma-concentration time curve (AUC),Area under the plasma-concentration time curve (AUC) normalized to a 30 mg/m2 administered dose averaged 0.89 mg/liter x h (coefficient of variation = 23.7%).,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),[mg] / [h·l],0.89,203196,DB00386,Alseroxylon
,10914711,total plasma clearance,The total plasma clearance averaged 0.93 liter/h/kg (0.61-1.83 liter/h/kg; coefficient of variation = 38.6%).,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),[l] / [h·kg],0.93,203197,DB00386,Alseroxylon
,10914711,elimination half-life,The elimination half-life was 38.1 +/- 5.8 h.,Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10914711/),h,38.1,203198,DB00386,Alseroxylon
,9653499,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,40,203676,DB00386,Alseroxylon
,9653499,overall response rate,Vinorelbine (VNR) is highly active in metastatic breast cancer (MBC) and has shown an overall response rate of 40%-50% as first-line treatment.,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,50,203677,DB00386,Alseroxylon
,9653499,overall response rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,36.5,203678,DB00386,Alseroxylon
,9653499,CR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,4.8,203679,DB00386,Alseroxylon
,9653499,PR rate,"The overall response rate was 36.5% with a CR rate of 4.8% (two of 41 patients, all at the highest dose level) and a PR rate of 31.7% (13 of 41 patients).",Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),%,31.7,203680,DB00386,Alseroxylon
,9653499,response duration,The median response duration was 7.0 months (range 2-13 months).,Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653499/),month,7.0,203681,DB00386,Alseroxylon
,9747681,peak vitreous concentration,"Mean measured peak vitreous concentration of carboplatin after intravenous administration was 0.31 microg/mL, which was 1% of the peak plasma value.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],0.31,203792,DB00386,Alseroxylon
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.38,203793,DB00386,Alseroxylon
,9747681,peak vitreous concentrations,"Mean measured peak vitreous concentrations of carboplatin after peribulbar or episcleral balloon administration were 2.38 microg/mL and 2.95 microg/mL, respectively, which represent 7.68- and 9.52-fold increases over the concentration achieved after intravenous administration.",Intraocular concentrations of chemotherapeutic agents after systemic or local administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9747681/),[μg] / [ml],2.95,203794,DB00386,Alseroxylon
,20641009,flow rate,The LC flow rate was set to 0.28 mL/min and the gradient (solvent B concentration) was processed from 40 to 90%.,Sensitive measurement of vinorelbine in dog plasma by liquid chromatography-electrospray ionization tandem mass spectrometry utilizing transitions from double-charged precursor ions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20641009/),[ml] / [min],0.28,204130,DB00386,Alseroxylon
,872088,t1/2 alpha,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,3.24,204345,DB00386,Alseroxylon
,872088,t1/2beta,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,99.0,204346,DB00386,Alseroxylon
,872088,t1/2gamma,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,1213,204347,DB00386,Alseroxylon
,872088,Vc (Valpha),"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,4.81,204348,DB00386,Alseroxylon
,872088,Vbeta,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,58.2,204349,DB00386,Alseroxylon
,872088,Vgamma,"The kinetic parameters included: t1/2 alpha=3.24+/-1.14 min, t1/2beta=99.0+/-44.5 min, t1/2gamma=1213+/-493 min, Vc (Valpha)=4.81+/-2.12 liters, Vbeta=58.2+/-50.5 liters, Vgamma=598+/-294 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,598,204350,DB00386,Alseroxylon
,872088,t1/2 alpha,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,3.37,204351,DB00386,Alseroxylon
,872088,t1/2beta,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),min,155,204352,DB00386,Alseroxylon
,872088,Valpha,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,4.53,204353,DB00386,Alseroxylon
,872088,Vbeta,"Vincristine, studied only for the first 4 hr, behaved like a two-compartment system, with values of t1/2 alpha=3.37+/-0.72 min, t1/2beta=155+/-18 min, Valpha=4.53+/-0.49 liters, and Vbeta=57.3+/-21.1 liters.",Pharmacokinetics of vindesine and vincristine in humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/872088/),l,57.3,204354,DB00386,Alseroxylon
,19651165,T(max),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),h,1,204744,DB00386,Alseroxylon
,19651165,T(max),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),h,3,204745,DB00386,Alseroxylon
,19651165,C(max),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),[ng] / [ml],163.82,204746,DB00386,Alseroxylon
,19651165,C(max),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),[ng] / [ml],166.43,204747,DB00386,Alseroxylon
,19651165,AUC(0-infinity),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),[ng] / [h·ml],1479.70,204748,DB00386,Alseroxylon
,19651165,AUC(0-infinity),"The pharmacokinetic parameters of vinpocetine and vinpocetine proliposomes in New Zealand rabbits were T(max) 1 h and 3 h (there was also an absorption peak at 1 h); C(max) 163.82+/-12.28 ng/ml and 166.43+/-21.04 ng/ml; AUC(0-infinity) 1479.70+/-68.51 ng/ml h and 420.70+/-35.86 ng/ml h, respectively.",Optimized preparation of vinpocetine proliposomes by a novel method and in vivo evaluation of its pharmacokinetics in New Zealand rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19651165/),[ng] / [h·ml],420.70,204749,DB00386,Alseroxylon
,20555126,Trough levels,"Trough levels of 4 patients on three-monthly schedule maintenance therapy remained constant, with a median concentration of 6 mu g/mL (range 0.5-11.7 microg/mL).",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),[g·mu] / [ml],6,204913,DB00386,Alseroxylon
,20555126,elimination half-life at steady state,"The elimination half-life at steady state of rituximab in all patients was estimated to be 19.2 (+/- 15.2%) days with a between-subject variability of 54%, indicating wide variability.",Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20555126/),d,19.2,204914,DB00386,Alseroxylon
,8667431,t1/2,"The t1/2 values with a 1-mg/kg dose were 3.6 hours +/- 0.3 hour (mean +/- standard error) and 2.1 hours +/- 0.3 hour, respectively (P < .05); with a 6-mg/kg dose, the values were 8.6 hours +/- 1.8 hours and 4.2 hours +/- 0.2 hour, respectively (P = .058).",Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667431/),h,3.6,205427,DB00386,Alseroxylon
,8667431,t1/2,"The t1/2 values with a 1-mg/kg dose were 3.6 hours +/- 0.3 hour (mean +/- standard error) and 2.1 hours +/- 0.3 hour, respectively (P < .05); with a 6-mg/kg dose, the values were 8.6 hours +/- 1.8 hours and 4.2 hours +/- 0.2 hour, respectively (P = .058).",Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667431/),h,2.1,205428,DB00386,Alseroxylon
,8667431,t1/2,"The t1/2 values with a 1-mg/kg dose were 3.6 hours +/- 0.3 hour (mean +/- standard error) and 2.1 hours +/- 0.3 hour, respectively (P < .05); with a 6-mg/kg dose, the values were 8.6 hours +/- 1.8 hours and 4.2 hours +/- 0.2 hour, respectively (P = .058).",Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667431/),h,8.6,205429,DB00386,Alseroxylon
,8667431,t1/2,"The t1/2 values with a 1-mg/kg dose were 3.6 hours +/- 0.3 hour (mean +/- standard error) and 2.1 hours +/- 0.3 hour, respectively (P < .05); with a 6-mg/kg dose, the values were 8.6 hours +/- 1.8 hours and 4.2 hours +/- 0.2 hour, respectively (P = .058).",Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8667431/),h,4.2,205430,DB00386,Alseroxylon
,9060524,overall response rate,The overall response rate was 40% (17 of 42; all partial responders).,Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9060524/),%,40,205517,DB00386,Alseroxylon
,6745306,elimination half life,Previous investigations have shown that the elimination half life of vinpocetine was 2.54 +/- 0.48 hours and half-life of AVA was 3.66 +/- 1.56 hours in healthy volunteers after i.v. administration of 10 mg vinpocetine.,Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745306/),h,2.54,205558,DB00386,Alseroxylon
,6745306,half-life,Previous investigations have shown that the elimination half life of vinpocetine was 2.54 +/- 0.48 hours and half-life of AVA was 3.66 +/- 1.56 hours in healthy volunteers after i.v. administration of 10 mg vinpocetine.,Pharmacokinetics of vinpocetine and apovincaminic acid in patients with impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6745306/),h,3.66,205559,DB00386,Alseroxylon
,22904620,LD(50),"The LD(50) values of brucine solution, BSL-SPC, BSL-DPPC, BSL-HSPC, and BSL-DSPC following intravenous injection were 13.17, 37.30, 37.69, 51.18, and 52.86 mg/kg, respectively.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),[mg] / [kg],13.17,206149,DB00386,Alseroxylon
,22904620,LD(50),"The LD(50) values of brucine solution, BSL-SPC, BSL-DPPC, BSL-HSPC, and BSL-DSPC following intravenous injection were 13.17, 37.30, 37.69, 51.18, and 52.86 mg/kg, respectively.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),[mg] / [kg],37.30,206150,DB00386,Alseroxylon
,22904620,LD(50),"The LD(50) values of brucine solution, BSL-SPC, BSL-DPPC, BSL-HSPC, and BSL-DSPC following intravenous injection were 13.17, 37.30, 37.69, 51.18, and 52.86 mg/kg, respectively.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),[mg] / [kg],37.69,206151,DB00386,Alseroxylon
,22904620,LD(50),"The LD(50) values of brucine solution, BSL-SPC, BSL-DPPC, BSL-HSPC, and BSL-DSPC following intravenous injection were 13.17, 37.30, 37.69, 51.18, and 52.86 mg/kg, respectively.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),[mg] / [kg],51.18,206152,DB00386,Alseroxylon
,22904620,LD(50),"The LD(50) values of brucine solution, BSL-SPC, BSL-DPPC, BSL-HSPC, and BSL-DSPC following intravenous injection were 13.17, 37.30, 37.69, 51.18, and 52.86 mg/kg, respectively.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),[mg] / [kg],52.86,206153,DB00386,Alseroxylon
above,22904620,T(m),DSPC or HSPC with T(m) above 50°C should be used to prepare the stealth liposomal formulation for the intravenous delivery of brucine.,Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),°,50,206154,DB00386,Alseroxylon
,22904620,T(m),"However, it was found in the present paper that the pharmacokinetics and toxicity of BSL were not influenced by the PC composition when the T(m) of the PC was in the range of -20°C to 41°C.",Improved pharmacokinetics and reduced toxicity of brucine after encapsulation into stealth liposomes: role of phosphatidylcholine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22904620/),,41,206155,DB00386,Alseroxylon
,27870477,t1/2,"Noribogaine had dose-linear increases for AUC and Cmax and was slowly eliminated (mean t1/2 range, 24-30 hours).","Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870477/),h,24-30,207699,DB00386,Alseroxylon
,6527972,elimination half-live,"The elimination half-live and clearance values calculated from time plasma concentration data for iv administration were 8.9 +/- 2.87 h and 4.2 +/- 1.06 1/kg/h, respectively.",Pharmacokinetics of vinpocetine (Cavinton) in dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527972/),h,8.9,209785,DB00386,Alseroxylon
,6527972,clearance,"The elimination half-live and clearance values calculated from time plasma concentration data for iv administration were 8.9 +/- 2.87 h and 4.2 +/- 1.06 1/kg/h, respectively.",Pharmacokinetics of vinpocetine (Cavinton) in dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527972/),[1] / [h·kg],4.2,209786,DB00386,Alseroxylon
,6527972,bioavailability,The bioavailability of the drug was found to be 21.5 +/- 19.3%.,Pharmacokinetics of vinpocetine (Cavinton) in dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6527972/),%,21.5,209787,DB00386,Alseroxylon
,33847897,peak plasma concentration (Cmax,"Absorption of 7-HMG was rapid, with a peak plasma concentration (Cmax, 56.4 ± 1.6 ng/ml) observed within 15 min post-dose.","Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33847897/),[ng] / [ml],56.4,211489,DB00386,Alseroxylon
,33847897,elimination half-life,"In contrast, 7-HMG elimination was slow, exhibiting a mono-exponential distribution and mean elimination half-life of 3.6 ± 0.5 h.","Oral Pharmacokinetics in Beagle Dogs of the Mitragynine Metabolite, 7-Hydroxymitragynine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33847897/),h,3.6,211490,DB00386,Alseroxylon
,23500380,absolute bioavailability,The absolute bioavailability of brucine was determined to be 40.83%.,Evaluation of the pharmacodynamics and pharmacokinetics of brucine following transdermal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23500380/),%,40.83,211687,DB00386,Alseroxylon
,28489458,maximum concentration,The maximum concentration of ibogaine was 1.45 mg/L.,Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489458/),[mg] / [l],1.45,212041,DB00386,Alseroxylon
,28489458,ratio k12/k21,"The ratio k12/k21 for noribogaine was 21.5 and 4.28 for ibogaine, implicating a lower distribution of noribogaine from the peripheral compartment into the central compartment compared to ibogaine.",Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489458/),,21.5,212042,DB00386,Alseroxylon
,28489458,ratio k12/k21,"The ratio k12/k21 for noribogaine was 21.5 and 4.28 for ibogaine, implicating a lower distribution of noribogaine from the peripheral compartment into the central compartment compared to ibogaine.",Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28489458/),,4.28,212043,DB00386,Alseroxylon
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,5.5,212050,DB00386,Alseroxylon
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,4.0,212051,DB00386,Alseroxylon
,6160601,terminal-phase half-life,IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration.,"The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,1.3,212052,DB00386,Alseroxylon
,3435205,t1/2 beta,The t1/2 beta was 75 +/- 13 min and whole body clearance was 18.9 +/- 1.5 (ml/min.kg).,Pharmacokinetics of xylazine in ponies: influence of yohimbine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435205/),min,75,214116,DB00386,Alseroxylon
,3435205,whole body clearance,The t1/2 beta was 75 +/- 13 min and whole body clearance was 18.9 +/- 1.5 (ml/min.kg).,Pharmacokinetics of xylazine in ponies: influence of yohimbine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435205/),[ml] / [kg·min],18.9,214117,DB00386,Alseroxylon
,27789032,pKa,Vinpocetine is a poorly water soluble weakly basic drug (pKa = 7.1) used for the treatment of several cerebrovascular and cognitive disorders.,Improving Biopharmaceutical Properties of Vinpocetine Through Cocrystallization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27789032/),,7.1,214221,DB00386,Alseroxylon
,7981015,AUC,The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%).,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),[ng] / [ml],4716,214596,DB00386,Alseroxylon
,7981015,AUC,The mean (+/- s.d.) AUC (ng ml-1h-1) of oxazepam over 24 h during combined treatment was 4716 +/- 2296 and for oxazepam treatment alone it was 4737 +/- 2448 (95% confidence intervals for ratio of means = 95.4-103.7%).,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),[ng] / [ml],4737,214597,DB00386,Alseroxylon
,7981015,plasma protein binding,The degree of plasma protein binding of oxazepam was 98.11 +/- 0.32% and was not affected by vinpocetine.,Lack of pharmacokinetic interaction between vinpocetine and oxazepam. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981015/),%,98.11,214598,DB00386,Alseroxylon
,23762298,volume of distribution,"Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h).",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),[l] / [kg],1.96,214863,DB00386,Alseroxylon
,23762298,elimination half life,"Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/kg) and a relatively long elimination half life (11 h).",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),h,11,214864,DB00386,Alseroxylon
,23762298,Plasma clearance,"Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil's ability to tolerate high dosage rates of vincristine.",Vincristine chemotherapy trials and pharmacokinetics in tasmanian devils with tasmanian devil facial tumor disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23762298/),[ml] / [kg·min],1.8,214865,DB00386,Alseroxylon
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,24,215174,DB00386,Alseroxylon
,17290615,release time,The release time of VCR from compound liposome was 24 h and that from free drug (in control solution) was 6 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,6,215175,DB00386,Alseroxylon
,17290615,release time,The release of MTO from compound liposome was 0.05% after 288 h and release time of MTO from free drug (in control solution) was 12 h.,[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,12,215176,DB00386,Alseroxylon
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.16,215177,DB00386,Alseroxylon
,17290615,elimination half-life time (T 1/2),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.14,215178,DB00386,Alseroxylon
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],2.69,215179,DB00386,Alseroxylon
,17290615,AUCs (0 - 48 h),"The elimination half-life time (T 1/2) in plasma of liposomal and free VCR were 0.16 h and 0.14 h, and the AUCs (0 - 48 h) of them were 2.69 (ug x g(-1)) x h and 1.58 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],1.58,215180,DB00386,Alseroxylon
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,21.6,215181,DB00386,Alseroxylon
,17290615,elimination half-life times (T 1/2),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),h,0.05,215182,DB00386,Alseroxylon
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],17.06,215183,DB00386,Alseroxylon
,17290615,AUCs (0 - 48 h),"The elimination half-life times (T 1/2) in plasma of liposomal and free MTO were 21.6 h and 0.05 h and the AUCs (0 - 48 h) of them were 17.06 (ug x g(-1)) x h and 0.42 (ug x g(-1)) x h, respectively.",[Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290615/),[h·ug] / [g],0.42,215184,DB00386,Alseroxylon
,21968951,plasma,"Vincristine plasma and intracellular concentrations ranged from 0.40 to 89.6 ng/ml and from 0.00225 to 1.85 ng/10(6) cells over a 24-h interval, respectively.","Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968951/),[ng] / [ml],0.40 to 89.6,216077,DB00386,Alseroxylon
,21968951,intracellular concentrations,"Vincristine plasma and intracellular concentrations ranged from 0.40 to 89.6 ng/ml and from 0.00225 to 1.85 ng/10(6) cells over a 24-h interval, respectively.","Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21968951/),[ng] / [10],0.00225 to 1.85,216078,DB00386,Alseroxylon
,11052624,survival time,"At a median follow-up time of 85.1 weeks, the median survival time was 43.6 weeks (95% confidence interval 34.4-52.7) for patients who had received chemotherapy, with a survival rate of 40% at 1 year.",Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052624/),weeks,43.6,218716,DB00386,Alseroxylon
over,11052624,ultrafilterable,Patients with progressive disease exhibited a shorter duration of ultrafilterable platinum concentration over 1 microg/ml (P = 0.046) than those with other responses.,Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052624/),,1,218717,DB00386,Alseroxylon
above,11052624,ultrafilterable,The duration of ultrafilterable platinum concentration above 1 microg/ml was an important pharmacokinetic parameter for predicting both chemotherapy-induced neutropenia and treatment outcome.,Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11052624/),,1,218718,DB00386,Alseroxylon
,15235341,area under the curve [AUC],"We present long-term results of a phase II trial of induction chemotherapy (IC) with uracilftegafur (UFT) 200 mg/m orally days 1 to 21, vinorelbine 25 mg/m intravenously (IV) days 1 and 8, and cisplatin 100 mg/m IV day 1 (UFTVP) each for 21 days for 4 courses, followed by radiotherapy concomitant with UFT 100 mg/m orally daily and carboplatin (area under the curve [AUC] = 0.5 IV weekly) (RT/ UFTJ), without surgery to the primary site if response, in patients (pts) with resectable locally advanced squamous cell carcinoma of the larynx and hypopharynx.","Long-term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine, and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in a primary site preservation setting for resectable locally advanced squamous cell carcinoma of larynx and hypopharynx. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15235341/),,0.5,219630,DB00386,Alseroxylon
,11822766,Tmax,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),h,1.4,220094,DB00386,Alseroxylon
,11822766,bioavailability,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,43,220095,DB00386,Alseroxylon
,11822766,bioavailability,"Oral vinorelbine was rapidly absorbed at 80 mg/m2 (Tmax 1.4 +/- 0.7 h) and showed a bioavailability of 43 +/- 14, and close to 40% based on AUC(last) and AUC(inf), respectively.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,40,220096,DB00386,Alseroxylon
,11822766,absolute bioavailability,"The absolute bioavailability of the oral vinorelbine (new, soft gelatine capsule) was close to 40%.",Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822766/),%,40,220097,DB00386,Alseroxylon
,3196392,Plasma peak concentration of radioactivity,Plasma peak concentration of radioactivity reached during the infusion was 1.6 +/- 0.2 micrograms eq/ml.,Pharmacokinetic study of 14C-radiolabelled elliptinium acetate in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3196392/),[eq·μg] / [ml],1.6,220577,DB00386,Alseroxylon
,6428762,biologic half-lives,"Following rapid IV administration of mitomycin C (10 mg/m2), serum concentration-time course data were biexponential, with biologic half-lives of 46.2 +/- 12.1 min (mean +/- SD).",Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428762/),min,46.2,220602,DB00386,Alseroxylon
,6428762,V area,"Pharmacokinetic analysis of data by the CSTRIP and NONLIN digital computer programs generated parameters which suggested extensive distribution (V area = 656.8 +/- 169.8 ml X kg-1, mean +/- SD) and, as reported for other alkylating agents, rapid elimination (total body clearance = 10.3 +/- 3.2 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428762/),[ml] / [kg],656.8,220603,DB00386,Alseroxylon
,6428762,total body clearance,"Pharmacokinetic analysis of data by the CSTRIP and NONLIN digital computer programs generated parameters which suggested extensive distribution (V area = 656.8 +/- 169.8 ml X kg-1, mean +/- SD) and, as reported for other alkylating agents, rapid elimination (total body clearance = 10.3 +/- 3.2 ml X kg-1 X min-1, mean +/- SD).",Pharmacokinetics of mitomycin C in non-oat cell carcinoma of the lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6428762/),[ml] / [kg·min],10.3,220604,DB00386,Alseroxylon
≤,29155086,maximum plasma concentration (Cmax),Vinpocetine was absorbed rapidly in dams with a maximum plasma concentration (Cmax) reaching ≤1.37h.,Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29155086/),h,1.37,222380,DB00386,Alseroxylon
≤,29155086,elimination half-life,Vinpocetine was cleared rapidly from dam plasma with an elimination half-life of ≤4.02h with no apparent dose-related effect.,Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29155086/),h,4.02,222381,DB00386,Alseroxylon
,1884568,initial phase (t1/2 alpha),"The plasma concentration curve showed a triexponential decay with half-lives as follows: initial phase (t1/2 alpha) 1.34 min, fast elimination phase (t1/2 beta) 10.13 min and terminal (slow) phase (t1/2 gamma) 258.6 min.",Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),min,1.34,222591,DB00386,Alseroxylon
,1884568,fast elimination phase (t1/2 beta),"The plasma concentration curve showed a triexponential decay with half-lives as follows: initial phase (t1/2 alpha) 1.34 min, fast elimination phase (t1/2 beta) 10.13 min and terminal (slow) phase (t1/2 gamma) 258.6 min.",Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),min,10.13,222592,DB00386,Alseroxylon
,1884568,terminal (slow) phase (t1/2 gamma),"The plasma concentration curve showed a triexponential decay with half-lives as follows: initial phase (t1/2 alpha) 1.34 min, fast elimination phase (t1/2 beta) 10.13 min and terminal (slow) phase (t1/2 gamma) 258.6 min.",Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),min,258.6,222593,DB00386,Alseroxylon
,1884568,total plasma clearance,Other relevant pharmacokinetic parameters calculated were: total plasma clearance 45.91 L/h; volume of distribution 285.6L; protein binding 47%.,Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),[l] / [h],45.91,222594,DB00386,Alseroxylon
,1884568,volume of distribution,Other relevant pharmacokinetic parameters calculated were: total plasma clearance 45.91 L/h; volume of distribution 285.6L; protein binding 47%.,Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),l,285.6,222595,DB00386,Alseroxylon
,1884568,protein binding,Other relevant pharmacokinetic parameters calculated were: total plasma clearance 45.91 L/h; volume of distribution 285.6L; protein binding 47%.,Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),%,47,222596,DB00386,Alseroxylon
,1884568,t1/2,"It is likely that the ajmaline t1/2 reported in the literature (13.4 min) does not reflect the true terminal t1/2 of the drug, because it was determined during an unduly short sampling period (30 min).",Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884568/),min,13.4,222597,DB00386,Alseroxylon
,8339259,"dissociation constant, Kd","The gamma-emitting probe used in the RIA, 125I-(deacetyl-O4-vinblastine)-tyramine, bound very tightly to the monoclonal antibody (dissociation constant, Kd = 2.5 x 10(-11) M), demonstrating a high affinity mainly directed toward the catharantine nucleus (vindesine, vincristine, vinblastine, 100% cross-reactivity; vinorelbine, 0.3% cross-reactivity).",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),M,2.5 x 10(-11),222912,DB00386,Alseroxylon
,8339259,terminal half-life; t1/2 gamma,"As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),h,49,222913,DB00386,Alseroxylon
,8339259,"plasma clearance, CL","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [h·kg],0.14,222914,DB00386,Alseroxylon
,8339259,"volume of distribution at steady state, Vdss","As determined by RIA, the S 12363 plasma profile was triphasic with a terminal half-life; t1/2 gamma = 49 +/- 16 h, a plasma clearance, CL = 0.14 +/- 0.04 liter/h/kg, and a volume of distribution at steady state, Vdss = 5.0 +/- 2.8 liter/kg.",Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339259/),[l] / [kg],5.0,222915,DB00386,Alseroxylon
,25651476,Tmax,"Compared with placebo-pretreated subjects, paroxetine-pretreated subjects had rapid (Tmax = 1.5 hours) and substantial absorption of ibogaine, with detectable levels out to 72 hours, and an elimination half-life of 10.2 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,1.5,224676,DB00386,Alseroxylon
,25651476,elimination half-life,"Compared with placebo-pretreated subjects, paroxetine-pretreated subjects had rapid (Tmax = 1.5 hours) and substantial absorption of ibogaine, with detectable levels out to 72 hours, and an elimination half-life of 10.2 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,10.2,224677,DB00386,Alseroxylon
,25651476,Tmax,"In this group, ibogaine was also rapidly converted to noribogaine with a median Tmax of 3 hours.",Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25651476/),h,3,224678,DB00386,Alseroxylon
,21699456,AUC,"There was substantial inter-individual variability in MTX AUC (median: 795.5 µM*h/L, range 44.8-8326.44).",Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699456/),[h·μM] / [l],795.5,224886,DB00386,Alseroxylon
,20083201,"t(1/2,beta)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),min,9.7,225094,DB00386,Alseroxylon
,20083201,"t(1/2,beta)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),min,44.5,225095,DB00386,Alseroxylon
,20083201,"t(1/2,gamma)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),h,60.3,225096,DB00386,Alseroxylon
,20083201,"t(1/2,gamma)","However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),h,85.6,225097,DB00386,Alseroxylon
,20083201,AUC(0-infinity),"However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),[ng] / [lh·m],"13,099",225098,DB00386,Alseroxylon
,20083201,AUC(0-infinity),"However, the t(1/2,beta) and t(1/2,gamma) were shorter in the obese mice (9.7 min vs. 44.5 min and 60.3h vs. 85.6h, respectively), resulting in a lower AUC(0-infinity) (13,099 ng/m Lh vs. 15,384 ng/mL h).",Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20083201/),[ng] / [h·ml],"15,384",225099,DB00386,Alseroxylon
,884663,half-life,"After the distribution phase, blood levels declined with a half-life near 10 hr.",Disposition and tissue levels of [3H]vindesine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/884663/),h,10,225874,DB00386,Alseroxylon
,16798116,m/,"MS data were acquired in single ion monitoring mode at m/z 311.2, 297.2 and 332.5 for ibogaine, noribogaine and fluorescein, respectively.",Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),,311.2,226057,DB00386,Alseroxylon
,16798116,m/,"MS data were acquired in single ion monitoring mode at m/z 311.2, 297.2 and 332.5 for ibogaine, noribogaine and fluorescein, respectively.",Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),,297.2,226058,DB00386,Alseroxylon
,16798116,m/,"MS data were acquired in single ion monitoring mode at m/z 311.2, 297.2 and 332.5 for ibogaine, noribogaine and fluorescein, respectively.",Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),,332.5,226059,DB00386,Alseroxylon
,16798116,peak area ratios,The drug/internal standard peak area ratios were linked via a quadratic relationship to plasma (0.89-179 microg/l for ibogaine; 1-200 microg/l for noribogaine) and to whole blood concentrations (1.78-358 microg/kg for ibogaine; 2-400 microg/kg for noribogaine).,Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),[μg] / [l],0.89-179,226060,DB00386,Alseroxylon
,16798116,peak area ratios,The drug/internal standard peak area ratios were linked via a quadratic relationship to plasma (0.89-179 microg/l for ibogaine; 1-200 microg/l for noribogaine) and to whole blood concentrations (1.78-358 microg/kg for ibogaine; 2-400 microg/kg for noribogaine).,Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),,1-200,226061,DB00386,Alseroxylon
> or =,16798116,Extraction recoveries,Extraction recoveries were > or =94% in plasma and > or =57% in whole blood.,Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),%,94,226062,DB00386,Alseroxylon
>,16798116,Extraction recoveries,Extraction recoveries were > or =94% in plasma and > or =57% in whole blood.,Liquid chromatography-electrospray mass spectrometry determination of ibogaine and noribogaine in human plasma and whole blood. Application to a poisoning involving Tabernanthe iboga root. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16798116/),%,57,226063,DB00386,Alseroxylon
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,6.88,226135,DB00386,Alseroxylon
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,7.50,226136,DB00386,Alseroxylon
,27730471,tumor-to-muscle ratio (T/M),"The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[18F]fluorothymidine ([18F]FLT) micro positron emission tomography (PET) images of D1V1- and D1fV1-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that D1V1 is a more efficacious regimen against CT-26 xenografts.",Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[18F]Fluorothymidine PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27730471/),,9.87,226137,DB00386,Alseroxylon
,23802738,overall response rate,The overall response rate was 96% (69/72) including complete response (CR) in 65 (90%) and unconfirmed CR in 2 (3%).,"Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23802738/),%,96,226475,DB00386,Alseroxylon
,7740337,response rate,"In one study of 98 advanced breast cancer patients aged 65 years and older with limited prior therapy, the response rate of oral vinorelbine was 24% (complete response, 5%; partial response, 19%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,24,226796,DB00386,Alseroxylon
,7740337,response rate,"In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,11,226797,DB00386,Alseroxylon
,7740337,response rate,"In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%).",Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7740337/),%,0,226798,DB00386,Alseroxylon
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],20.5,227142,DB00386,Alseroxylon
,15728147,AUC(0-8),"When indinavir was given concomitantly with CHOP, the AUC(0-8) increased by 38% (20.5 +/- 9.0 versus 14.9 +/- 9.5 mg.h/L; P=0.03), and was comparable to historical controls.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[h·mg] / [l],14.9,227143,DB00386,Alseroxylon
,15728147,IC(50),"Likewise, we observed a significant number of patients with C(0) and C(8) below the IC(50) for the wild-type virus (0.1 mg/L) when the drug was administered without CHOP.",Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15728147/),[mg] / [l],0.1,227144,DB00386,Alseroxylon
,16303864,response rate,"Objective responses were reported in 18 patients (three complete responses and 15 partial responses), yielding a response rate of 40.9% in the intention-to-treat population according to the investigator assessment.",Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303864/),%,40.9,227968,DB00386,Alseroxylon
less,6697425,plasma clearance,"Moreover, the computed dose of MTX had to be increased by a larger amount if the MTX plasma clearance after the identification IV push was low (less than 9 l/h).",Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6697425/),l,9,228260,DB00386,Alseroxylon
,12398788,initial concentration,"The initial concentration at 1.5 hours after ingestion was 4.73 mg/l, falling to 0.38 mg/l at 74 hours postingestion.","Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398788/),[mg] / [l],4.73,228305,DB00386,Alseroxylon
,12398788,initial concentration,"The initial concentration at 1.5 hours after ingestion was 4.73 mg/l, falling to 0.38 mg/l at 74 hours postingestion.","Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398788/),[mg] / [l],0.38,228306,DB00386,Alseroxylon
,12398788,elimination half-life,Serum concentrations followed a monoexponential elimination curve with a calculated elimination half-life of 12 hours.,"Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398788/),h,12,228307,DB00386,Alseroxylon
,12398788,initial serum concentration,The initial serum concentration of 4.73 mg/l is the highest reported concentration in a patient who has survived.,"Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398788/),[mg] / [l],4.73,228308,DB00386,Alseroxylon
,12398788,elimination half-life,"Previous reports of the elimination half-life have suggested it is between 10 and 16 hours, which conforms to the elimination data in our case.","Case report: Survival after deliberate strychnine self-poisoning, with toxicokinetic data. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12398788/),h,10 and 16,228309,DB00386,Alseroxylon
,10494000,oral absolute bioavailability,The mean (+/-S.D.) oral absolute bioavailability of YO was 22.3+/-21. 5%.,Biopharmaceutics and metabolism of yohimbine in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),%,22.3,228477,DB00386,Alseroxylon
,10494000,Total plasma clearance (CL),"Total plasma clearance (CL) and renal clearance (CL(r)) of YO following i.v. dosing were 0.728+/-0.256 ml/min and 0.001+/-0.002 ml/min, respectively.",Biopharmaceutics and metabolism of yohimbine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),[ml] / [min],0.728,228478,DB00386,Alseroxylon
,10494000,renal clearance (CL(r)),"Total plasma clearance (CL) and renal clearance (CL(r)) of YO following i.v. dosing were 0.728+/-0.256 ml/min and 0.001+/-0.002 ml/min, respectively.",Biopharmaceutics and metabolism of yohimbine in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),[ml] / [min],0.001,228479,DB00386,Alseroxylon
,10494000,V(ss),"Based on the steady-state volume of distribution (V(ss)), YO had a relatively low distribution (V(ss) = 32.2+/-12.1 l).",Biopharmaceutics and metabolism of yohimbine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),l,32.2,228480,DB00386,Alseroxylon
,10494000,overall renal excretion,"The overall renal excretion of YO, 10-OH-YO and 11-OH-YO, expressed as percent of the dose of YO administered, were not different following i.v. and oral dosing, and were around 0.1, 0.2 and 14%, respectively.",Biopharmaceutics and metabolism of yohimbine in humans. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),%,0.1,228481,DB00386,Alseroxylon
,10494000,overall renal excretion,"The overall renal excretion of YO, 10-OH-YO and 11-OH-YO, expressed as percent of the dose of YO administered, were not different following i.v. and oral dosing, and were around 0.1, 0.2 and 14%, respectively.",Biopharmaceutics and metabolism of yohimbine in humans. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),%,0.2,228482,DB00386,Alseroxylon
,10494000,overall renal excretion,"The overall renal excretion of YO, 10-OH-YO and 11-OH-YO, expressed as percent of the dose of YO administered, were not different following i.v. and oral dosing, and were around 0.1, 0.2 and 14%, respectively.",Biopharmaceutics and metabolism of yohimbine in humans. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),%,14,228483,DB00386,Alseroxylon
,10494000,apparent terminal half-life,"Following i.v. dosing of YO, the mean apparent terminal half-life of 11-OH-YO (347+/-63 min) was almost four times higher than that of YO (91.0+/-33.6 min) suggesting an elimination rate-limited kinetics for 11-OH-YO.",Biopharmaceutics and metabolism of yohimbine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),min,347,228484,DB00386,Alseroxylon
,10494000,apparent terminal half-life,"Following i.v. dosing of YO, the mean apparent terminal half-life of 11-OH-YO (347+/-63 min) was almost four times higher than that of YO (91.0+/-33.6 min) suggesting an elimination rate-limited kinetics for 11-OH-YO.",Biopharmaceutics and metabolism of yohimbine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10494000/),min,91.0,228485,DB00386,Alseroxylon
,12902890,overall response rate,"The overall response rate was 49%, which included 3 of 29 complete responses (10%) and 11 of 29 partial responses (38%).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),%,49,229295,DB00386,Alseroxylon
,12902890,complete,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,20,229296,DB00386,Alseroxylon
,12902890,partial response durations,"Median complete and partial response durations were 20+ and 5.5 months, respectively.",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,5.5,229297,DB00386,Alseroxylon
,12902890,Overall median survival,"Overall median survival was 10 months (range, 2-30+).",Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902890/),month,10,229298,DB00386,Alseroxylon
,8383742,IC50,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,374,229428,DB00386,Alseroxylon
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,683,229429,DB00386,Alseroxylon
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,759,229430,DB00386,Alseroxylon
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,679,229431,DB00386,Alseroxylon
,8383742,peak felbamate concentrations,"Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively.",Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8383742/),μM,807,229432,DB00386,Alseroxylon
,6260340,terminal half-life,"Despite a prolonged terminal half-life of vincristine in the serum (14.4 to 37.5 hr) following i.v. bolus injection, concentrations of vincristine in the CSF ranged between undetectable within the limits of the assay and 1.1 X 10(-9) M during the 24-hr period of observation.",Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6260340/),h,14.4 to 37.5,230364,DB00386,Alseroxylon
,9135505,apparent volume of distribution,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),[l] / [kg],23.4,230953,DB00386,Alseroxylon
,9135505,terminal half-life,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),h,26.2,230954,DB00386,Alseroxylon
,9135505,systemic clearance rate,"Vinorelbine showed a large apparent volume of distribution (mean 23.4 l/kg), a long terminal half-life (mean 26.2 h) and a large systemic clearance rate (mean 1.2 l/kg).",Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9135505/),[l] / [kg],1.2,230955,DB00386,Alseroxylon
,24828449,flow rate,The flow rate was set at 0.4 mL/min.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),[ml] / [min],0.4,231005,DB00386,Alseroxylon
,24828449,recoveries,Mean recoveries were in the range of 87.3-92.6% for vindoline in rat plasma and 88.5-96.5% for catharanthine.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,87.3-92.6,231006,DB00386,Alseroxylon
,24828449,recoveries,Mean recoveries were in the range of 87.3-92.6% for vindoline in rat plasma and 88.5-96.5% for catharanthine.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,88.5-96.5,231007,DB00386,Alseroxylon
,24828449,Matrix effects,Matrix effects for vindoline and catharanthine were measured to be between 95.3 and 104.7%.,Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,95.3 and 104.7,231008,DB00386,Alseroxylon
,24828449,bioavailability,"The bioavailability of vindoline and catharanthine were 5.4 and 4.7%, respectively.",Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,5.4,231009,DB00386,Alseroxylon
,24828449,bioavailability,"The bioavailability of vindoline and catharanthine were 5.4 and 4.7%, respectively.",Liquid chromatography mass spectrometry simultaneous determination of vindoline and catharanthine in rat plasma and its application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828449/),%,4.7,231010,DB00386,Alseroxylon
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],925,231628,DB00386,Alseroxylon
,10613614,systemic clearance,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[ml] / [min],569,231629,DB00386,Alseroxylon
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,12.7,231630,DB00386,Alseroxylon
,10613614,elimination half-life,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),h,19.4,231631,DB00386,Alseroxylon
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],37.3,231632,DB00386,Alseroxylon
,10613614,total area under the plasma concentration-time curve,"The systemic clearance of vincristine was 63% higher (925 +/- 61 versus 569 +/- 76 mL/min [mean +/- SEM]; P = .004), the elimination half-life was 35% shorter (12.7 +/- 0.6 versus 19.4 +/- 3.6 hours; P = .13), and the total area under the plasma concentration-time curve was 43% smaller (37.3 +/- 2.4 versus 65.1 +/- 10.1 ng x h/mL; P = .04) in patients who were receiving carbamazepine or phenytoin than in the control group.",Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10613614/),[h·ng] / [ml],65.1,231633,DB00386,Alseroxylon
,3370551,mean residence time,"The mean residence time (+/- SD) of yohimbine was 86.7 +/- 46.2 min in steers, 106.2 +/- 72.1 to 118.7 +/- 35.0 min in horses, and 163.6 +/- 49.7 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,86.7,233264,DB00386,Alseroxylon
,3370551,mean residence time,"The mean residence time (+/- SD) of yohimbine was 86.7 +/- 46.2 min in steers, 106.2 +/- 72.1 to 118.7 +/- 35.0 min in horses, and 163.6 +/- 49.7 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,106.2,233265,DB00386,Alseroxylon
,3370551,mean residence time,"The mean residence time (+/- SD) of yohimbine was 86.7 +/- 46.2 min in steers, 106.2 +/- 72.1 to 118.7 +/- 35.0 min in horses, and 163.6 +/- 49.7 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,118.7,233266,DB00386,Alseroxylon
,3370551,mean residence time,"The mean residence time (+/- SD) of yohimbine was 86.7 +/- 46.2 min in steers, 106.2 +/- 72.1 to 118.7 +/- 35.0 min in horses, and 163.6 +/- 49.7 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,163.6,233267,DB00386,Alseroxylon
,3370551,apparent volume of distribution,"The mean apparent volume of distribution of yohimbine at steady state was 4.9 +/- 1.4 L/kg for steers, 2.7 +/- 1.0 to 4.6 +/- 1.9 L/kg for horses, and 4.5 +/- 1.8 L/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[l] / [kg],4.9,233268,DB00386,Alseroxylon
,3370551,apparent volume of distribution,"The mean apparent volume of distribution of yohimbine at steady state was 4.9 +/- 1.4 L/kg for steers, 2.7 +/- 1.0 to 4.6 +/- 1.9 L/kg for horses, and 4.5 +/- 1.8 L/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[l] / [kg],2.7,233269,DB00386,Alseroxylon
,3370551,apparent volume of distribution,"The mean apparent volume of distribution of yohimbine at steady state was 4.9 +/- 1.4 L/kg for steers, 2.7 +/- 1.0 to 4.6 +/- 1.9 L/kg for horses, and 4.5 +/- 1.8 L/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[l] / [kg],4.6,233270,DB00386,Alseroxylon
,3370551,apparent volume of distribution,"The mean apparent volume of distribution of yohimbine at steady state was 4.9 +/- 1.4 L/kg for steers, 2.7 +/- 1.0 to 4.6 +/- 1.9 L/kg for horses, and 4.5 +/- 1.8 L/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[l] / [kg],4.5,233271,DB00386,Alseroxylon
,3370551,total body clearance,"The total body clearance of yohimbine was 69.6 +/- 35.1 mL/min/kg for steers, 34.0 +/- 19.4 to 39.6 +/- 16.6 mL/min/kg for horses, and 29.6 +/- 14.7 mL/min/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[ml] / [kg·min],69.6,233272,DB00386,Alseroxylon
,3370551,total body clearance,"The total body clearance of yohimbine was 69.6 +/- 35.1 mL/min/kg for steers, 34.0 +/- 19.4 to 39.6 +/- 16.6 mL/min/kg for horses, and 29.6 +/- 14.7 mL/min/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[ml] / [kg·min],34.0,233273,DB00386,Alseroxylon
,3370551,total body clearance,"The total body clearance of yohimbine was 69.6 +/- 35.1 mL/min/kg for steers, 34.0 +/- 19.4 to 39.6 +/- 16.6 mL/min/kg for horses, and 29.6 +/- 14.7 mL/min/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[ml] / [kg·min],39.6,233274,DB00386,Alseroxylon
,3370551,total body clearance,"The total body clearance of yohimbine was 69.6 +/- 35.1 mL/min/kg for steers, 34.0 +/- 19.4 to 39.6 +/- 16.6 mL/min/kg for horses, and 29.6 +/- 14.7 mL/min/kg for dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),[ml] / [kg·min],29.6,233275,DB00386,Alseroxylon
,3370551,effective half-life,"The harmonic mean effective half-life (+/- pseudo standard deviation) of yohimbine was 46.7 +/- 24.4 min in steers, 52.8 +/- 27.8 to 76.1 +/- 23.1 min in horses, and 104.1 +/- 32.1 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,46.7,233276,DB00386,Alseroxylon
,3370551,effective half-life,"The harmonic mean effective half-life (+/- pseudo standard deviation) of yohimbine was 46.7 +/- 24.4 min in steers, 52.8 +/- 27.8 to 76.1 +/- 23.1 min in horses, and 104.1 +/- 32.1 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,52.8,233277,DB00386,Alseroxylon
,3370551,effective half-life,"The harmonic mean effective half-life (+/- pseudo standard deviation) of yohimbine was 46.7 +/- 24.4 min in steers, 52.8 +/- 27.8 to 76.1 +/- 23.1 min in horses, and 104.1 +/- 32.1 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,76.1,233278,DB00386,Alseroxylon
,3370551,effective half-life,"The harmonic mean effective half-life (+/- pseudo standard deviation) of yohimbine was 46.7 +/- 24.4 min in steers, 52.8 +/- 27.8 to 76.1 +/- 23.1 min in horses, and 104.1 +/- 32.1 min in dogs.","Comparative pharmacokinetics of yohimbine in steers, horses and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370551/),min,104.1,233279,DB00386,Alseroxylon
,27541873,"tissue/plasma partition coefficient, Kp,uu","Unbound vinorelbine tissue/plasma partition coefficient, Kp,uu, equaled ~1.0 in systemic metastases, but 0.03-0.22 in brain metastases, documenting restricted equilibration.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,1.0,233888,DB00386,Alseroxylon
,27541873,"tissue/plasma partition coefficient, Kp,uu","Unbound vinorelbine tissue/plasma partition coefficient, Kp,uu, equaled ~1.0 in systemic metastases, but 0.03-0.22 in brain metastases, documenting restricted equilibration.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,0.03-0.22,233889,DB00386,Alseroxylon
,27541873,"Kp,uu","In select sub-regions of highest drug-uptake brain metastases, Kp,uu approached 1.0, indicating complete focal barrier breakdown.",Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),,1.0,233890,DB00386,Alseroxylon
,27541873,IC50,The in vivo unbound vinorelbine IC50 for TUNEL-positive staining (56 nM) was 4-fold higher than that measured in vitro (14 nM).,Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),nM,56,233891,DB00386,Alseroxylon
,27541873,IC50,The in vivo unbound vinorelbine IC50 for TUNEL-positive staining (56 nM) was 4-fold higher than that measured in vitro (14 nM).,Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27541873/),nM,14,233892,DB00386,Alseroxylon
,15315776,extraction recoveries,"The extraction recoveries of vincristine were 57 and 60% from plasma and brain tissues, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),%,57,234128,DB00386,Alseroxylon
,15315776,extraction recoveries,"The extraction recoveries of vincristine were 57 and 60% from plasma and brain tissues, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),%,60,234129,DB00386,Alseroxylon
,15315776,retention times,"The mobile phase consisted of methanol and 15 mM ammonium acetate in 0.02% formic acid (70:30) that was pumped at 0.2 ml/min to yield retention times of 1.6 and 1.8 min for vincristine and vinblastine, the internal standard, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),min,1.6,234130,DB00386,Alseroxylon
,15315776,retention times,"The mobile phase consisted of methanol and 15 mM ammonium acetate in 0.02% formic acid (70:30) that was pumped at 0.2 ml/min to yield retention times of 1.6 and 1.8 min for vincristine and vinblastine, the internal standard, respectively.",Determination of vincristine in mouse plasma and brain tissues by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315776/),min,1.8,234131,DB00386,Alseroxylon
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"25.3 to 15,864",234197,DB00386,Alseroxylon
,32060866,clearance,"After yohimbine 5 mg, the clearance ranged from 25.3 to 15,864 mL/min and after yohimbine 50 µg, the clearance ranged from 39.6 to 38,822 mL/min.",Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32060866/),[ml] / [min],"39.6 to 38,822",234198,DB00386,Alseroxylon
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00386,Alseroxylon
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00386,Alseroxylon
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00386,Alseroxylon
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00386,Alseroxylon
,9213325,overall response rate,"Responses were seen at all dose levels, with an 80% overall response rate at the higher recommended dose; the overall response rate for patients at all dose levels was 66%.",Docetaxel combined with vinorelbine: phase I results and new study designs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213325/),%,66,235338,DB00386,Alseroxylon
,12045458,CL,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),[l] / [h],47.1,236034,DB00386,Alseroxylon
,12045458,V,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),l,16.6,236035,DB00386,Alseroxylon
,12045458,k21,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.776,236036,DB00386,Alseroxylon
,12045458,k31,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.0346,236037,DB00386,Alseroxylon
,12045458,alpha,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.431,236038,DB00386,Alseroxylon
,12045458,beta,"The population average parameters and the interindividual variabilities (CV%) were: CL=47.1 l/h (31.7%), V=16.6 l (64%), k21=0.776 h-1 (20%), k31=0.0346 h-1 (15.2%), alpha=0.431 h-1 (6.84%) and beta=0.0167 h-1 (25%).",A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12045458/),1/[h],0.0167,236039,DB00386,Alseroxylon
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],1680,237233,DB00386,Alseroxylon
,11976829,plasma AUC,"In the PK study, GemLip achieved a 35-fold higher plasma AUC (1680 mg x h/ml) than GemConv (47.6 mg x h/ml).",Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),[h·mg] / [ml],47.6,237234,DB00386,Alseroxylon
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,0.15,237235,DB00386,Alseroxylon
,11976829,serum half-lives,The serum half-lives were 0.15 h for free gemcitabine and 13.3 h for liposomal gemcitabine (6 mg/kg each i.v.).,Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11976829/),h,13.3,237236,DB00386,Alseroxylon
,12172972,IC50,"Although tumor cell proliferation and accumulation of cells in the G2 phase of the cell cycle were similarly affected by the two compounds after a continuous exposure (IC50 values of 30-50 n M), S 30972-1 was about tenfold less potent than S 16020-2 after short exposures.",Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12172972/),M·n,30-50,239299,DB00386,Alseroxylon
,8258199,maximal,"The serum concentrations decreased rapidly from a maximal value of 208.6 ng/ml (SD, 111.7 ng/ml).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[ng] / [ml],208.6,239485,DB00386,Alseroxylon
,8258199,half-life,"The mean half-life was 10.9 h (SD, 8.6 h) and the mean AUC0-48 h was 292.8 ng ml-1 h (SD, 79.4 ng ml-1 h).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),h,10.9,239486,DB00386,Alseroxylon
,8258199,AUC0-48 h,"The mean half-life was 10.9 h (SD, 8.6 h) and the mean AUC0-48 h was 292.8 ng ml-1 h (SD, 79.4 ng ml-1 h).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[h·ng] / [ml],292.8,239487,DB00386,Alseroxylon
,8258199,bile concentrations,"The bile concentrations were high, amounting to 16.0 micrograms/ml (range, 5.4-27.7 micrograms/ml).",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),[μg] / [ml],16.0,239488,DB00386,Alseroxylon
,8258199,bi,"The 0- to 48-h biliary excretion of unchanged NVB accounted for 25.8% (SD, 5.7%) of the injected dose, with 21.5% (SD, 4.0%) being eliminated during the 0- to 8-h period.",Biliary elimination and pharmacokinetics of vinorelbine in micropigs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8258199/),%,25.8,239489,DB00386,Alseroxylon
,16898072,t1/2,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),h,18.38,240122,DB00386,Alseroxylon
,16898072,t1/2,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),h,17.05,240123,DB00386,Alseroxylon
,16898072,t1/2,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),h,18.35,240124,DB00386,Alseroxylon
,16898072,AUC0-t,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),[h·μg] / [ml],3.48,240125,DB00386,Alseroxylon
,16898072,AUC0-t,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),[h·μg] / [ml],6.54,240126,DB00386,Alseroxylon
,16898072,AUC0-t,"The t1/2 values for vinflunine were estimated to be 18.38+/-1.20, 17.05+/-0.77, 18.35+/-1.57 h, and the mean AUC0-t values were 3.48+/-0.38, 6.54+/-0.68, 12.79+/-2.93 microg x h/ml, respectively.","Pharmacokinetics, tissue distribution and excretion of vinflunine. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),[h·μg] / [ml],12.79,240127,DB00386,Alseroxylon
,16898072,binding,The binding of vinflunine in human and rat plasma proteins were 39.6% and 58.4% respectively.,"Pharmacokinetics, tissue distribution and excretion of vinflunine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),%,39.6,240128,DB00386,Alseroxylon
,16898072,binding,The binding of vinflunine in human and rat plasma proteins were 39.6% and 58.4% respectively.,"Pharmacokinetics, tissue distribution and excretion of vinflunine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898072/),%,58.4,240129,DB00386,Alseroxylon
,3940223,half-life of absorption,At single doses from 1.5 to 36.5 mg/m2 (0.034-0.919 mg/kg) radioactivity was rapidly absorbed with a half-life of absorption of 1 h and a peak at 4 h.,Clinical pharmacology of vinzolidine. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940223/),h,1,240191,DB00386,Alseroxylon
,3940223,alpha half-life,Plasma decay of radiolabel followed a biphasic pattern with an alpha half-life of 10.48 h and a beta half-life of 172 h.,Clinical pharmacology of vinzolidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940223/),h,10.48,240192,DB00386,Alseroxylon
,3940223,beta half-life,Plasma decay of radiolabel followed a biphasic pattern with an alpha half-life of 10.48 h and a beta half-life of 172 h.,Clinical pharmacology of vinzolidine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940223/),h,172,240193,DB00386,Alseroxylon
,3940223,total radiolabel recovered,"The total radiolabel recovered was 52.9% +/- 11.4% of the administered label, with 90% in the feces.",Clinical pharmacology of vinzolidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940223/),%,52.9,240194,DB00386,Alseroxylon
,3940223,total radiolabel recovered,"The total radiolabel recovered was 52.9% +/- 11.4% of the administered label, with 90% in the feces.",Clinical pharmacology of vinzolidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3940223/),%,90,240195,DB00386,Alseroxylon
,8311488,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 30 mg/m2 in single administration and 25 mg/m2 in the repeated administration provided that administration is made weekly for 4 consecutive weeks.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),[mg] / [m2],30,241958,DB00386,Alseroxylon
,8311488,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was 30 mg/m2 in single administration and 25 mg/m2 in the repeated administration provided that administration is made weekly for 4 consecutive weeks.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),[mg] / [m],25,241959,DB00386,Alseroxylon
,8311488,half-life,The pharmacokinetics of KW-2307 in blood after single administration showed a triphasic disappearance pattern with half-life of about 20 to 60 hrs.,"[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8311488/),h,20 to 60,241960,DB00386,Alseroxylon
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00386,Alseroxylon
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00386,Alseroxylon
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00386,Alseroxylon
,22996801,total clearance,"Geometric mean values for vinflunine total clearance were 47.8, 37.5 and 45.4 L/h in the 3 groups of increasing degrees of LD, as compared to 42.5 L/h in reference patients with no LD.",Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996801/),[l] / [h],47.8,243318,DB00386,Alseroxylon
,22996801,total clearance,"Geometric mean values for vinflunine total clearance were 47.8, 37.5 and 45.4 L/h in the 3 groups of increasing degrees of LD, as compared to 42.5 L/h in reference patients with no LD.",Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996801/),[l] / [h],37.5,243319,DB00386,Alseroxylon
,22996801,total clearance,"Geometric mean values for vinflunine total clearance were 47.8, 37.5 and 45.4 L/h in the 3 groups of increasing degrees of LD, as compared to 42.5 L/h in reference patients with no LD.",Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996801/),[l] / [h],45.4,243320,DB00386,Alseroxylon
,22996801,total clearance,"Geometric mean values for vinflunine total clearance were 47.8, 37.5 and 45.4 L/h in the 3 groups of increasing degrees of LD, as compared to 42.5 L/h in reference patients with no LD.",Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996801/),[l] / [h],42.5,243321,DB00386,Alseroxylon
,26666045,extraction recoveries,"The linear concentration ranges of brucine and strychnine were 0.301-104.4 µg · L(-1) (r = 0.999 5) and 0.305-106 µg · L(-1) (r = 0.999 7), respectively; The intra-day and inter-day variable coefficients were both less than 10.0% with good precision; The average extraction recoveries of brucine and strychnine were 116.23% and 112.82%, and RSD were 3.2% and 2.3% separately;The average matrix effects of brucine and strychnine were 122.48% and 116.36%, and RSD were 7.7% and 4.4%, respectively.",[Contrasted study on pharmacokinetics of Tibetan medicine Renqing Mangjue compatible with Zuota]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666045/),%,116.23,244570,DB00386,Alseroxylon
,26666045,extraction recoveries,"The linear concentration ranges of brucine and strychnine were 0.301-104.4 µg · L(-1) (r = 0.999 5) and 0.305-106 µg · L(-1) (r = 0.999 7), respectively; The intra-day and inter-day variable coefficients were both less than 10.0% with good precision; The average extraction recoveries of brucine and strychnine were 116.23% and 112.82%, and RSD were 3.2% and 2.3% separately;The average matrix effects of brucine and strychnine were 122.48% and 116.36%, and RSD were 7.7% and 4.4%, respectively.",[Contrasted study on pharmacokinetics of Tibetan medicine Renqing Mangjue compatible with Zuota]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26666045/),%,112.82,244571,DB00386,Alseroxylon
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.71,244792,DB00386,Alseroxylon
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],4.32,244793,DB00386,Alseroxylon
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.95,244794,DB00386,Alseroxylon
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],6.51,244795,DB00386,Alseroxylon
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],118.30,244796,DB00386,Alseroxylon
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],82.11,244797,DB00386,Alseroxylon
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],245.54,244798,DB00386,Alseroxylon
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],86.62,244799,DB00386,Alseroxylon
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],346.69,244800,DB00386,Alseroxylon
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],2499.44,244801,DB00386,Alseroxylon
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],45.90,244802,DB00386,Alseroxylon
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],5800.05,244803,DB00386,Alseroxylon
less,20926995,Total analysis run time,Total analysis run time was less than 15 minutes.,A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926995/),min,15,245162,DB00386,Alseroxylon
,18318429,area under the concentration-time curve,"The median (range) topotecan lactone area under the concentration-time curve after the first dose was 85.4 L/hour/m(2) (range, 38.7-229.3 L/hour/m(2)).","Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318429/),[h·l] / [m(2],85.4,246782,DB00386,Alseroxylon
,17132721,peak serum concentration,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],1,247719,DB00386,Alseroxylon
,17132721,elimination half-life,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),d,7,247720,DB00386,Alseroxylon
,17132721,volume of distribution,"The population mean peak serum concentration of asparaginase enzymatic activity was 1 IU/mL, the elimination half-life was 7 days, and the volume of distribution was 2.43 L/m2.",Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[l] / [m2],2.43,247721,DB00386,Alseroxylon
,17132721,enzymatic activity,A pharmocodynamic correlation model showed minimal enzymatic activity of 0.2 IU/mL for optimal asparagine depletion.,Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17132721/),[iu] / [ml],0.2,247722,DB00386,Alseroxylon
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.53,249772,DB00386,Alseroxylon
,3359064,total plasma clearance,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),[l] / [h],0.72,249773,DB00386,Alseroxylon
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,23.2,249774,DB00386,Alseroxylon
,3359064,apparent elimination half-life,"Following IV bolus injection, the mean pharmacokinetic parameters are: total plasma clearance: 0.53 l/h-1kg-1, 0.72 l/h-1kg-1 and apparent elimination half-life: 23.2 h, 39.5 h for VDS and NVB, respectively.",[Clinical pharmacokinetics of vinca alkaloids]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3359064/),h,39.5,249775,DB00386,Alseroxylon
,1688516,major response rate (CR + MR),The major response rate (CR + MR) was thus 35%.,A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688516/),%,35,250050,DB00386,Alseroxylon
,6654533,Tmax,"The average value of Tmax is 1.4 +/- 0.5 h-1 with the tablets and 1 +/- 0.6 h-1 with the solution; the Cmax are, respectively, 155 +/- 82 micrograms . 1(-1) and 133 +/- 104 micrograms . 1(-1).",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),1/[h],1.4,250931,DB00386,Alseroxylon
,6654533,Tmax,"The average value of Tmax is 1.4 +/- 0.5 h-1 with the tablets and 1 +/- 0.6 h-1 with the solution; the Cmax are, respectively, 155 +/- 82 micrograms . 1(-1) and 133 +/- 104 micrograms . 1(-1).",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),1/[h],1,250932,DB00386,Alseroxylon
,6654533,Cmax,"The average value of Tmax is 1.4 +/- 0.5 h-1 with the tablets and 1 +/- 0.6 h-1 with the solution; the Cmax are, respectively, 155 +/- 82 micrograms . 1(-1) and 133 +/- 104 micrograms . 1(-1).",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),μg,155,250933,DB00386,Alseroxylon
,6654533,Cmax,"The average value of Tmax is 1.4 +/- 0.5 h-1 with the tablets and 1 +/- 0.6 h-1 with the solution; the Cmax are, respectively, 155 +/- 82 micrograms . 1(-1) and 133 +/- 104 micrograms . 1(-1).",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),μg,133,250934,DB00386,Alseroxylon
,6654533,AUC,The AUC are 443 +/- 156 micrograms . 1(-1) h with the tablets and 315 +/- 178 micrograms . 1(-1) h with the solution.,Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),h·μg,443,250935,DB00386,Alseroxylon
,6654533,AUC,The AUC are 443 +/- 156 micrograms . 1(-1) h with the tablets and 315 +/- 178 micrograms . 1(-1) h with the solution.,Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),h·μg,315,250936,DB00386,Alseroxylon
,6654533,elimination phases,"The short elimination phases, 1.43 +/- 0.80 h with the tablets and 1.55 +/- 0.78 h with the solution should be taken into account during chronic administration.",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),h,1.43,250937,DB00386,Alseroxylon
,6654533,elimination phases,"The short elimination phases, 1.43 +/- 0.80 h with the tablets and 1.55 +/- 0.78 h with the solution should be taken into account during chronic administration.",Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6654533/),h,1.55,250938,DB00386,Alseroxylon
,26801247,PFS,"Median PFS for all 50 patients was 5.5 months (95% confidence interval, 4.1-6.7).",Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26801247/),month,5.5,251225,DB00386,Alseroxylon
,6683519,plasma concentrations during steady state conditions,Mean plasma concentrations during steady state conditions were 218 ng/ml.,[Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683519/),[ng] / [ml],218,251551,DB00386,Alseroxylon
,6683519,Plasma half-life,Plasma half-life was determined 7.3 h.,[Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683519/),h,7.3,251552,DB00386,Alseroxylon
,6683519,therapeutic plasma concentrations,The lower limit of therapeutic plasma concentrations was between 43 and 145 ng/ml.,[Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683519/),[ng] / [ml],43 and 145,251553,DB00386,Alseroxylon
,6683519,total clearance,A mean total clearance of 344 ml/min indicates a low hepatic extraction of prajmalium bitartrate.,[Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683519/),[ml] / [min],344,251554,DB00386,Alseroxylon
,6683519,distribution volume,"Moreover, the distribution volume of 204 l suggests a high tissue affinity of the drug.",[Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6683519/),l,204,251555,DB00386,Alseroxylon
,30542768,OS,"Median OS and treatment duration were 27 weeks (range 1.3-183) and 15 weeks (range 1.3-144), respectively.",Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30542768/),weeks,27,251670,DB00386,Alseroxylon
,21056658,bioavailability,Vinpocetine (Vin) existing oral formulations suffer poor bioavailability (∼7%) since Vin undergoes a marked first-pass effect (∼75%) and its absorption is dissolution rate-limited.,Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056658/),%,∼7,252275,DB00386,Alseroxylon
,21056658,relative bioavailability (F(rel)),The extent of absorption of Vin from proniosomes was larger when compared to the oral tablet with a relative bioavailability (F(rel)) of 206%.,Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056658/),%,206,252276,DB00386,Alseroxylon
,21107682,progression-free survival,"ORR was 19.1%, with a disease control rate of 83.0% and median progression-free survival of 30.7 weeks.",Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21107682/),weeks,30.7,252471,DB00386,Alseroxylon
,33277117,volume of distribution,"The plasma was analyzed to obtain concentration-time profiles and results were subjected to non-compartmental analysis to determine pharmacokinetic parameters including volume of distribution (6.2 ± 2.3 L/kg I.V.), clearance (0.7 ± 0.2 L/hr/kg), and absolute oral bioavailability (20.7 %).","Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277117/),[l] / [kg],6.2,252546,DB00386,Alseroxylon
,33277117,clearance,"The plasma was analyzed to obtain concentration-time profiles and results were subjected to non-compartmental analysis to determine pharmacokinetic parameters including volume of distribution (6.2 ± 2.3 L/kg I.V.), clearance (0.7 ± 0.2 L/hr/kg), and absolute oral bioavailability (20.7 %).","Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277117/),[l] / [h·kg],0.7,252547,DB00386,Alseroxylon
,33277117,absolute oral bioavailability,"The plasma was analyzed to obtain concentration-time profiles and results were subjected to non-compartmental analysis to determine pharmacokinetic parameters including volume of distribution (6.2 ± 2.3 L/kg I.V.), clearance (0.7 ± 0.2 L/hr/kg), and absolute oral bioavailability (20.7 %).","Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33277117/),%,20.7,252548,DB00386,Alseroxylon
,2384117,drug accumulation site,The most important drug accumulation site was the spleen (615.0 ng/g at 24 h).,In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384117/),[ng] / [g],615.0,252661,DB00386,Alseroxylon
,2384117,Urine excretion,Urine excretion of drug over 7 days was low (10.1 +/- 1.8% of total dose) and consisted mainly of unchanged drug (more than 85%).,In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide). ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2384117/),%,10.1,252662,DB00386,Alseroxylon
,22864874,overall response rate,"All patients were evaluable, and the overall response rate was 73.3 % (95 % CI 54.1-87.7).",A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864874/),%,73.3,252774,DB00386,Alseroxylon
,22864874,progression-free survival,The median progression-free survival was 11.3 months (95 % CI 9.4-21.0).,A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22864874/),month,11.3,252775,DB00386,Alseroxylon
,27616886,EE%,"However, the EE% was ~99.0% with drug loading at 2.0 mg/mL, which did not change after the coating process.",The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616886/),%,99.0,252974,DB00386,Alseroxylon
,16357174,t(1/2),Pharmacokinetic and biodistribution studies confirmed long circulation times (t(1/2) = 21 hours) and efficient accumulation in tumors (up to 15% ID/g) irrespective of the presence of the targeting ligand.,Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16357174/),h,21,253278,DB00386,Alseroxylon
,17541591,AUCs,"Mean AUCs were 1,230 +/- 290 and 1,216 +/- 521 ng/ml for i.v. and oral, respectively.",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),[ng] / [ml],"1,230",254433,DB00386,Alseroxylon
,17541591,AUCs,"Mean AUCs were 1,230 +/- 290 and 1,216 +/- 521 ng/ml for i.v. and oral, respectively.",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),[ng] / [ml],"1,216",254434,DB00386,Alseroxylon
,17541591,absolute bioavailability,"The absolute bioavailability was 37.8 +/- 16.0%, and close to the value from the first study (40%).",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),%,37.8,254435,DB00386,Alseroxylon
,17541591,absolute bioavailability,"The absolute bioavailability was 37.8 +/- 16.0%, and close to the value from the first study (40%).",Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17541591/),%,40,254436,DB00386,Alseroxylon
,2410121,Steady-state concentrations,Steady-state concentrations ranged from 4 to 15 micrograms/L and showed important variations among patients.,Clinical pharmacokinetics of vindesine infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410121/),[μg] / [l],4 to 15,255313,DB00386,Alseroxylon
,26838831,serum half-life,"However, poor biopharmaceutical and pharmacokinetic traits of VCS like short serum half-life (12 min), high dosing frequency (1.4 mg/m(2) per week for 4 weeks) and extensive protein binding (75%) limit the clinical potential of VCS in cancer therapy.","Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),min,12,255702,DB00386,Alseroxylon
,26838831,protein binding,"However, poor biopharmaceutical and pharmacokinetic traits of VCS like short serum half-life (12 min), high dosing frequency (1.4 mg/m(2) per week for 4 weeks) and extensive protein binding (75%) limit the clinical potential of VCS in cancer therapy.","Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),%,75,255703,DB00386,Alseroxylon
,26838831,zeta-potential,Particle size and zeta-potential of VCS-Dextran-MSs were measured to be 6.8 ± 2.4 μm and -18.3 ± 0.11 mV along with the encapsulation efficiency of about 60.4 ± 4.5%.,"Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),mv,-,255704,DB00386,Alseroxylon
,26838831,zeta-potential,Particle size and zeta-potential of VCS-Dextran-MSs were measured to be 6.8 ± 2.4 μm and -18.3 ± 0.11 mV along with the encapsulation efficiency of about 60.4 ± 4.5%.,"Vincristine sulfate loaded dextran microspheres amalgamated with thermosensitive gel offered sustained release and enhanced cytotoxicity in THP-1, human leukemia cells: In vitro and in vivo study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26838831/),mv,18.3,255705,DB00386,Alseroxylon
,2591421,distribution half-life,A distribution half-life of 6 +/- 1 min and an elimination half-life of 95 +/- 6 min was determined in Group 1.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),min,6,256955,DB00386,Alseroxylon
,2591421,elimination half-life,A distribution half-life of 6 +/- 1 min and an elimination half-life of 95 +/- 6 min was determined in Group 1.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),min,95,256956,DB00386,Alseroxylon
,2591421,plasma protein binding,The ajmaline plasma protein binding was 76 +/- 9%.,Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591421/),%,76,256957,DB00386,Alseroxylon
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [kg·min],19.9,259481,DB00386,Alseroxylon
,7931891,clearance,"Vincristine clearance, estimated by Bayesian methods, was highly variable, with a mean (SD) clearance of 19.9 (14.9) ml/min per kilogram or 482 (342) ml/min per square meter.",Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931891/),[ml] / [meter·min·square],482,259482,DB00386,Alseroxylon
,1455905,terminal half-life,2. Plasma levels of I declined in a triphasic manner with a terminal half-life of approximately 50 h; most drug elimination (55%) being associated with the terminal phase.,Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455905/),h,50,259656,DB00386,Alseroxylon
,1455905,Clearance,3. Clearance of I was relatively low (245 +/- 160 ml/min) and remained constant with increasing doses.,Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455905/),[ml] / [min],245,259657,DB00386,Alseroxylon
,1455905,distribution volume,"Initial distribution volume was low (approximately 71) but once distribution was complete, it was comparatively high (327 +/- 2121).",Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455905/),,71,259658,DB00386,Alseroxylon
,1455905,distribution volume,"Initial distribution volume was low (approximately 71) but once distribution was complete, it was comparatively high (327 +/- 2121).",Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455905/),,327,259659,DB00386,Alseroxylon
less,1455905,Hill constant,"The Hill constant was less than 1, indicating a relatively shallow exposure/response curve and a predictable, graded increase in response with increasing I exposure, rather than a sudden quantal response.",Value of early pharmacodynamic and pharmacokinetic investigations with anticancer drugs: data from phase I tolerance studies on a new vinca alkaloid derivative. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1455905/),,1,259660,DB00386,Alseroxylon
,24365981,flow rate,"Chromatographic separation of these anticancer drugs was achieved with an isocratic mobile phase consisting of acetonitrile/aqueous buffer (10 mmol/L ammonium acetate and 0.1% formic acid in 70:30, vol/vol) at a flow rate of 0.25 mL/min in a short time (4.5 minutes).","Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365981/),[ml] / [min],0.25,260934,DB00386,Alseroxylon
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261637,DB00386,Alseroxylon
,6498821,systemic clearance,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261638,DB00386,Alseroxylon
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.9,261639,DB00386,Alseroxylon
,6498821,area under the concentration-time curves,"Navelbine systemic clearance was estimated from the area under the concentration-time curves [1.9 +/- 0.5 (S.D.) liters/hr/kg] and was found to be larger than that of vinblastine (1.1 +/- 0.4 liters/hr/kg) measured under similar conditions (dose, 0.6 mg/kg).",Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),[l] / [h·kg],1.1,261640,DB00386,Alseroxylon
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.9,261641,DB00386,Alseroxylon
,6498821,Terminal half-lives,Terminal half-lives were 8.9 +/- 2.1 hr for navelbine and 8.1 +/- 2.6 hr for vinblastine.,Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6498821/),h,8.1,261642,DB00386,Alseroxylon
,8287634,final half-life,Plasma concentration decay followed a triexponential time course with a final half-life much longer (7.3 +/- 3.6 hours) than that previously found by other investigators (about 15 minutes).,Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),h,7.3,262064,DB00386,Alseroxylon
,8287634,final half-life,Plasma concentration decay followed a triexponential time course with a final half-life much longer (7.3 +/- 3.6 hours) than that previously found by other investigators (about 15 minutes).,Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),min,15,262065,DB00386,Alseroxylon
,8287634,total plasma clearance,"Mean total plasma clearance and renal clearance were 9.76 ml/min/kg and 0.028 ml/min/kg, respectively.",Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),[ml] / [kg·min],9.76,262066,DB00386,Alseroxylon
,8287634,renal clearance,"Mean total plasma clearance and renal clearance were 9.76 ml/min/kg and 0.028 ml/min/kg, respectively.",Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),[ml] / [kg·min],0.028,262067,DB00386,Alseroxylon
,8287634,steady-state volume of distribution,"The steady-state volume of distribution averaged 6.17 L/kg, and plasma protein binding ranged between 29 and 46%.",Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),[l] / [kg],6.17,262068,DB00386,Alseroxylon
,8287634,plasma protein binding,"The steady-state volume of distribution averaged 6.17 L/kg, and plasma protein binding ranged between 29 and 46%.",Pharmacokinetics and electrophysiological effects of intravenous ajmaline. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8287634/),%,29 and 46,262069,DB00386,Alseroxylon
,3774624,T1/2,"The drug, when administered orally, was readily absorbed from the gastrointestinal tract (T1/2 0.3 h) and underwent similarly fast distribution (T1/2 0.8 h) in the organism.",Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),h,0.3,262079,DB00386,Alseroxylon
,3774624,T1/2,"The drug, when administered orally, was readily absorbed from the gastrointestinal tract (T1/2 0.3 h) and underwent similarly fast distribution (T1/2 0.8 h) in the organism.",Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),h,0.8,262080,DB00386,Alseroxylon
,3774624,elimination half-life,The mean value of the elimination half-life was 8.2 h.,Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),h,8.2,262081,DB00386,Alseroxylon
,3774624,Fecal,Fecal and urinary excretion of radioactivity applied amounted to about 82%.,Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),%,82,262082,DB00386,Alseroxylon
,3774624,u,Fecal and urinary excretion of radioactivity applied amounted to about 82%.,Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),%,82,262083,DB00386,Alseroxylon
,3774624,excretion,Fecal and urinary excretion of radioactivity applied amounted to about 82%.,Pharmacokinetic and metabolic studies of vinpocetine on dogs. I. Pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774624/),%,82,262084,DB00386,Alseroxylon
,2624613,AUC,"Oral administration of 20 mg vinpocetine resulted in 4.60 x 10(-8) mol l-1 h, 1.71 x 10(-8) mol l-1 and 2.33 h for AUC, Cmax and tmax, respectively.",Vinpocetine pharmacokinetics in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),[mol] / [l],1.71 x 10(-8),262424,DB00386,Alseroxylon
,2624613,Cmax,"Oral administration of 20 mg vinpocetine resulted in 4.60 x 10(-8) mol l-1 h, 1.71 x 10(-8) mol l-1 and 2.33 h for AUC, Cmax and tmax, respectively.",Vinpocetine pharmacokinetics in elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),h,2.33,262425,DB00386,Alseroxylon
,2624613,tmax,"Oral administration of 20 mg vinpocetine resulted in 4.60 x 10(-8) mol l-1 h, 1.71 x 10(-8) mol l-1 and 2.33 h for AUC, Cmax and tmax, respectively.",Vinpocetine pharmacokinetics in elderly subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),h,2.33,262426,DB00386,Alseroxylon
,2624613,AUC,"When 10 mg vinpocetine were infused for 1 h, AUC values for vinpocetine and apovincaminic acid were 3.42 x 10(-7) mol l-1 h and 1.69 x 10(-6) mol l-1 h.",Vinpocetine pharmacokinetics in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),[h·mol] / [l],3.42 x 10(-7),262427,DB00386,Alseroxylon
,2624613,AUC,"When 10 mg vinpocetine were infused for 1 h, AUC values for vinpocetine and apovincaminic acid were 3.42 x 10(-7) mol l-1 h and 1.69 x 10(-6) mol l-1 h.",Vinpocetine pharmacokinetics in elderly subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),[h·mol] / [l],1.69 x 10(-6),262428,DB00386,Alseroxylon
,2624613,Absolute bioavailability,Absolute bioavailability of vinpocetine was 6.7%.,Vinpocetine pharmacokinetics in elderly subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2624613/),%,6.7,262429,DB00386,Alseroxylon
,8141830,half-life,"2. Plasma concentrations of drug-related radioactivity declined in a bi- or tri-exponential manner, initially rapidly and then slowly (half-life of 35 h or more).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,35,263164,DB00386,Alseroxylon
,8141830,terminal half-lives,Unchanged drug concentrations declined with terminal half-lives of 35.8 h in rats and 34.5h in dogs: a terminal phase was not observed in mice.,"Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,35.8,263165,DB00386,Alseroxylon
,8141830,terminal half-lives,Unchanged drug concentrations declined with terminal half-lives of 35.8 h in rats and 34.5h in dogs: a terminal phase was not observed in mice.,"Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),h,34.5,263166,DB00386,Alseroxylon
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],3.78,263167,DB00386,Alseroxylon
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],1.73,263168,DB00386,Alseroxylon
,8141830,clearance,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [h·kg],1.20,263169,DB00386,Alseroxylon
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],12.7,263170,DB00386,Alseroxylon
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],41.9,263171,DB00386,Alseroxylon
,8141830,volume of distribution,"KW-2307 can be characterised as a drug of high clearance (3.78, 1.73 and 1.20 l/h/kg in the mice, rats and dogs, respectively) and large volume of distribution (12.7, 41.9 and 49.6 l/kg in the mouse, rat and dog, respectively).","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),[l] / [kg],49.6,263172,DB00386,Alseroxylon
,8141830,accumulation ratio,"After repeated administrations for 21 days in the rat, the accumulation ratio for unchanged drug concentrations in plasma was 1.5.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),,1.5,263173,DB00386,Alseroxylon
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,89,263174,DB00386,Alseroxylon
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,90,263175,DB00386,Alseroxylon
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,93,263176,DB00386,Alseroxylon
,8141830,binding,"3. The extent of binding of 3H-KW-2307 in vitro to proteins in the plasma of humans, dogs, rats and mice was 89, 90, 93 and 97%, respectively.","Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8141830/),%,97,263177,DB00386,Alseroxylon
,12367795,area under the curve (AUC),"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,1.5,263280,DB00386,Alseroxylon
,12367795,AU,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,0.5,263281,DB00386,Alseroxylon
,12367795,maximum AUC,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,3,263282,DB00386,Alseroxylon
,12367795,AUC,"It consisted of vinorelbine at 15 mg/m(2) and carboplatin administered at an initial area under the curve (AUC) of 1.5, and increased by an AUC of 0.5 per dose level to a maximum AUC of 3, corresponding with an AUC of 6 per cycle of chemotherapy.",Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),1/[cycle],6,263283,DB00386,Alseroxylon
,12367795,AUC,The recommended phase II dose of carboplatin is an AUC of 3 on 2 consecutive weeks.,Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),,3,263284,DB00386,Alseroxylon
,12367795,survival,The median survival for the entire group and for patients with stage II/III disease was 13.5 months.,Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12367795/),month,13.5,263285,DB00386,Alseroxylon
,15668288,overall response rate,"In 30 patients evaluated for response and toxicity, the overall response rate was 37% and 10% of patients achieved stable disease.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),%,37,263607,DB00386,Alseroxylon
,15668288,time to progression,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,5.5,263608,DB00386,Alseroxylon
,15668288,overall survival,"Median time to progression and overall survival were 5.5 months (range 1-10) and 9 months (range 2-16), respectively.",Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15668288/),month,9,263609,DB00386,Alseroxylon
,15519515,disease control rate,"Six partial responses (11%) and 25 stable disease responses were recorded, with a disease control rate of 55%.","Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),%,55,264079,DB00386,Alseroxylon
,15519515,overall survival,Median overall survival was 8.2 months (95% Confidence Interval (CI) [6.2-11.3]).,"Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),month,8.2,264080,DB00386,Alseroxylon
,15519515,clinical benefit response rate,The clinical benefit response rate was 31% on 32 evaluable patients.,"Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15519515/),%,31,264081,DB00386,Alseroxylon
,12394263,T/C,VCR-Lip at a dose of 1.0 mg/kg (dose near the maximum tolerated dose) led to partial remissions in the MX1 tumor xenograft model (T/C=3.9%).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,3.9,264594,DB00386,Alseroxylon
,12394263,T/C,VCR-Conv at an equitoxic dose of 0.6 mg/kg produced only a tumor growth inhibition (T/C=7.0%).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,7.0,264595,DB00386,Alseroxylon
,12394263,T/C,"In LXFS 650 tumor-bearing mice, VCR-Lip was highly active at doses of 0.75 (T/C=0.7%) and 1.0 (T/C=0.0%) mg/kg, and complete tumor regressions were observed.",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,0.7,264596,DB00386,Alseroxylon
,12394263,T/C,"In LXFS 650 tumor-bearing mice, VCR-Lip was highly active at doses of 0.75 (T/C=0.7%) and 1.0 (T/C=0.0%) mg/kg, and complete tumor regressions were observed.",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,0.0,264597,DB00386,Alseroxylon
,12394263,T/C,"In contrast, equitoxic doses of VCR-Conv (0.6 mg/kg) resulted only in less pronounced tumor remissions (T/C=4.1%).",Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),%,4.1,264598,DB00386,Alseroxylon
,12394263,plasma AUC,The PK study revealed that VCR-Lip achieved an over 10-fold higher plasma AUC (22.6 microg x h/ml) than VCR-Conv (2.16 microg x h/ml).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),[h·μg] / [ml],22.6,264599,DB00386,Alseroxylon
,12394263,plasma AUC,The PK study revealed that VCR-Lip achieved an over 10-fold higher plasma AUC (22.6 microg x h/ml) than VCR-Conv (2.16 microg x h/ml).,Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12394263/),[h·μg] / [ml],2.16,264600,DB00386,Alseroxylon
,15197807,steady-state plasma concentration,The steady-state plasma concentration of VCR during continuous infusion ranged from 1 to 3 microg/L in all patients.,Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197807/),[μg] / [l],1 to 3,265714,DB00386,Alseroxylon
,2295217,elimination half-life,"Overall mean values for the pharmacokinetic variables were as follows: elimination half-life, 31.5 hours; distribution volume, 4.43 L; and clearance, 0.09 L/hr.",Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295217/),h,31.5,265947,DB00386,Alseroxylon
,2295217,distribution volume,"Overall mean values for the pharmacokinetic variables were as follows: elimination half-life, 31.5 hours; distribution volume, 4.43 L; and clearance, 0.09 L/hr.",Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295217/),l,4.43,265948,DB00386,Alseroxylon
,2295217,clearance,"Overall mean values for the pharmacokinetic variables were as follows: elimination half-life, 31.5 hours; distribution volume, 4.43 L; and clearance, 0.09 L/hr.",Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2295217/),[l] / [h],0.09,265949,DB00386,Alseroxylon
,22337718,Total clearance,Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],9.43,266008,DB00386,Alseroxylon
,22337718,Vd(ss),Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l.,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),l,9.61,266009,DB00386,Alseroxylon
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],8.21,266010,DB00386,Alseroxylon
,22337718,clearance,Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),[ml] / [h],12.68,266011,DB00386,Alseroxylon
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,30.7,266012,DB00386,Alseroxylon
,22337718,t(1/2β),Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003).,The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337718/),d,24.7,266013,DB00386,Alseroxylon
,7850920,maximal tolerated AUC,"The maximal tolerated AUC was 5 mg ml-1 min, with neutropenia being the dose-limiting toxicity.",A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850920/),[mg·min] / [ml],5,266538,DB00386,Alseroxylon
,7850920,AUC,The recommended AUC for phase II study is 4 mg ml-1 min.,A pharmacologically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7850920/),[mg·min] / [ml],4,266539,DB00386,Alseroxylon
,27613245,elimination t½,VCR demonstrated a rapid distribution phase (6-8 h) followed by a slower elimination phase with a mean elimination t½ of ~ 14 h.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),h,14,267377,DB00386,Alseroxylon
,27613245,Vc,It showed a relatively small Vc (~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicating good tissue distribution.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),[l] / [kg],0.17,267378,DB00386,Alseroxylon
,27613245,Vβ,It showed a relatively small Vc (~0.17 L/Kg) and a larger Vβ (1.53 L/Kg) indicating good tissue distribution.,The effect of increased lipoproteins levels on the disposition of vincristine in rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27613245/),[l] / [kg],1.53,267379,DB00386,Alseroxylon
,2891480,t1/2,"The t1/2 values, determined radiometrically, were 145 hr and 62 hr in male rats after 10 and 100 mg/kg doses and 92 hr and 90 hr in male and female monkeys after a 40 mg/kg dose.","Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891480/),h,145,268759,DB00386,Alseroxylon
,2891480,t1/2,"The t1/2 values, determined radiometrically, were 145 hr and 62 hr in male rats after 10 and 100 mg/kg doses and 92 hr and 90 hr in male and female monkeys after a 40 mg/kg dose.","Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891480/),h,62,268760,DB00386,Alseroxylon
,2891480,t1/2,"The t1/2 values, determined radiometrically, were 145 hr and 62 hr in male rats after 10 and 100 mg/kg doses and 92 hr and 90 hr in male and female monkeys after a 40 mg/kg dose.","Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891480/),h,92,268761,DB00386,Alseroxylon
,2891480,t1/2,"The t1/2 values, determined radiometrically, were 145 hr and 62 hr in male rats after 10 and 100 mg/kg doses and 92 hr and 90 hr in male and female monkeys after a 40 mg/kg dose.","Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891480/),h,90,268762,DB00386,Alseroxylon
,27257769,absolute bioavailability,The absolute bioavailability of voacangine was determined to be 11-13 %.,Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS Method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27257769/),%,11-13,269127,DB00386,Alseroxylon
,30465727,Cmax,Oral reserpine administration demonstrated low plasma concentrations with a Cmax of 0.2 ± 0.06 ng/mL and a prolonged half-life of 23.6 ± 6.24 h.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),[ng] / [ml],0.2,269652,DB00386,Alseroxylon
,30465727,half-life,Oral reserpine administration demonstrated low plasma concentrations with a Cmax of 0.2 ± 0.06 ng/mL and a prolonged half-life of 23.6 ± 6.24 h.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),h,23.6,269653,DB00386,Alseroxylon
,30465727,Cmax at steady state,Simulations over a dose range of 2-8 μg/kg predicted Cmax at steady state between 0.06-0.9 ng/mL.,Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30465727/),[ng] / [ml],0.06-0.9,269654,DB00386,Alseroxylon
,582790,half-life,"The drug is rapidly eliminated, its half-life was found to be 125 min.",Kinetic metabolism of vinpocetine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582790/),min,125,269694,DB00386,Alseroxylon
,582790,apparent volume of distribution,The apparent volume of distribution was 3.8 l/kg and the clearance rate 33 ml/min/kg.,Kinetic metabolism of vinpocetine in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582790/),[l] / [kg],3.8,269695,DB00386,Alseroxylon
,582790,clearance rate,The apparent volume of distribution was 3.8 l/kg and the clearance rate 33 ml/min/kg.,Kinetic metabolism of vinpocetine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582790/),[ml] / [kg·min],33,269696,DB00386,Alseroxylon
,582790,Bioavailability,Bioavailability of vinpocetine after p.o. administration was about 50%.,Kinetic metabolism of vinpocetine in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582790/),%,50,269697,DB00386,Alseroxylon
,582790,half-life,"The main metabolite, free apovincaminic acid, is formed very rapidly in rats and is eliminated from plasma with a half-life of 360 min.",Kinetic metabolism of vinpocetine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582790/),min,360,269698,DB00386,Alseroxylon
,30339904,cytotoxicity ratios (HCR),"The hypoxic cytotoxicity ratios (HCR) of CPD100 and CPD100Li are 0.16 and 0.11, respectively.",Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339904/),,0.16,270458,DB00386,Alseroxylon
,30339904,cytotoxicity ratios (HCR),"The hypoxic cytotoxicity ratios (HCR) of CPD100 and CPD100Li are 0.16 and 0.11, respectively.",Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339904/),,0.11,270459,DB00386,Alseroxylon
,30339904,DLT,The DLT for both CPD100 and CPD100Li is 45 mg/kg and the MTD is 40 mg/kg in nude mice.,Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339904/),[mg] / [kg],45,270460,DB00386,Alseroxylon
,30339904,MTD,The DLT for both CPD100 and CPD100Li is 45 mg/kg and the MTD is 40 mg/kg in nude mice.,Liposomal formulation of hypoxia activated prodrug for the treatment of ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339904/),[mg] / [kg],40,270461,DB00386,Alseroxylon
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,754.6,271193,DB00386,Alseroxylon
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,123.8,271194,DB00386,Alseroxylon
,24721203,m/z,"The ion transitions recorded in multiple reaction monitoring mode were m/z 754.6→123.8 for VDS and 779.4→323.3 for IS, respectively.",Validated HILIC-MS/MS assay for determination of vindesine in human plasma: Application to a population pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24721203/),,779.4,271195,DB00386,Alseroxylon
,30602,half-times,"The rate of elimination of ellipticine from blood was species-dependent, half-times ranging from 22 min in mouse to 210 min in rat, and probably reflected the rate of metabolism of the drug.",Comparative physiological disposition of ellipticine in several animal species after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602/),min,22,271540,DB00386,Alseroxylon
,30602,half-times,"The rate of elimination of ellipticine from blood was species-dependent, half-times ranging from 22 min in mouse to 210 min in rat, and probably reflected the rate of metabolism of the drug.",Comparative physiological disposition of ellipticine in several animal species after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602/),min,210,271541,DB00386,Alseroxylon
,30602,half-times,"The rate of elimination of metabolites from blood was also species-dependent, half-times ranging from 140 min in mouse to 380 min in rat, and probably reflected the rate of biliary secretion of the metabolites.",Comparative physiological disposition of ellipticine in several animal species after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602/),min,140,271542,DB00386,Alseroxylon
,30602,half-times,"The rate of elimination of metabolites from blood was also species-dependent, half-times ranging from 140 min in mouse to 380 min in rat, and probably reflected the rate of biliary secretion of the metabolites.",Comparative physiological disposition of ellipticine in several animal species after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30602/),min,380,271543,DB00386,Alseroxylon
<,21958965,T(max),"Upon oral administration, brucine was rapidly absorbed (T(max)<0.5h), which was consistent with previously reported high Caco-2 P(app) values.",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),h,0.5,271629,DB00386,Alseroxylon
,21958965,oral bioavailability (F),"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,40.31,271630,DB00386,Alseroxylon
,21958965,oral bioavailability (F),"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,47.15,271631,DB00386,Alseroxylon
,21958965,oral bioavailability (F),"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,43.02,271632,DB00386,Alseroxylon
,21958965,F,"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,40.31,271633,DB00386,Alseroxylon
,21958965,F,"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,47.15,271634,DB00386,Alseroxylon
,21958965,F,"The oral bioavailability (F) did not vary with the dose (F=40.31%, 47.15% and 43.02% for 10, 20, 40 mg/kg doses, respectively).",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),%,43.02,271635,DB00386,Alseroxylon
,21958965,C(max)/Dose,"The values of C(max)/Dose were calculated to be 92.92±45.83, 55.73±24.01 and 36.29±22.44 μg/L for 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),[μg] / [l],92.92,271636,DB00386,Alseroxylon
,21958965,C(max)/Dose,"The values of C(max)/Dose were calculated to be 92.92±45.83, 55.73±24.01 and 36.29±22.44 μg/L for 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),[μg] / [l],55.73,271637,DB00386,Alseroxylon
,21958965,C(max)/Dose,"The values of C(max)/Dose were calculated to be 92.92±45.83, 55.73±24.01 and 36.29±22.44 μg/L for 10, 20 and 40 mg/kg, respectively.",Pharmacokinetics of brucine after intravenous and oral administration to rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21958965/),[μg] / [l],36.29,271638,DB00386,Alseroxylon
,19043234,accumulation potential E(acc),"The optimal experimental variables as well as accumulation parameters were investigated as; frequency f=120 Hz, scan increment DeltaE(i)=10 mV, pulse-amplitude DeltaE(a)=25 mV and an accumulation potential E(acc) of 0.0 V using a Britton-Robinson (B-R) universal buffer of pH 5 as a supporting electrolyte.",Development and validation of an adsorptive stripping voltammetric method for the quantification of vincamine in its formulations and human serum using a Nujol-based carbon paste electrode. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043234/),v,0.0,272296,DB00386,Alseroxylon
,19043234,recovery,Mean recovery of 100.41+/-0.74 (n=5) was achieved for assay of vincamine in Oxybral capsules.,Development and validation of an adsorptive stripping voltammetric method for the quantification of vincamine in its formulations and human serum using a Nujol-based carbon paste electrode. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043234/),,100.41,272297,DB00386,Alseroxylon
,19043234,recovery,"Limits of detection and quantitation of 6.0 x 10(-9) M (2.20 ng ml(-1)) and 2 x 10(-8) M (7.33 ng ml(-1)) vincamine were achieved in human serum with a mean recovery of 99.5+/-1.79%, without prior extraction of the drug.",Development and validation of an adsorptive stripping voltammetric method for the quantification of vincamine in its formulations and human serum using a Nujol-based carbon paste electrode. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19043234/),%,99.5,272298,DB00386,Alseroxylon
,8652269,half-life,"In a preliminary pharmacokinetic investigation, Ro 44-5912 appeared to have a longer half-life in mice than did its (R) enantiomer Ro 44-5911 (3.15 +/- 0.02 h versus 2.15 +/- 0.14 h) as measured by total radiolabel in plasma.",The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652269/),h,3.15,272928,DB00386,Alseroxylon
,8652269,half-life,"In a preliminary pharmacokinetic investigation, Ro 44-5912 appeared to have a longer half-life in mice than did its (R) enantiomer Ro 44-5911 (3.15 +/- 0.02 h versus 2.15 +/- 0.14 h) as measured by total radiolabel in plasma.",The dithiane Ro 44-5912 enhances vinblastine sensitivity of drug resistant and parental KB lines in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8652269/),h,2.15,272929,DB00386,Alseroxylon
,2735930,maximal concentration,"At this dose, the maximal concentration in plasma was 24 microM, with rapid elimination such that plasma concentrations reported to modulate resistance in vitro (approximately 5-10 microM) were maintained for less than 60 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),μM,24,273488,DB00386,Alseroxylon
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,350,273489,DB00386,Alseroxylon
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,91,273490,DB00386,Alseroxylon
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,3,273491,DB00386,Alseroxylon
,11087081,Extraction recoveries,"Extraction recoveries from plasma and blood averaged 101 and 75%, respectively.",High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087081/),%,101,273888,DB00386,Alseroxylon
,11087081,Extraction recoveries,"Extraction recoveries from plasma and blood averaged 101 and 75%, respectively.",High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11087081/),%,75,273889,DB00386,Alseroxylon
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],1509,274180,DB00386,Alseroxylon
,8339389,Peak plasma DOX levels,"Peak plasma DOX levels were higher after the bolus injection than after continuous administration (1509 +/- 80 ng/ml vs 11.6 +/- 1.8 ng/ml, respectively), whereas the plasma area under the curve (AUC) levels were similar.",Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [ml],11.6,274181,DB00386,Alseroxylon
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],8629,274182,DB00386,Alseroxylon
,8339389,Maximum DOX cellular concentrations,Maximum DOX cellular concentrations were 8629 +/- 2902 ng/10(9) cells (bolus injection) and 2745 +/- 673 ng/10(9) cells (96 h infusion).,Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8339389/),[ng] / [10(9)·cells],2745,274183,DB00386,Alseroxylon
